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Preface 
The research presented in this thesis was performed under the supervision of Professor Gregers 
Jungersen, Professor Jenny Emnéus and Associate Professor Anders Wolff. The practical work was 
performed at the Section for Immunology and Vaccinology, National Veterinary Institute, Technical 
University of Denmark and at the Department of Micro- and Nanotechnology, Technical University of 
Denmark from December 2011 to January 2016. The project was financed by DTU. 
The original aim of this thesis was to develop a diagnostic chip for detection of CMI responses in a 
blood sample by recall antigen stimulation and direct IFN-γ detection as readout. This goal was not 
reached, however, and the focus of the thesis changed into looking at optimization of conditions for 
in vitro culture of primary immune cells. The work included in this thesis is presented in four studies. 
Study I (chapter 3) looks at the effect of performing interferon-γ release assays using cultures of 
whole blood or PBMCs and the study is presented in paper I. Study II (chapter 4) presents the results 
from interferon-γ release assay-optimization by addition of a third dimension to the culture using 
three dimensional scaffolds. Study III (chapter 5) presents the manufacture of a prototype chip. The 
last study - study IIII (chapter 6) - looks at the effect of changing the culture environment when 
studying the differentiation of monocytes to monocyte-derived dendritic cells in vitro. This is 
presented in paper II.    
This thesis contains two manuscripts: 
Paper I:  
Hartmann, S., Emnéus, J., Wolff, A. and Jungersen, G. “Revisiting the IFN-γ release assay: Whole blood 
or PBMC cultures? - And other factors of influence”. Manuscript ready for submission. 
 
Paper II 
Hartmann, S., Mohanty, S., Skovgaard, K., Brogaard, L., Flagstad, F., Emnéus, J., Wolff, A., 
Summerfield, A. and Jungersen, G. “Investigating the role of surface materials and three dimensional 
architecture on in vitro differentiation of porcine monocyte-derived dendritic cells”. Manuscript 
submitted to PLOS ONE.  
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Summery 
T lymphocytes are key players during the initiation of an adaptive immune response. The activation of 
these cells in vivo requires migration within the lymph nodes until they encounter antigen presenting 
cells (APCs) that can activate them to secrete IFN-γ which mediates downstream effector functions. 
The in vitro reactivation of antigen-experienced T lymphocytes and detection of IFN-γ from cell 
cultures can be used in a diagnostic assay to test for disease or vaccine efficacy. Practical procedures 
of the IFN-γ release assay (IGRA) was investigated using bovine cells and whole blood cultures was 
found preferable compared to PBMC cultures, partly due to the risk of losing cell subsets after 
purification of PBMCs.  
The development of in vitro culture systems for more than 50 years ago revolutionized the 
biomedical world. It became possible to study cell behavior using cell lines or primary cells in culture 
and to measure cell activity such as IGRA, as described above. The traditional way of culturing cells 
are done using polystyrene (PS) plastic ware in flask-, Petri dish- or micro titer plate format. However, 
these artificial two dimensional (2D) surfaces on which the cells grow, has shown to interfere with cell 
morphology, gene expression and overall behavior and as such gives a poor reflection of in vivo cell 
behavior. Therefore, it is believed that by mimicking the in vivo conditions within the cultures, this 
would generate “closer-to-in vivo” results. For this purpose three dimensional (3D) culture setups 
have been developed including artificial scaffolds and extracellular matrix gels.  
Optimization of IGRA was attempted using solid 3D scaffolds in various formats. The purpose 
of the 3D scaffolds was to facilitate T lymphocyte migration and subsequently activation due to 
increased chances of T lymphocyte/APC encounter. However, it turned out that the addition of this 
extra dimension to the cultures did not translate into increased de novo secretion of IFN-γ in these 
cultures. Furthermore, we often observed a non-specific effect on the level of IFN-γ when cells were 
cultures in 3D. This suggested that cells were sensitive to the geometry surrounding them and that 
this was independent on antigen stimulation.  
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Based on these findings and a previous discovery that the polymer PDMS, gave rise to 
increased differentiation of a nerve cell line in vitro, we tested the effect of PDMS on the 
differentiation of porcine monocytes. Monocytes are immune cells of high plasticity, and thus we 
speculated that they might be sensitive to culture conditions. Indeed, monocytes differentiated into 
monocyte-derived DC (moDCs) when cultured conventionally (2D PS) in the presence of GM-CSF and 
IL-4, but adopted a macrophage-like gene expression profile when cultured on PDMS. Further it was 
found that 3D culturing resulted in increased activation of the monocyte-derived cells.  
The work in this thesis covers several aspects within primary cell culture, but central to the 
work is the investigation of 3D cell culture setups for improved activation/differentiation of immune 
cells. Conclusively, this work highlights the importance of acknowledging the effect from external 
factors when analyzing data generated from in vitro cultures. This being even more important when 
working with immune cells since these cells adopt traits and functions simply based on the nature of 
the culture system.  
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Sammendrag (Danish summery) 
T-lymfocytter er centrale celler i aktiveringen af det adaptive immunrespons. Aktiveringen af disse 
celler in vivo sker i lymfeknuderne og indebærer migration af T lymfocytterne indtil de støder på en 
relevant antigen-præsenterende celle (APC), som kan aktivere dem. Herved responderer T-
lymfocytterne ved at udskille IFN-γ, som er med til at initiere andre dele af immunresponset. In vitro 
reaktivering af primede T-lymfocytter og efterfølgende detektion af IFN-γ fra cellekulturer, kan 
anvendes i et diagnostisk assay til sygdomsdetektion eller til at teste vaccineeffektivitet. Praktiske 
procedurer omkring opsætningen af dette assay, kaldet IFN-γ release assay (IGRA), blev undersøgt 
med immunceller fra kalve. Det viste sig, at fuldblod var bedre egnet end PBMC kulturer, dels på 
grund af risikoen for at miste specielle celletyper under oprensningen af PBMC'erne. 
Udviklingen af metoder til in vitro-dyrkning af celler for mere end 50 år siden, revolutionerede 
den biomedicinske verden. Det blev bl.a. muligt at studere celler og deres adfærd vha. både cellelinjer 
og primære celler, samt at måle celleaktivitet vha assays såsom IGRA. Den traditionelle måde at dyrke 
celler på, har været vha. plastikprodukter såsom flasker, skåle eller flerbrøndsplader lavet i polystyren 
(PS). Disse kunstige todimensionale (2D) overflader, hvorpå cellerne vokser, har dog vist sig at påvirke 
cellemorfologien, genekspressionen og cellernes generelle opførsel, hvilket resulterer i en dårlig 
afspejling af cellernes in vivo-adfærd. Det antages derfor, at man ville kunne opnå bedre resultater, 
som i højere grad afspejler in vivo-forholdene, hvis der blev optimeret på cellekulturforholdene. Til 
dette formål er tredimensionelle (3D) kulturer blevet udviklet, herunder kunstige matricer el netværk 
samt ekstracellulær proteinholdige geler. 
I denne afhandling blev IGRA forsøgt optimeret ved at tilføje 3D matricer i forskellige formater 
til cellekulturerne. Formålet med 3D matricerne var at facilitere effektiv migration af T-lymfocytterne 
og deres efterfølgende aktivering som følge af øget chancer for T-lymfocyt/APC interaktion. Det viste 
sig dog, at tilføjelsen af denne ekstra dimension til kulturerne ikke resultere i en øget de novo 
produktion af IFN-γ i disse kulturer. Vi observerede derimod en uspecifik påvirkning af IFN-γ niveauet 
når cellerne var i 3D kulturer. Dette antydede, at cellerne var følsomme overfor cellekultur-
geometrien, og at dette var uafhængigt af antigenstimuleringen. 
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På baggrund af disse resultater, samt tidligere studier som viste at polydimethylsiloxane 
(PDMS) gav anledning til øget in vitro differentiering af en nervecellelinje, satte vi os for at teste 
virkningen af PDMS på differentieringen af monocytter oprenset fra svineblod. Monocytter er 
immunceller med høj plasticitet, og dermed potentielt følsomme over for dyrkningsbetingelserne. Det 
viste sig at monocytterne differentierede sig til monocyt-deriverede DCer (moDCer), når de blev 
dyrket konventionelt (2D PS) med GM-CSF og IL-4, mens de fik en makrofag-lignende 
genekspressionsprofil når de blev dyrket på PDMS. Yderligere fandt vi, at 3D dyrkning resulterede i 
øget aktivering af disse monocyt-deriverede celler. 
Arbejdet i denne afhandling dækker flere aspekter inden for primær cellekultur, men centralt 
for arbejdet er undersøgelsen af 3D cellekulturenes effekt på aktiveringen/differentieringen af 
immunceller. Konklusionsvis fremhæver dette arbejde, hvor vigtigt det er at anerkender virkningen af 
eksterne faktorer når man analyserer data fra in vitro cellekulturer. Dette er især vigtigt, når der 
arbejdes med immunceller, da disse celler har vist sig at være sensitive overfor ydre ændringer i 
cellekulturopsættet. 
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Chapter 1 - General background 
1.1 The immune system  
We live in a world of daily exposure to millions of potential pathogenic microorganism through 
inhalation, contact and digestion. Yet we manage to stay alive, and the reason for this can be ascribed 
to our immune system. It consists of a diverse group of cells and molecules specialized in protecting 
us from pathogens by identifying and targeting them or their products for destruction. The responses 
carried out by the immune system needs to be tightly regulated in terms of type, intensity and 
duration to effectively overcome an intruding pathogen, but doing so with minimal collateral tissue 
destruction and alteration of homeostasis (Goldszmid & Trinchieri 2012). Typically the immune 
system is divided into innate and adaptive immunity (Figure 1), which serves as a rapid first and a 
slower second line of defense, respectively. Whereas the adaptive immune system consist of a 
defined physiologic system that rely on a few subsets of helper and effector cells, the innate system is 
a product of multiple and diverse defense mechanisms (Medzhitov 2008).    
 
Figure 1: Overview of cells involved in the adaptive and innate immune system. Figure from:  
http://currentscienceperspectives.com/what-is-immunology/ 
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1.1.1 Innate immunity 
The innate immune response is our first line of defense against intruding pathogens. It is 
characterized as being a fast and non-specific response (though it can discriminate between self and 
non-self), which is constant over time and does not result in immunological memory.  It is comprised 
of physical barriers, such as skin and mucosal surfaces lining the gastrointestinal, respiratory, and 
urogenital tracts. Microbes that manage to breach these physical barriers are met by the cells of the 
innate immune system. These include professional phagocytes such as macrophages, dendritic cells 
(DC) and neutrophils which exerts phagocytic uptake of both intracellular and extracellular bacterial 
and fungal pathogens (Savina & Amigorena 2007). The natural killer (NK) cells are specialized in direct 
killing of virus-infected host cells and also help clearing intracellular infection by production of 
cytokines, especially interferon (IFN)-γ (Zhang et al. 2006). Finally anti-parasitic cells of the innate 
immune system consist of mast cells, eosinophils and basophils (Haig & Miller 1990). Apart from the 
cells listed above, the innate immune system also comprises antimicrobial peptide and secreted 
proteins of the complement system which functions include opsonization of pathogens for phagocytic 
uptake. Key factors defining the innate immune system is the recognition of conserved pathogenic 
structures specific for non-eukaryotic cells, by germline-encoded pattern-recognition receptors (PRRs) 
as well as the ability to recruit cells of the adaptive immune system by secretion of cytokines (Murphy 
2012).        
1.1.2 Adaptive immunity 
The adaptive immune system takes over as a second line of defense. In contrast to the innate 
response, the adaptive response is characterized as being slow but specific, it continuously develops 
during the lifetime of an individual and it provides immunological memory. Cells involved in the 
adaptive immunity is termed B- and T lymphocytes, referring to the location in which they mature; 
the primary lymphoid organs, namely bone marrow and thymus, respectively. Once matured these 
cells initiates their function in the spleen, lymph nodes and mucosal lymphoid tissues, collectively 
termed secondary lymphoid organs (Murphy 2012). Whereas B lymphocytes produce antibodies and 
are responsible for the humoral immunity, T lymphocytes constitutes the cell mediated immunity 
(CMI) involving cytotoxicity and regulatory functions (Danilova 2012). Three major molecules are 
  General background 
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central for the adaptive immunity: the T cell receptor (TCR), B cell receptor (BCR) and major 
histocompatibility complex (MHC). The TCR and BCR are similar in structure; they are both dimers 
with BCR being composed of a heavy and a light immunoglobulin chain, and TCR being composed of 
an α and β chain (in αβT lymphocytes) or a γ and δ chain (in γδT lymphocytes) (Murphy 2012). Despite 
the similarity of their receptors, B and T cells differ functionally in the way they recognize antigens; B 
cells recognize antigens (non-self) directly via BCR, whereas T cells recognize “non-self” in 
combination with “self” through antigen:MHC complexes via TCR (Danilova 2012). During the process 
of maturation, BCR and TCR undergo somatic recombination of gene segments (Schatz 2004; 
Tonegawa 1983) and through imprecise joining mechanisms a high degree of functionally important 
for diversity is introduced, creating huge numbers of receptors with unique specificities (Murphy 
2012). Through this genomic recombination, the diversity of TCRs with distinctive specificities exceeds 
1015 (Davis & Bjorkman 1988). The specificities of BCR is even higher due to secondary processes of 
somatic hypermutation and class switch recombination (Muramatsu et al. 2000; Liu & Schatz 2009) 
which occur following antigen binding and B lymphocyte activation thus ensuring the production of 
high affinity antibodies. B lymphocytes with BCRs specific for “self” antigens are negatively selected 
during development in the bone marrow (Hartley et al. 1993; Gay et al. 1993). In the thymus, T 
lymphocytes whose receptors interact weakly with antigen:MHC complexes is positively selected for 
whereas T lymphocytes with strongly self-reactive receptors are negatively selected (Murphy 2012). 
In this way, autoreactive lymphocytes are eliminated and the remaining pool of naïve (antigen-
unexperienced) B and T lymphocytes enter the blood stream and travels to peripheral lymphoid 
tissues where they, following antigen recognition, become activated and clonally expands and 
differentiates into antibody-producing plasma cells or cytotoxic/helper T lymphocytes, respectively 
(Danilova 2012).    
1.2 CMI 
The immunological response performed by T lymphocytes is the CMI response. During development T 
lymphocytes commits to expression of either cluster of differentiation (CD)-8 or CD4 co-receptor 
molecules (Tanaka & Taniuchi 2014). CD8+ T lymphocytes recognize antigen in combination with MHC 
class I expressed by all nucleated cells, and develops into cytotoxic T lymphocytes (CTLs) following 
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activation. CD4+ T lymphocytes recognizes antigen bound to MHC class II expressed by professional 
antigen-presenting cells (APCs) primarily DCs and macrophages, but also B lymphocytes as well as 
monocytes which are APC precursors (Randolph et al. 2008). Upon activation these lymphocytes 
develop into cytokine-secreting helper T (TH) lymphocytes, with TH1 being key players within the CMI 
response (Figure 2).   
 
Figure 2: Cells and molecules important for innate and adaptive immune responses. From (Thakur et al. 2012). 
 
Depending on activation factors, including local cytokine milieu, the naïve CD4+ T lymphocyte 
differentiates into TH1, TH2, TH17 or T regulatory (Treg) lymphocytes. Each of these lymphocytes has 
specific functions in terms of which cytokines they secrete. TH1 lymphocytes secretes several 
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cytokines, but the primary one being IFN-γ (Romagnani 1994) that activates macrophages and CTLs 
and enabling them to kill pathogens and induce apoptosis in infected cells, respectively. The function 
of TH2 lymphocytes is to initiate humoral immunity by B lymphocyte activation, mediated primarily by 
secretion of interleukin (IL)-4 (Romagnani 1994). TH17 and Treg lymphocytes are responsible for 
neutrophils activation and immune regulation through IL-17A and IL-10/transforming growth factor 
(TGF)-β secretions, respectively (Thakur et al. 2012). Together, these cells orchestrate a complicated 
network of signals that eventually leads to development of long lived memory cells that due to their 
antigen-experienced nature, are capable of triggering a strong and fast response upon reencounter 
with the same antigen.     
1.2.1 IFN-γ and IP10 
IFN-γ is an 18.8 kD cytokine secreted by TH1 lymphocytes, however other cells are also capable of 
producing IFN-γ. These cells includes CD8+ CTLs in the adaptive response as well as NK/NKT cells and 
γδ T lymphocytes which are cells bridging the innate and adaptive immune system. The latter cells 
have been shown to be a source of innate IFN-γ production in in vitro cultures of bovine cells (Olsen et 
al. 2005; Kennedy 2002). γδ T lymphocytes have been shown to have immune regulatory functions 
and are active during the early responses to infection (Hiromatsu et al. 1992; King et al. 1999). Of yet 
unknown reasons, they are present in much higher numbers in cattle and pigs, especially in young 
animals where they constitute app. 40% and 23-57% of total circulating T lymphocytes, respectively 
(Wilson et al. 1996; Yang & Parkhouse 1996; Yang & Parkhouse 2000). IFN-γ has broad biological 
functions which includes anti-viral activity, enhancement of antigen-presentation via MHC I/II 
pathways, leucocyte trafficking, antibody isotype switching and immune regulation by means of TH2 
commitment inhibition (Boehm et al. 1997; Schoenborn & Wilson 2007; Schroder et al. 2004).   
IP10 (encoded by the CXCL10 gene) is a 7.4 kD small chemokine secreted by APCs (Moser & Loetscher 
2001; Dhillon et al. 2007). It is expressed in pathogen-infected cells, but can also be induced at high 
levels by cells of the adaptive immune response (Ruhwald et al. 2012). In this case, it is expressed by 
APC in response to T lymphocyte-derived IFN-γ, but can also be induced by other cytokines. It is thus 
considered to be a downstream marker to IFN-γ which is the typical CMI readout marker(Chen & Liu 
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2009; Farrar & Schreiber 1993), and is expressed 100-fold compared to IFN-γ (Aabye et al. 2012). Thus 
both IFN-γ and IP10 can be used a markers for TH1 type CMI responses. 
1.2.2 Activation of CD4+ T lymphocytes through antigens and superantigens 
Once a pathogen or antigen is taken up by an APC, for example a DC, this delivers activating signals via 
PRR such as toll-like receptors (TLRs). As a downstream process the antigen peptide-processing within 
the DC accelerates, involving assembling of MHC II dimers in the endoplasmic reticulum, and loading 
of peptide in the lysosome compartment before being transported to the cell surface as a 
peptide:MHC complex (Blum et al. 2013). When this complex is presented to naïve CD4+ T 
lymphocytes, three signals occur eventually leading to T lymphocyte activation and differentiation 
into effector cells. The activation is initiated by binding of the peptide:MHC complex by the TCR in 
combination with CD4 co-receptor and results in increased adhesive interactions between the two 
cells. This represents the first “activating” signal. The second signal comes from binding of co-
stimulatory molecules, B7.1/B7.2 (also known as CD80/CD86). These receptors are expressed by the 
APC and binds to CD28 on the T lymphocyte resulting in a “survival” signal necessary for clonal 
expansion of the T lymphocyte. This leads to differentiation of the T lymphocyte into various helper 
cells depending on the nature of the inflammatory cytokines, and the cytokines produced by the APC 
which represents the third “differentiating” signal (Murphy 2012).  Differentiated or antigen-
experienced T lymphocytes do not require the same co-stimulatory signals to become activated upon 
encounter with the same antigen, and can thus be reactivated to induce a fast and strong response.  
Superantigens such as the staphylococcal enterotoxin B (SEB) differs from “regular” protein 
antigens in the way they activate T cells; they are not processed and presented via MHC II but instead 
binds to the MHC II molecules already present at the cell surface. In addition they are able to bind to 
the β chain of many TCRs and initiate activation of these T lymphocyte by bridging the two cells 
(Murphy 2012; Pinchuk et al. 2010) (Figure 3). The binding site preferences differ between 
superantigens, and each superantigen shows specificity towards a few different β chains, and can thus 
bind to and stimulate up to 20% of all T lymphocytes (Choi et al. 1989). This type of polyclonal 
stimulation does not result in immunological memory by the adaptive immune system, but mediates 
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a huge secretion of cytokines including IFN-γ (Assenmacher et al. 1998). Therefore, SEB is frequently 
used as a positive control within in vitro assays to assure viability of T cells.  
 
Figure 3: Concept of antigen vs. superantigen activation. SEB binds MHC II on the APC and TCR on the T lymphocyte and 
initiates a burst in cytokine secretion from the T-lymphocyte, including IFN-γ. During specific T-lymphocyte activation, TCR 
binds to processed antigen presented by MHC II in combination with CD4 (signal 1). Co-stimulatory receptors CD80/86 
binds to CD28 (signal 2) and following cytokines released by the APC (signal 3), this induces T lymphocyte differentiation 
into TH1 IFN-γ secreting lymphocytes. 
 
1.3 Lymph nodes  
Lymph nodes are essential for the activation of the adaptive immune response by providing an 
environment that favours the interaction of APC and T lymphocytes. Naïve T lymphocytes constantly 
patrol our body, trafficking between the vasculature and lymphatic system in search for cognate 
antigen (Girard et al. 2012). They enter the lymph nodes by the vascular route via high endothelial 
venules (HEVs). APCs (mainly DCs) that have taken up antigen in the peripheral tissue becomes 
activated and upregulate the expression of CCR7 (a G protein-coupled receptor), which homes them 
via the lymphatic system to the nearest lymph node by the chemokines CCL19 and CCL21 expressed in 
lymphoid tissue by stromal cells termed fibroblastic reticular cells (FRCs) (Worbs et al. 2008; Förster et 
al. 2012). FRCs produces and ensheaths a reticular network of collagen fibers and extracellular matrix 
proteins (ECM) which provides a network on which lymphocytes can migrate and DCs settle, ensuring 
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encounter of the two cell subsets (Bajénoff et al. 2007). T lymphocytes migrate using an ’amoeboid’ 
mode of locomotion in 3D in vivo environments (Weninger et al. 2014), and the migration can both be 
random and directed, depending on the local chemokine milieu (Figure 4).  
 
Figure 4: Modes of T lymphocyte migration within the three dimensional network of a lymph node. (a) Overall 
organisation of a lymph node. DCs enter via afferent lymphatics and T lymphocytes enter via HEVs in the T cell zones. T 
lymphocyte migration within lymph nodes is guided via the reticular network (FRC network) but can be (b) random during 
homeostatic conditions via constitutively expressed chemokines CCL19 and CCL21, or (c) guided by inflammatory 
chemokines (CCL3/4) expressed by the DCs following activation. This attracts more naïve T lymphocytes bearing the 
  General background 
21 
 
chemokine receptor CCR5. (d) Lymph-born pathogenic particles are captured by resident macrophages that become 
activated and recruits effector T lymphocytes. From (Munoz et al. 2014).  
1.4 In vitro culture 
Cell culture became recognized as a research field when the Tissue Culture Commission (now known 
as The Society for In Vitro Biology) was established in 1946 (Berthier et al. 2012). However, already in 
1907 with the demonstration of nerve fiber outgrowth from a frog embryo on a glass dish (Harrison 
1911), this marked the beginning of the cell culture discipline. In 1955 Harry Eagle established the first 
widely used chemically defined medium (Eagle 1955). Glass was the choice for culture ware, but as 
the field began to expand, glass became a limiting factor and thus alternative materials such as plastic 
with properties that included reduction of the labor intensive cleaning as well as low production and 
operational costs, was introduced (Berthier et al. 2012). The plastic industry expanded enormously 
and companies such as Dow Corning and Falcon Plastics developed techniques decreasing the cost for 
plastic fabrication, particularly for polystyrene (Teach & Kiessling 1960). Because of its low production 
costs and other attractive properties such as optical clarity, mechanical strength and durability, 
polystyrene became the material of choice for disposable cell culture ware. Furthermore, when 
Falcon Plastics developed the oxygen plasma surface treatment, rendering the polystyrene surfaces 
more hydrophilic, resulting in improved cell attachment and growth (Barker & LaRocca 1994; Curtis et 
al. 1983), this cemented the use of polystyrene as in vitro culture ware, and from the 1960s it became 
the dominant material produced by many manufacturers (Curtis et al. 1983). Today many options are 
available, but the       
1.4.1 IFN-γ assay 
As a tool to measure CMI in vitro, the IFN-γ assay has been available for more than 25 years. Within 
the field of veterinary medicine, bovine tuberculosis and paratuberculosis were the first infections 
studied using this method (Wood et al. 1989; Wood et al. 1990; Rothel et al. 1990; Billman-Jacobe et 
al. 1992). The principle of the test is to measure the level of de novo secreted IFN-γ by cells in 
response to overnight culture with antigen. This is usually done by subtracting the concentrations of 
IFN-γ obtained in non-stimulated cultures (background) from the concentrations obtained in antigen-
stimulated cultures. The assay can be based on whole blood cultures or cultures of purified peripheral 
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blood mononuclear cells (PBMCs), and following incubation, plasma/supernatant is harvested and 
used for IFN-γ detection by enzyme-linked immunosorbent assay (ELISA). The assay measures the 
overall level of IFN-γ upon antigen-recall, with no discrimination of the producing cell subsets. The 
rationale of using IFN-γ as a diagnostic measure, is that previous sensitized T lymphocytes will, via 
their TCR, recognize cognate antigen:MHC complexes presented to them by APCs, thus only pre-
exposed, or vaccinated individuals will harbor sensitized T cells specific for the antigen and this will 
translate into de novo IFN-γ secretion. QuantiFERON-TB test (QFT) was the first commercial IGRA 
approved by the Food and Drug Administration (FDA) in 2001 (Mazurek & Villarino 2003).                  
1.4.2 3D culture 
The ability of study cells by in vitro cultures has resulted in increased understanding of basic cell 
biology and behavior, and has proven to be indispensable for a variety of applications from research 
to industry. However, there is an increasing interest in optimizing the culture format by making 3D in 
vitro cultures for the “closer-to-in vivo” investigation of cells using matrices and scaffolds (Ravi et al. 
2015). The translation of findings made using 2D cell culture to in vivo behavior has proven somewhat 
challenging and 3D cultures can be used as a bridge between relatively easy-to-use, but inaccurate 2D 
in vitro culture systems and more difficult, but physiologically relevant in vivo models (Yamada & 
Cukierman 2007). Several scaffold-based 3D culture models exist, and they include prefabricated 
polymer scaffolds where cells attach and migrate within the pores of the scaffold, and biological 
scaffolds such as hydrogels that trap cells in an artificial ECM environment (Maltman & Przyborski 
2010).  
1.5 moDCs  
The generation of DCs in vitro from monocytes harvested from peripheral blood, by using a 
combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and Interleukin (IL)-4 
was first described in 1994 (Sallusto & Lanzavecchia 1994; Romani et al. 1994). This made it possible 
to study DCs in vitro and has laid the foundation of our present DC knowledge. Most clinical studies 
using DCs are based on monocyte-derived DCs (moDCs) (Barbuto 2013). Monocytes develop in the 
bone marrow from hematopoietic stem cells (HSCs) and circulate the blood constituting app. 10% of 
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total leukocytes in humans. (Italiani & Boraschi 2014). Circulating monocytes have previously been 
thought to give rise to macrophages and DCs (mononuclear phagocytes) in the tissue (van Furth et al. 
1972; van Furth 1980), but the identification of the common DC progenitor (CDP) and pre-
conventional DC (pre-cDC) app. 10 years ago (Naik et al. 2007; Naik et al. 2006; Diao et al. 2006), 
changed the theory of DC development and an updated version on macrophage/DC precursors is 
presented in Figure 5.  
 
 
Figure 5: Overview of mononuclear phagocytes and their precursors. Mф, macrophage; EMP, embryonic precursor; HSC, 
hematopoietic stem cells; CDP, common DC progenitor; pDC, plasmacytoid DC; cDC, conventional DC; cMop, monocyte-
committed common monocyte progenitor; M1, classically activated Mф; M2, alternatively activated Mф. From (Guilliams 
& van de Laar 2015).  
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Chapter 2 - General methods 
In this chapter, methods used during the PhD studies are presented and the protocols described. 
However, some protocols are described in detail in paper I and II and are therefore not explained in 
detail in this section.   
2.1 Animals 
Blood from calves, pigs and goats was used for the experimental studies performed in this thesis. 
Bovine blood was used for testing and optimization of IGRA (study I and II). For studying the flow and 
capture of cells within the prototype chip, and for direct one-step blood qRT-PCR reaction 
optimization (study III), both bovine and goat whole blood was used for practical reasons and since 
the origin of the cells made no difference to the experiments. For the generation of moDCs (study IIII), 
porcine cells were chosen over ruminant cells since the research within porcine models for human 
diseases are expanding and because the DC biology in pigs and humans are similar, making the pig an 
obvious choice for this particular experiment. All animals were housed at the Veterinary Institute, 
Technical University of Denmark, except for a few calves (used for testing the effect of microtiter-
plates from different suppliers, presented in paper I) housed at a collaborating farm (Freerslev Kotel, 
Gørløse, Denmark).   
Most of the calves were enrolled in preexisting Paratuberculosis vaccine studies, and thus had 
acquired antigen specific immune responses against Mycobacterium avium subsp. paratuberculosis 
(MAP). The presence of an acquired immune response within the calves was exploited in this work. 
These animals were used to test the effect of culture conditions on specific CMI responses by means 
of IFN-γ release when restimulated with MAP antigens in the format of single antigen-peptide or 
crude extract. Polyclonal activation by superantigen stimulation was used with control animals, or 
animals with no acquired Paratuberculosis responses.  
2.2 PBMC purification 
Two protocols were applied for purification of PBMCs during the course of work presented in this 
thesis. The first protocol is described in paper I and II and included a 1:2 dilution of fresh stabilized 
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whole blood with phosphate buffered saline (PBS) as a first step. The diluted whole blood was then 
laid on Ficoll-Paque™ Plus (GE Healthcare) with room temperature (RT) in a 2:1 ratio (i.e. 8ml 
blood/PBS:4ml Ficoll-Paque™ Plus) followed by centrifugation at 2500 rpm (≈1400 x g) for 15 min at 
RT with low brake. In the second protocol, fresh stabilized whole blood was centrifuged at 2800 rpm 
(≈1700 x g) for 5 min at RT with low brake. Approximately 2ml of the cloudy middle layer (buffy coat) 
was harvested and laid on Ficoll-Paque™ Plus (1:2) and centrifuged as described for the first protocol. 
In both protocols, PBMCs were recovered using Pasteur pipettes and washed twice in RPMI 1640 
medium with GlutaMAX™ (Gibco, Life Technologies™) containing 1% heat inactivated fetal calf serum 
(FCS) (Sigma). Cells were counted manually on a Olympus CH-2 microscope (Olympus Optical Co., Ltd.) 
using an Improved Neubauer, bright-line hemocytometer chamber (Assistent®) or using an 
automated cell counter (Nucleocounter® NC-200™, ChemoMetec), and diluted at appropriate 
concentrations in medium containing 10% FCS. The second protocol (with buffy coat isolation) was 
used for purifying PBMCs from young animals, since the PBMC fragment in these animals occasionally 
were difficult to separate from the bottom red blood cell layer.  
2.3 Cell culture 
For testing the effect of culture conditions on specific responses, whole blood or PBMCs from 
vaccinated or experimentally infected animals were used. For this purpose, cells were restimulated 
with either a MAP latency peptide antigen called MAP9436c (herein referred to as MAP antigen) or 
Johnin purified protein derivative (PPDj) which is a crude extract of undefined MAP antigens, often 
used for restimulation in IGRAs (Jungersen et al. 2002; Jungersen et al. 2012). SEB stimulation was 
used for the generation of CMI responses when no animals with specific MAP immune responses 
were available, or for comparison of specific vs. polyclonal activation. Concentrations of antigens used 
for stimulations (unless otherwise stated) was 1µg/ml MAP antigen, as well as 10µg/ml PPDj and 1 
µg/ml SEB, concentrations that have previously been found to induce optimal responses (Jungersen et 
al. 2002). Individual culture times, plate formats- and cell concentrations used for the different 
culture setups, is described in the results sections of chapter 3-6. All 48 well-plates was from Cellstar®, 
Greiner Bio-One, and 96 well-plates were from Costar, Corning.     
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The 3D culture setup applied for testing 3D IGRA (presented in chapter 4) consisted of somewhat 
untraditional 3D scaffolds, including glass wool, small shavings made of polypropylene (PP), filter 
paper disks and 3D scaffolds made in polydimethylsiloxane (PDMS) polymer using the sugar cube 
method, as described in paper II (only the scaffold was made from solid sugar cubes and not sugar 
crystals as described in the paper). Two commercially available 3D scaffolds were tested; 3D 
polystyrene (PS) and 3D polycaprolactone (PCL) scaffolds. An overview of the different scaffolds and 
their specifications is listed in Table 1, and images of the scaffolds are presented in appendix 1. Prior 
to culture, 3D PS scaffolds were treated with 70% ethanol and washed twice in PBS to render the 
scaffolds hydrophilic.   
 
Table 1: 3D scaffolds used for optimization of IGRA (presented in chapter 4) 
Scaffold  Pore size  Source  Supplier 
Glass wool NA VWR 
Glaswarenfabrik 
Karl Hecht 
PP shavings  NA Prepared for the experiment - 
3D PDMS scaffold Pore size 300-600µm Prepared for the experimenta - 
3D PS scaffold Pore size 40µm Reinnervate Amsbio 
3D PCL scaffold Pore size 300µm 3D Biotec Sigma-Aldrich 
Filter paper  Pore size 20-25µm Whatman® Sigma-Aldrich 
a
Prepared by Soumyaranjan Mohanty, DTU Nanotech, Technical University of Denmark. NA, Not 
applicable; PP, polypropylene; PDMS, polydimethylsiloxane; PS, polystyrene; PCL, polycaprolactone.  
 
In order to improve cell attachment and migration within the 3D cultures, different types of protein 
coatings were tested. The first one was MaxGel™ ECM (Sigma), which is a basement membrane 
extract of human ECM components including collagens, laminin, fibronectin, tenascin, elastin, 
proteoglycans and glycosaminoglycans. Culture-wells/scaffolds were coated with MaxGel in a 100x 
dilution for 30 min at 37°C, 5% CO2 and washed prior to culture. The second ECM mix was Matrigel™ 
(BD Biosciences), an ECM-based hydrogel extracted from mouse tumor cells rich in laminin, collagen 
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IV, heparin sulfate proteoglycans, entactin/nidogen including several growth factors. Culture 
wells/scaffolds were coated with Matrigel in a 2-20x dilution and incubated for app. 1 hour at room 
temperature (RT) and washed prior to culture. The last protein coating that was tested was 
recombinant human CCL21 (BioLegend®), a chemokine that is highly expressed in lymph nodes. 
Culture wells were coated with CCL21 at 0.01µg/well (Figure 13) or 0.02µg/well (Figure 14) and air 
dried prior to cell culture.  
2.4 Flow cytometry 
Flow cytometry was used to identify the ratio of cell subpopulations present before and after PBMC 
purifications (Chapter 3, paper I) and to characterize monocytes before and after culture with 
differentiating cytokines (Chapter 6, paper II). This was done by staining cells for surface markers 
using specific antibodies either directly conjugated to a fluorochrome or by the addition of 
fluorochrome-conjugated secondary antibodies. Different fluorochromes emit light when hit by lasers 
of particular wavelengths. Stained cells in suspension are led through different lasers one by one and 
when hit by the laser light, one detector measures the forward scatter (FSC) which is a measure of cell 
size, and another detector measures the side scatter (SSC) which is the granularity of the cells. Thus, 
data generated for each cell includes: cell size, granularity and fluorescent labelling. A detailed 
description on staining protocols is presented in paper I and II. All flow cytometry analysis were 
performed on a BD FACSCanto™II flow cytometer (BD Biosciences) and the results were analyzed 
using the BD FACSDiva software version 8.0.1.         
2.5 IFN-γ specific ELISA 
An in house-developed IFN-γ specific sandwich enzyme-linked immunosorbent assay (sandwich-ELISA) 
was used to detect and quantify IFN-γ levels in supernatant/plasma harvested from PBMC or whole 
blood cultures. The protocol is described in detail in paper I and it was slightly modified from the 
protocol described in (Mikkelsen et al. 2009). In this assay, a monoclonal capture antibody specific 
against the IFN-γ F(ab)2 fragment was coated in the wells of a micro-well plate. The 
supernatant/plasma containing IFN-γ to be measured was added and as a following step, a 
biotinylated anti-IFN-γ monoclonal antibody was added. Finally, enzyme-linked streptavidin was 
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added and the enzyme was converted to a detectable signal by addition of substrate. Quantity of IFN-
γ was measured as optical density (OD) and was calculated using linear regression on log transformed 
OD values from dilution series of a reference SEB-stimulated plasma standard with known IFN-γ 
concentrations included on each plate. All samples/standards were added in duplicate, including a 
blank control.         
2.6 Total RNA purification  
The RNeasy Mini Kit (Qiagen) was used to purify total RNA from cultured moDCs (chapter 6, study IIII) 
and purification was performed according to manufacturer’s instructions. Briefly, cell lysates were 
homogenized using a QIAshredder spin column and ethanol was added to bind total RNA to the 
RNeasy spin column. After a DNase treatment and a following washing step, total RNA could be eluted 
and stored for cDNA synthesis.   
The QIAamp RNA Blood Mini Kit (Qiagen) was used to purify total RNA from 3D-cultured whole blood 
and PBMCs (chapter 4, study II) and purification was performed according to manufacturer’s 
instructions. Briefly, the steps included lysing of erythrocytes followed by homogenization of cell 
lysates using the QIAshredder spin column. Ethanol was then added to bind total RNA to the QIAamp 
membrane and after three washes, total RNA could be eluted and stored for cDNA synthesis.  
2.7 cDNA synthesis 
QuantiTect® reverse Transcription Kit (Qiagen) was used to reverse transcribe 180-200ng total RNA 
according to the manufacturer’s instructions. Briefly, 2µl gDNA Wipeout Buffer(7X) and various 
volumes of total RNA and RNase-free water to a total volume of 14ml was mixed in a tube and 
incubated in a Thermocycler (Qiagen) for 2 min at 42°C. A Mastermix was prepared containing 1µl 
Reverse Transcriptase (RT), 1µl RT Primer mix and 4µl RT Buffer, and the mix was added to the tube 
with RNA. Tubes were then incubated in the Thermocycler for 15 min at 42°C allowing the reverse 
transcription to take place, followed by 3 min at 95°C in order to inactivate the reverse transcriptase. 
cDNA was stored until qRT-PCR analysis. 
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2.8 qRT-PCR 
Two platforms for detection of specific cDNA were used for the studies performed during the PhD. For 
detection of IFNG (IFN-γ) and CXCL10 (IP10) in 3D cultures (chapter 4, study II) and for testing the 
direct one-step blood qRT-PCR reaction (chapter 5, study III), the Rotor-Gene Q (Qiagen) qPCR 
platform (Corbett research) with Rotor-Gene 4.4.1 software was applied. This platform is convenient 
when testing the expression of a few genes. Testing the gene expression in moDCs (chapter 6 study 
IIII) was done in a 96.96 Dynamic Array Integrated Fluidic Circuits (IFC) (Fluidigm) chip, placed in a 
BioMark real time PCR instrument (Fluidigm) and analysis was done using the Fluidigm Real Time PCR 
Analysis software 3.0.2 (Fluidigm). This high-throughput BioMark platform is ideal when analyzing 
multiple genes and samples simultaneously. The protocol used for the BioMark platform, is described 
in detail in paper II. 
For the analysis of IFNG and CXCL10 gene expression in cells from 3D cultures using the Rotor-
Gene Q qPCR platform, 24µl reaction mix consisting of 12.5µl 2XMastermix (SYBR Green Jumpstart 
Taq Readymix without MgCL2, Sigma), 3µl primer mix (5µM of each primer), 3µl MgCl2 and 5.5µl MiliQ 
water was added in each PCR tube. Then 1µl of cDNA, pre-diluted 10x in miliQ water was added. A 
non-template control (NTC) was included for each primer pair to test for non-specific amplification. 
Tubes were placed in the Rotor-Gene Q instrument and the following cycle conditions were applied: 2 
min at 50°C and 10 min at 95°C followed by 40 cycles with denaturation for 15 sec at 95° and 
annealing/elongation for 1 min at 60°C. Melting curves were generated after each run to confirm a 
single PCR product (from 50°C to 95°C, increasing 1°C/5 sec).  
For testing the direct one-step blood qRT-PCR SYBR Green Kit (VitaNavi Technology), stabilized 
whole blood from bovine or goat was directly added to the reaction mix containing 16µl Blood qRT-
PCR mix, 0.75µl Blood qRT-PCR polymerase mix, 0.5µl SYBR Green, 2.5µl primer mix (5µM of each 
primer) and MiliQ to a final volume of 25µl. Blood concentrations of 2-10% was tested. A non-
template control (NTC) was included for each primer pair to test for non-specific amplification. For 
the detection of IFNG and CXCL10, blood was pre-incubated with 1µg/ml SEB for two hours prior to 
qRT-PCR analysis. Tubes were placed in the Rotor-Gene Q instrument and the following cycle 
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conditions were applied: 58°C for 30 min (reverse transcriptase step), 95°C for 5 min (initial 
denaturation step), followed by 45 cycles of 94°C for 45 sec (denaturation step) and 63°C (or 60°C) for 
90 sec (annealing/extension). A final melting curve analysis was performed to verify a single product, 
with the temperature rising from 50°C to 99°C, increasing 1°C/5 sec. See appendix 2 for a list of 
primers used for experiments analyzed on the Rotor-Gene Q qPCR platform. 
2.9 Confocal microscopy 
For visualization of cells within 3D PS scaffolds or in the prototype chip, bovine PBMCs were purified 
as described in section 2.2, and cells were stained with Alexa Flour 647 (AF647)-conjugated anti-
bovine CD4 monoclonal IgG2a antibody (clone CC8, AbD Serotec) and AF488-conjugated anti-human 
CD14 IgG2a antibody (cross-reactive to bovine) (clone M5E2, BioLegend®). 1x106 cells in 100 µl were 
stained with a cocktail of both antibodies in a 40x dilution, washed and resuspended in RPMI medium. 
3D PS scaffolds (Alvetex®) were made hydrophilic by addition of 70% ethanol and washed in PBS prior 
to cell plating/imaging. Scaffolds and cells were imaged on a Zeiss LSM 710 confocal microscope using 
ZEN 2009 software. The microscope was inverted and equipped with an incubator for temperature 
control and imaging was performed at 37°C. Prior to plating on the scaffold, cells were mixed with SEB 
to a final concentration of 1µg/ml. Scaffolds, or scaffolds with SEB-stimulated cells, were placed 
between two glass microscope slides and imaged. Z-stacks were recorded with (in average) 25 stacks 
with 10 slices in each, and with app. 20 seconds in between stacks. Maximum projection images were 
created to show the structure of the autofluorescent scaffold. Movies intending to show cell 
migration in 2D and 3D surfaces was created using ImageJ/Fiji software.  
2.10 Light microscopy 
To visualize cell capture on the prototype chip during flow, PBMCs were purified from goat whole 
blood, and heated to 37°C in an incubator. Using a sp260p syringe pump (WPI, Florida, USA) with a 
20ml Luer syringe (Omnifix), elbow Luer connector and silicone tubing (Ibidi GmbH, Germany), cell 
flow and capture was imaged on an inverted Leica DMIL contrasting microscope equipped with a Leica 
DFC290 camera (Leica Microsystems). 
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Chapter 3 - Study I (IGRA) 
3.1 Introduction 
In vitro cultures of freshly isolated primary cells are being used for cytokine release assays. IGRA is an 
assay testing the presence of a TH1-mediated CMI-response by detection of de novo produced IFN-γ 
by the cultured cells upon antigen recall. In veterinary medicine, IGRA was first used to diagnose 
infections of bovine tuberculosis and paratuberculosis (Wood et al. 1990; Rothel et al. 1992; Billman-
Jacobe et al. 1992). For this type of assay, either whole blood or purified PBMCs are typically used. 
Cultures of PBMCs consist of a mix of lymphocytes (T lymphocytes, B lymphocytes and NK cells), 
monocytes and dendritic cells, kept in synthetic media typically with a supplement of bovine serum 
containing growth factors necessary for cell survival. Apart from the mentioned cell types, whole 
blood also contains erythrocytes, platelets, and granulocytes (neutrophils, basophils and eosinophils). 
Several cell types produce IFN-γ, including CD4+ T cells, CD8+ T cells, γδ T cells and NK cells. However, 
upon antigen recall the major secretion of IFN-γ is believed to come from TH1 CD4
+ T cells.  
3.2 Hypothesis 
Due to the presence of natural occurring activating and suppressive mediators such as cytokines, 
hormones and growth factors in vivo, it is hypothesized that the activation profile of cells activated in 
settings close to their natural environment (i.e. whole blood) will differ from the activation profile of 
cells purified and kept in synthetic media with serum supplement (i.e. PBMCs). 
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3.3 Results  
Paper I 
 
Revisiting the IFN-γ release assay: Whole blood or PBMC cultures? 
- And other factors of influence 
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In this study we investigate factors of influence for the validity of interferon-gamma release assays 
performed with whole blood or peripheral blood mononuclear cells (PBMC) cultures. We find large 
differences in the optimal diagnostic conditions with each individual animal and that PBMC cultures 
are amenable to differences in cellular composition compared to whole blood. Finally, we were able 
to show effect of culture plates from different suppliers, although this effect was not statistically 
significant. We believe these studies highlight the need to include detailed descriptions of procedures 
and warrant that different conditions infer different results in the same animal. 
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Abstract  
The interferon-gamma release assay is a widely used test for the presence of a cell-mediated immune 
response in vitro. Factors potentially influencing the results when performing interferon-gamma 
release assays in cultures of bovine whole blood and PBMCs, were investigated. It was found that 
optimal culture conditions varied between individual animals; when polyclonal activated, cells from 
whole blood cultures were most responsive, but when activated specifically half of the animals had 
highest responses in whole blood cultures and half of them had highest responses in PBMC cultures. A 
further investigation of the distribution of cell populations in PBMCs compared to whole blood was 
conducted, and a significant (p<0.001) decrease in the percentage of CD3+ T cells within the PBMCs 
was found. More specifically, this reduction was due to a significant (p<0.01) decrease in the 
percentage of γδ+ T cells. Thus measuring immune responses on purified PBMCs might not give a 
physiologically relevant output. Additionally, it was tested if the choice of incubation plate would 
interfere with the level of secreted interferon-gamma in whole blood cultures. There was no 
significant difference in the interferon-gamma levels from the six incubation plates tested, but it was 
observed that six of eight calves had optimal interferon-gamma production in a flat bottom 
polystyrene plate from Corning®. Altogether these findings highlight the potential weaknesses of the 
interferon-gamma release assay in terms of the many variables that can influence the results, and 
stresses the importance of documenting the precise assay conditions when publishing results of in 
vitro interferon-gamma release assays.     
   
1. Introduction 
Cytokines are small signaling proteins produced by various cell types including cells of the immune 
system. Since specific cytokines are associated with different types of cell-mediated immune (CMI) 
responses, they can be used to characterize such responses. For example IFN-γ, IL-2, -12, -18, TNF-α, 
GM-CSF, are all associated with a T helper (TH) 1 response, IL-4, -5, -6, -10, -13, and TGF-β with a TH2 
response, IL-17, -21, -22 with TH17, and IL-10 and TGF-β with a T regulatory (Treg)  response (1). 
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Cytokines usually act in a paracrine or autocrine manner, thus being produced and taken up at local 
sites where immune reactions take place. Therefore, most cytokine levels are too low for direct 
detection in peripheral blood. Instead CMI can be analyzed in vitro by measuring the function of T 
cells in terms of their ability to proliferate and to produce cytokines in response to antigen. The IFN-γ 
release assay (IGRA) is based on the detection of de novo produced IFN-γ by cultured immune cells 
including TH1 cells. This is used to measure the efficacy of a vaccine or as a diagnostic measure to test 
if a subject is suffering from a specific intracellular pathogen, for example Mycobacterium bovis or M. 
avian subsp. paratuberculosis (MAP) in cattle or Mycobacterium tuberculosis in humans. In the latter 
case two FDA approved IGRAs exists (QuantiFERON-TB Gold in-Tube, Cellestis, Austria and T-Spot.TB, 
Oxford Immunotec, UK). IGRAs (and cytokine release assays in general) can be performed using 
cultures of whole blood or purified peripheral blood mononuclear cells (PBMCs). In the present study, 
an investigation and discussion of the different factors potentially influencing the results when testing 
CMI in vitro by means of IFN-γ secretion in cultures of whole blood or PBMCs is presented.  
 
2. Materials and methods 
2.1. Animals 
For the purpose of this study, blood was drawn using heparinized vacutainer tubes from sixteen 
Danish Jersey calves (#1-16) aged 16-22 weeks. The calves were enrolled in three preexisting 
Paratuberculosis vaccine programs, and thus had obtained different levels of antigen-specific 
immunity against a MAP peptide-antigen. The different vaccination regimes used were irrelevant for 
the present study since immunological responses were merely used to test if assay conditions/cell 
concentrations had an influence on the specific responses within each individual animal. The calves 
were housed at the animal facility at the Veterinary Institute, Technical University of Denmark, or at a 
collaborating farm and were, apart from the vaccinations, handled the same way. Not all calves were 
used for all experiments and the numbering of the calves used for the individual experiments appears 
on the figures/tables. All animals were handled in accordance with the Danish animal experiments 
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legislation and registered in studies approved by the Danish Animal Experiments Inspectorate, license 
number 2012-15-2934-00269.     
 
2.2. Isolation of PBMCs 
Fresh, heparinized whole blood was diluted 1:2 with PBS, laid on Ficoll-Paque™Plus (GE Healthcare) 
and centrifuged 2500 rpm (≈1400 x g) for 15 min at room temperature (RT) with low brake. PBMCs 
were recovered and washed twice in RPMI 1640 medium with GlutaMAX™ (Gibco, Life 
Technologies™) containing 1% heat inactivated fetal bovine serum (FCS) (Sigma). Cells were counted 
using Improved Neubauer, bright-line hemocytometer chamber (Assistent®) and diluted at different 
concentrations in medium containing 10% FCS.   
 
2.3. Stimulation and incubation of whole blood and PBMCs for comparison of IFN-γ-release  
Fresh stabilized whole blood was drawn from eight vaccinated calves (#1-8) aged 16-22 weeks. 
Samples were split in two; one half was used for PBMC purification (see above), the other half was 
used for whole blood cultures. Non-diluted whole blood and whole blood diluted 1:2 with PBS was 
plated in triplicates of 500µl in 48-well plates (Cellstar®, Greiner Bio-One). Prior to cell-plating, 50µl of 
either PBS, the superantigen Staphylococcal enterotoxin B (SEB) (Sigma), or vaccine MAP antigen 
(Statens Serum Institute) plus co-stimulatory antibodies anti-CD28 and anti-CD49d  (clone TE1A and 
FW3-218, respectively, Monoclonal Antibody Center, Washington State University) (2), all at a final 
concentration of 1µg/ml, was added to the wells. Cultures were incubated for 20 hours at 37°C, 5% 
CO2. PBMCs were purified from the other half using density gradient centrifugation, and cells were 
diluted in media with 10% FCS to obtain final concentrations of 10, 5, 2.5, 1.25 and 0.625x106 cells/ml. 
PBMCs were stimulated and incubated the same way as whole blood samples. Plates were 
centrifuged and approximately 350µl supernatant/plasma was harvested and stored at -20°C until 
further analysis. The quantity of IFN-γ in the plasma and supernatant was measured by ELISA  
 
 
 
   Paper I 
36 
 
2.4. Stimulation and incubation of whole blood for testing the effect of micro-well plates  
Fresh, heparinized whole blood from eight calves (#9-16) aged 18-22 weeks, was plated in double 
triplicates of 200µl in the following six different 96-well plates: a) Nunc™, clear, flat-bottom, 
Nunclon™ Delta surface, polystyrene, cat# 167008; b) Corning®, clear, flat-bottom, tissue culture 
treated, polystyrene, cat# 3596; c) BD Falcon® Optilux, black, clear flat-bottom, tissue culture surface, 
polystyrene, cat# 353948; d) Corning®, clear, flat-bottom, tissue culture treated, polystyrene, low 
evaporation lid, cat# 3595; e) Corning®, clear, round-bottom, tissue culture treated, polystyrene, cat# 
3799 and f) Cellstar® Greiner bio-one, clear, round bottom, tissue culture treated, polystyrene, cat# 
650108. Prior to cell-plating, 20µl of PBS, SEB or vaccine MAP antigen (both at a final concentration of 
1µg/ml) was added to the wells. Cultures were incubated for 20 hours at 37°C, 5% CO2. Plates were 
centrifuged following the addition of 55µl heparin solution (at a final concentration of 10 IU/ml) to 
avoid clotting when freezing. Approximately 140µl plasma was harvested from each well and double 
triplicates were pooled resulting in 280µl plasma in triplicates from each calf and stimulus. Plasma 
was stored at -20°C until further analysis. 
 
2.5. Measurement of IFN-γ production by ELISA 
The IFN-γ-secretion in plasma and supernatant was determined using an in-house developed 
monoclonal sandwich ELISA, as described elsewhere (3), with a few modifications. Briefly, MaxiSorp™ 
microtiter plates (Nunc) were coated overnight with 100µl anti-bovine IFN-γ F(ab)2 monoclonal 
antibody (clone 6.19) (National Veterinary Institute, Technical University of Denmark) at 0.49µg/ml. 
After a one-hour blocking with 200 µl blocking buffer (PBS, 0.05% Tween 20, 0.1% Casein) followed by 
5 washes with washing buffer (PBS, 0.05% Tween 20), 50µl blocking buffer and 50µl thawed 
supernatant/plasma was added to the wells in duplicate. A two/three-fold standard dilution series 
prepared from calf plasma stimulated with 0.2µg/ml SEB and with previously determined 
concentrations of IFN-γ was also added in duplicate to each plate in order to generate a standard 
curve used for quantification of IFN-γ levels after log-log transformation. The plates were incubated 
for 1 hour at room temperature with gentle agitation followed by 5 washes. 100µl biotinylated 
secondary anti-bovine IFN-γ monoclonal antibody (clone 6.22) (National Veterinary Institute, 
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Technical University of Denmark) was added in final concentrations of 0.95µg/ml and 0.087µg/ml 
(different batches for the ELISA used in the experiment comparing PBMC and whole blood cultures 
(figure 1) and for the experiment testing different microwell plates (figure 3)) and incubated for 1 
hour at room temperature with gentle agitation followed by 5 washes. Next, 100µl  streptavidin-
horseradish peroxidase conjugate (Invitrogen) was added at a final concentration of 0.125µg/ml and 
incubated for 1 hour at room temperature with gentle agitation followed by 5 washes. Finally, 100µl 
TMB-Plus ready-to-use substrate (Kem-En-Tec Diagnostics) was added and the plates were incubated 
at room temperature in the dark for app. 10-20 minutes. The enzyme reaction was stopped by adding 
100µl 0.5 M H2SO4 and the optical density (OD) measured at 450 nm with 650 nm as a reference using 
a Multiscan® EX reader (Thermo Scientific). The level of IFN-γ (pg/ml) was calculated by inserting the 
log-transformed OD values in the equation obtained from linear regression of the log-transformed OD 
values from the dilution series of a reference SEB stimulated plasma standard with known IFN-γ 
concentrations.  
             
2.6. Flow cytometry 
For determination of the cell distribution before and after PBMC purification, cells were stained and 
analyzed by flow cytometry. Tubes containing 100µl whole blood or PBMC (1x107cells/ml) were 
incubated with 20µl primary antibodies in the four cocktails as summarized in Table 1 for 30 minutes 
in the dark at 5°C. One ml 1X BD FACS lysis solution was added to the whole blood tubes which were 
incubated for ten minutes at room temperature in order to lyse the red blood cells.  All cells were 
washed in wash buffer (PBS, 0.1% sodium azide, 1% FCS) and incubated with a 20µl secondary 
antibody cocktail (see Table 1) for 30 minutes in the dark at 5°C. Cells were washed twice in wash 
buffer and resuspended in FACS sheath fluid containing 0.5% paraformaldehyde. For compensation 
adjustments, pooled lysed whole blood cells were stained with primary staining cocktail 1 plus either 
anti-mouse IgG1-PE or anti-mouse IgG2a-AF647 (Table 1). Cells were acquired on a BD FACSCanto™II 
flow cytometer (BD Biosciences) with a lymphocyte gate based on FSC SSC profile and the results 
were analyzed using the BD FACSDiva software version 8.0.1.  
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2.7. Statistics 
When analyzing the level of IFN-γ production, one way analysis of variance in combination with 
Bonferroni´s Multiple Comparison test was used. Two-way analysis of variance and Bonferroni´s 
posttest was used when analyzing the cell distribution in whole blood compared to PBMCs.. All 
statistical analyses were done using GraphPad Prism version 5.02. 
 
Table 1: Staining overview 
 Primary staining  Secondary staining 
Cocktail Monoclonal Absa Isotype Clone (Company)  
Secondary 
Absc 
Fluoro-
chrome 
Company 
1 
Anti-bovine CD3 
Anti-bovine CD4 
IgG1 
IgG2a 
MM1A (VMRD) 
IL-A11 (VMRD) 
Anti-IgG1 
Anti-IgG2a 
PE 
AF647 
Southern Biotechn. 
Invitrogen 
2 
Anti-bovine CD3 
Anti-bovine CD8 
IgG1 
IgG2a 
MM1A (VMRD) 
CC63 (AbD Serotec) 
Anti-IgG1 
Anti-IgG2a 
PE 
AF647 
Southern Biotechn. 
Invitrogen 
3 
Anti-bovine CD3 
Anti-bovine WC1  
IgG1 
IgG2a 
MM1A (VMRD) 
CC15 (AbD Serotec) 
Anti-IgG1 
Anti-IgG2a 
PE 
AF647 
Southern Biotechn. 
Invitrogen 
4 
Anti-bovine NKp46 
Anti-human CD14 
IgG1 
IgG2a 
AKS1b  
Tük4 (DAKO) 
Anti-IgG1 
Anti-IgG2a 
PE 
AF647 
Southern Biotechn. 
Invitrogen 
For compensation (pool of lysed whole blood cells) 
A 
Anti-bovine CD3 
Anti-bovine CD4 
IgG1 
IgG2a 
MM1A (VMRD) 
IL-A11 (VMRD) 
Anti-IgG1 PE Southern Biotechn. 
B 
Anti-bovine CD3 
Anti-bovine CD4 
IgG1 
IgG2a 
MM1A (VMRD) 
IL-A11 (VMRD) 
Anti-IgG2a AF647 Invitrogen 
a
All antibodies were generated in mouse and directed against bovine (except for CD14 which is directed against human but 
is cross-reactive against bovine. 
b 
A kind gift from Anne K Storset, Norway. 
c
Both antibodies were generated in goats and 
directed against mouse. PE, phycoerythrin; AF647, Alexa Fluor® 647      
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3. Results 
3.1. Culture conditions for optimal IFN-γ production varies from individual to individual 
Using ELISA, quantity of IFN-γ was measured from overnight cultures of whole blood, diluted whole 
blood or PBMCs at various cell concentrations (i.e. 10, 5, 2.5, 1.25, and 0.623x106 cells/ml) from eight 
calves (#1-8). Cells were incubated with MAP antigen+ co-stimulation, SEB or PBS (background).. In 
the MAP antigen-stimulated samples (Ag-specific activation) four of eight tested calves had highest 
IFN-γ production in non-diluted whole blood (calf # 2, 4, 5 and 7), two in PBMC cultures with 10x106 
cells/ml (calf # 1 and 6) and finally two calves had highest production in PBMC cultures with 5x106 
cells/ml (calf # 3 and 8) (figure 1 A). Some of the calves had very low IFN-γ levels in all incubation 
settings but they did show high levels when stimulated with SEB (polyclonal non-specific activation). 
In this case, six of eight calves had highest IFN-γ levels in non-diluted whole blood (calf # 1, 2, 3, 4, 5 
and 7), one in the diluted whole blood culture (calf # 6), and one had highest level in PBMC cultures 
with 10x106 cells/ml (calf # 8) (figure 1 B). In general, the background concentration of IFN-γ was low 
but there was a tendency of higher levels in whole blood cultures compared to PBMC cultures (figure 
1 C).  
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Figure 1) Mode of activation and type of cell culture population influences the IFN-γ release  
Stabilized fresh whole blood, diluted whole blood and titrations of purified PBMCs from eight vaccinated calves (#1-8) 
were stimulated with MAP antigen + co-stimulation (A), SEB (B) or PBS as a negative control (C) and incubated 20 hours at 
37°C and 5% CO2. Plasma and supernatant was analyzed for IFN-γ levels by ELISA.  Left graphs: shows the mean + SD of 
three technical replicates from each calf. Arrows indicate individual IFN-γ level optima. Right graphs: shows the mean + 
SEM of all eight calves. A statistical difference in IFN-γ levels was observed for whole blood (WB) cultures compared to 
PBMC cultures with concentrations equal to or less than 5x10
6
 cells/ml in polyclonal activated cultures. Statistics: One way 
ANOVA and Bonferroni’s Multiple Comparison test (n=8), ** = p<0.01, * = p<0.05. 
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3.2. Selective cell loss of γδ-T cells during PBMC purification 
In order to investigate if isolation of PBMCs by density gradient centrifugation had an influence on cell 
distribution, unstimulated whole blood and PBMCs from seven calves (same animals as above, only 
samples from one animal (#4) was discarded due to technical errors) were stained for selected surface 
markers and analyzed by flow cytometry (figure 2). A significant decrease in the percentage of CD3+ T 
cells was observed within the mononuclear leukocyte population from PBMCs compared to whole 
blood (from 64.5% to 55.3%). No difference in the distribution of NK cells and monocytes was 
detected. Since the cells were gated on the mononuclear leukocytes the granulocytes present in 
whole blood samples did not influence the relative levels. Further gating on the CD3+ T cells showed a 
significant loss of γδ+ T cells in the PBMCs (from 28.8% to 22.9%) while no significant difference was 
seen for the CD4+ - and CD8+ T cells.  
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Figure 2) Selective loss of γδ T cells after PBMC purification 
Stabilized fresh whole blood and purified PBMCs from seven calves (#1, 2, 3, 5, 6, 7, and 8) were stained for surface 
markers and analyzed by flow cytometry in parallel. A) Gating strategy. Nkp46
+
 = NK cells, CD14
+
 = monocytes, CD3
+
/CD4
+
 
= CD4
+
 T cells, CD3
+
/CD8
+
 = CD8
+
 T cells, CD3
+
/WC1
+
 = γδ T cells. B) Bar graph showing the distribution of cell 
subpopulations within whole blood and PBMCs. Top graph: percent of total mononuclear leukocytes, bottom graph: 
percent of total CD3
+
 cells.  Statistics: Two way ANOVA and Bonferroni posttest (n=7), *** = p<0.001, ** = p<0.01. 
 
3.3. No significant effect of incubation plate on whole blood IGRA performance 
When cells are incubated for in vitro stimulation assays, it is typically done in micro-well plates. These 
are commercially available from several companies and are often tissue culture treated for optimal 
cell performance. It could be speculated if choice of incubation plate would influence the levels of 
IFN-γ since the surface-treatment and shape of the micro wells differ between brands. To clarify this, 
a whole blood stimulation assay using stabilized blood from eight vaccinated 18-22 weeks old calves 
(#9-16) was conducted in 6 different culture plates. Two of the animals (#12 and 15) belonged to a 
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non-vaccinated control group, but were included in order to cover all ranges of activation. Stimulation 
was done with MAP antigen, SEB or PBS (background) and after 20 hours of incubation at 37°C, 5% 
CO2 plasma was harvested and used for IFN-γ quantification by ELISA. No significant difference was 
found between the six plates tested when looking at IFN-γ levels after both polyclonal and Ag-specific 
activation (figure 3). However, 5 out of 6 animals had their highest IFN-γ concentrations following Ag-
specific activation when incubated on plate b, and the relative-to-maximum concentration showed 
that plate b had significantly higher relative concentration compared to plate a and e (Table 2).      
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Figure 3) Effect of incubation plate on level of IFN-γ production 
Stabilized whole blood from eight calves (#9-16) was stimulated with SEB (1µg/ml) or MAP antigen (1µg/ml) for 20 hours 
at 37°C and 5% CO2 in six different 96 well-microtiter plates. Plasma was harvested and analyzed for IFN-γ by ELISA. The 
plates tested were: a) Nunc™, clear, flat-bottom, Nunclon™ Delta surface, polystyrene, cat# 167008; b) Corning®, clear, 
flat-bottom, tissue culture treated, polystyrene, cat# 3596: c) BD Falcon® Optilux, black, clear flat-bottom, tissue culture 
surface, polystyrene, cat# 353948: d) Corning®, clear, flat-bottom, tissue culture treated, polystyrene, cat# 3595; e) 
Corning®, clear, round-bottom, tissue culture treated, polystyrene, cat# 3799 and f) Cellstar® Greiner bio-one, clear, round 
bottom, tissue culture treated, polystyrene, cat# 650108. Shown is the IFN-γ concentration (pg/ml) of SEB-stimulated 
whole blood (polyclonal activation) and MAP antigen-stimulated whole blood (Ag-specific activation). Background levels of 
IFN-γ (PBS) have been subtracted and each value represents the mean of three technical replicates. 
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Table 2: Relative-to-maximum IFN-γ concentration (%)  
 Polyclonal activation  Ag-specific activation  
Animal # a b c d e f  a ba c d e f  
9 80 100 80 72 95 66  41 100 52 40 56 36  
10 69 69 58 75 68 100  79 100 53 72 50 44  
11 92 91 65 85 82 100  74 100 52 74 74 93  
12 100 87 71 75 76 78  51 100 66 52 62 62  
13 100 97 95 97 99 85  8 100 80 62 63 50  
14 97 76 100 83 81 84  81 99 98 98 68 100  
15 100 70 58 63 65 56  4 15 100 7 75 16  
16 86 86 87 83 100 83  49 100 57 50 59 63  
Average 90 84 77 79 83 81  48 77 70 57 63 58  
Relative IFN-γ concentration within each calf (#9-16) on the different incubation plates (a-f). Highest 
concentration is set to 100%. 
a 
The average relative concentration on plate b is significant compared to 
plate a (p>0.05). Statistics = One way ANOVA and Bonferroni’s Multiple Comparison test 
 
4. Discussion 
In vitro measurement of CMI responses is an important tool for vaccine evaluation and disease 
detection. When performing this type of assay, one question is whether to use whole blood- or PBMC 
cultures for the basis of CMI response detection. This study compares IFN-γ levels upon antigen recall 
(i.e. Ag-specific activation), superantigen stimulation (i.e. polyclonal non-specific activation) and 
background levels in cultures of both whole blood and PBMCs (figure 1). The optimal culture 
conditions varied between animals; when activated specifically via recall MAP antigen, half of the 
animals showed highest IFN-γ production in whole blood cultures with an average cell concentration 
of 7.9x106 cells/ml, and half of them had optimal conditions in PBMC cultures with the two highest 
cell concentrations (i.e. 10- and 5x106 cells/ml). When averaging the response from the eight calves, 
5x106cells/ml seemed to be the optimal PBMC concentration with a response similar to the non-
diluted whole blood samples. The individual cell concentration-, and maybe more important, the 
individual cell population optima (i.e. whole blood or PBMC), makes it difficult to choose the best 
assay conditions. Calf # 3 is a disturbing example of an animal that only shows high IFN-γ levels in the 
PBMC but not in whole blood cultures during Ag-specific activation. 
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In the polyclonal activated cultures, numerous CD4+ T cells are able to become activated since 
SEB, as a superantigen, non-specifically cross-binds the variable part of the β-chain (Vβ) of the T cell 
receptor and the MHC class II on the antigen presenting cell, resulting in activation and cytokine 
release, especially IFN-γ (4, 5). Thus, higher cell concentration theoretically equals higher IFN-γ 
release. In the present study the highest response was seen in the whole blood cultures, with the 
exception of one calf which had optimum IFN-γ levels in the PBMC 10x106 cells/ml culture. On 
average the PBMC did not have an optimal concentration comparable to whole blood samples as was 
the case with the Ag-specific activation. Following the polyclonal activation, the whole blood assay 
resulted in more than twice the amount of IFN-γ compared to the optimal PBMC assay (with 10x106 
cells/ml). This indicates that factors other than the total cell number influence the IFN-γ production. 
This could be due to granulocytes and platelets present in whole blood cultures but absent in PBMC 
cultures, and studies have shown that both granulocytes and platelets are able to produce cytokines 
(6–8). Other factors possibly present in the autologous plasma of the whole blood cultures include 
cytokines, soluble cytokine receptors and antagonists and growth factors – elements that potentially 
are important regulators of cell viability (9). In a study of apoptosis, Hodge and colleagues found a 
greater level of leukocyte apoptosis in human PBMC cultures compared to whole blood cultures 
following stimulation (9). Maybe not surprisingly they observed a decreased percentage of IFN-γ-
producing T cells in the Annexin V-positive apoptotic cells population compared to the viable 
population. Thus, if the PBMCs have an increased tendency to become apoptotic during culture, this 
may explain the lower levels of IFN-γ in cultures of PBMC compared to whole blood cultures seen in 
the polyclonal non-specific activation assays.  
This phenomenon of lower IFN-γ levels in cultures of PBMC, however, does not apply to the 
assays of specific activation. One explanation could be that when cells are non-specifically stimulated 
with a superantigen such as SEB they will be more prone to apoptosis as a result of exhaustion due to 
the massive activation as compared to PBMCs that have undergone Ag-specific activation. 
Interestingly, Hodge and colleagues found that the addition of plasma could protect PBMCs from 
apoptosis (9). It is therefore likely that survival factors present in whole blood contribute to the higher 
IFN-γ levels observed in these cultures.  
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A concern when using PBMC cultures is the risk of losing cells during the purification process. 
This could affect the overall distribution of cells in the sample, thus introducing a bias in the cell-
mediated response observed after in vitro stimulation. Therefore, the distribution of cells in PBMCs 
and whole blood was compared, and a significant decrease in the percentage of γδ-T cells was found. 
Since this cell type is an important early contributor to the IFN-γ production during a CMI response 
after stimulation (10), the results obtained from in vitro-stimulated PBMC cultures may be somewhat 
misleading. Other groups have also found selective cell loss after PBMC purification. De Groote et al. 
describes a decreased ratio of monocytes:lymphocytes (monocytes concentrations being reduced) 
after PBMC purification using ready-to-use leukoprep tubes (Becton Dickinson) (11). They speculate 
that monocytes disappear due to adsorption to structures such as glass and gels used during the 
purification process. Their isolation system is different from the one used in the present study (Ficoll-
Paque™Plus, GE Healthcare) which might explain the discrepancy in the type of cell-loss. Also they 
look at human, not bovine cells. Another study by Hokland and Heron on purification of human 
PBMCs reports selective cell loss of T cells when using Isopaque-Ficoll with a density of 1.076 g/ml 
(12). They found that the cell-loss was due to autorosette formation in which some cells, primarily T 
cells, were binding to red blood cells and were lost due to the higher density of the rosettes. 
Numerous studies of bovine PBMCs have used Ficoll for separation with a density of 1.077 g/ml, as in 
the present study (2, 13–16).  
To our knowledge this is the first study reporting selective cell loss of bovine T cell subsets 
during PBMC purification. It is a possibility, however, that the actual number of CD3+/γδ+ T cells 
present after PBMC purification is not detected due to surface marker internalization. This has been 
described in mice by Koenecke and colleagues who found that mAbs targeting the γδ+ T cells used in a 
depletion model, actually did not result in γδ+ T cell depletion, but instead induced γδ T cell receptor 
(TCR) internalization generating “invisible” cells (17). If the anti-γδ+ T cell antibody used in the present 
study should result in internalization of the receptor, this does not explain the difference in the two 
cell populations though. The internalization would have to happen after PBMC purification but before 
staining in order to explain the difference. The same applies for the CD3 marker. If the decrease in γδ 
TCR and CD3 is caused by internalization of multiple surface markers due to PBMC purification or in 
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fact caused by loss of a cell subset during the purification process, can only be speculated. If the 
former is the case, then the presence of cells being CD3 negative and γδ TCR positive (i.e. cells that 
have internalized CD3 but not γδ TCR) would be expected, but this is not the case (data not shown). 
The observation of selective cell loss during purification deserves attention and should be taken into 
account when PBMC assays are used for measurement of CMI responses.  
The variety of culture plates available for cell-incubation assays are plenty and the choice of 
plate used in published studies is rarely described nor elaborated on. Therefore, a comparison of the 
IFN-γ levels in antigen-specific and polyclonal activated whole blood cultures incubated in six 
commercially available cell-incubation plates was performed. Even though the overall level of IFN-γ 
did not differ significantly across the different plates in both cultures, it was observed that six out of 
eight calves had highest specific IFN-γ levels when incubated on plate b (Corning®, clear, flat-bottom, 
tissue culture treated, polystyrene, cat# 3596), and that this relative level was significant compared to 
plate a, which was from Nunc™. Based on the present experiment it seems that flat bottom plates 
from Corning® was the optimal plate, although it remains unresolved why polyclonal SEB stimulation 
was less responsive than  antigen-specific stimulation to the type of culture plate.  
 
Choosing whether to use whole blood and PBMC assays or choosing which PBMC 
concentration to use for in vitro stimulation experiments is complex due to individual cell 
concentration optima. A number of studies have focused on comparing cytokine levels in cultures of 
human whole blood and PBMCs measured by ELISA (18–20), cytokine arrays (11, 21, 22) or by 
measuring the intracellular cytokine concentration using flow cytometry (9, 23). Most of these studies 
come to the conclusion that whole blood assays correlates well with PBMC cultures and are even 
preferable since this type of assay require no complex cell separation steps which saves both time and 
money and only requires small amounts of blood. On the contrary, Silberer and colleagues who 
compared cytokine release from cultures of diluted (1:5) whole blood and PBMCs (106 cells/well) in 25 
human volunteers found no correlation of the IFN-γ levels in the two culture systems (24). 
Additionally they observed a significant increase in IFN-γ levels in serum-free PBMC cultures 
compared to PBMCs cultured in medium containing fetal bovine serum (FBS). Altogether they 
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conclude that a standardized approach with clearly defined culture conditions is needed for better 
comparability of cytokine data in the literature. The relevance of this request is further emphasized 
with the data presented here. Table 3 summarizes the advantages and disadvantages of using whole 
blood compared to PBMC cultures for IFN-γ release assays. If the purpose of the assay is to measure 
CMI responses against e.g. vaccine antigens in order to assess the quality of a vaccine or for diagnostic 
purposes, then whole blood cultures is preferable since the physiological conditions (such as cell-cell 
communications, cell ratios, growth factors, cytokines and other regulators) are preserved. This can 
be important since some cells rely on the presence of IL-2 for survival, and when removed they 
undergo apoptosis (25). In respect to this, the whole blood assay thus reflects the in vivo milieu in the 
most appropriate way. If long term incubation is needed, or if the purpose of the assay is to compare 
the in vitro-effect of different drugs on an exact number of cells, then PBMC cultures could be 
preferable.  
In conclusion, this study shows the potential weaknesses of IFN-γ release assays in terms of 
the many variables that can influence the results. A difference in the response when comparing whole 
blood assays with PBMC assays was observed.  The highest IFN-γ levels was found in a plate from 
Corning® (cat# 3596) following specific activation in 6 out of 8 calves tested. Last but most 
importantly, it was shown that purification of PBMC using Ficoll-Paque™Plus resulted in selective loss 
of γδ T cells. This highlights the limitations of the assay and stresses the importance of documenting 
the precise assay conditions when publishing results of in vitro IFN-γ release assays, or cytokine 
release assays in general. 
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Table 3: Advantages and disadvantages of whole blood compared to PBMC cultures for cytokine 
release assays 
Characteristic Whole blood cultures PBMC cultures 
Ease of 
performing 
Immediate culture   
Time-consuming cell separation 
necessary 
 
Sample volume Small blood sample  
Require larger blood volumes due to 
the purification process 
 
Cell 
environment 
Cells are kept in their natural 
environment and physiological 
proportions of blood-borne 
regulatory mediators are present    
 
Cells are kept in synthetic media 
containing serum containing 
hormones and nutrients that can 
influence the immunological 
responsiveness of the cells 
 (26) 
 
Cell number 
Cell number is unknown and may 
vary from donor to donor 
 
Cell number is controlled, helping 
standardizing the assay 
 
Culture period 
Only suited for short term culture 
due to granulocyte lysis in cultures 
beyond 48 hours, but most 
cytokines are produced within this 
time frame 
(9) 
(11) 
(27) 
Long term culture possible due to 
sufficient nutrient supply within the 
media 
 
Cell loss No cell loss  
Risk of selective cell loss during 
purification potentially resulting in 
skewed cell ratios 
(11) 
Apoptosis No apoptosis in short term culture  
Increased apoptosis which may mask 
the intensity of immunological 
responses due to lower levels of 
produced cytokines 
 (9) 
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Chapter 4 - Study II (3D IGRA) 
4.1 Introduction 
The initiation of CMI responses requires the presentation of antigen peptides by APCs to rare T 
lymphocytes having TCRs specific for the unique antigen:MHC complex. This compares to finding a 
needle in a haystack with frequencies of naïve epitope specific T lymphocytes ranging from 0.2-10 per 
million naïve CD4+ T lymphocytes in humans (Kwok et al. 2012; Jenkins & Moon 2012). This challenge 
is solved in vivo by the internal structures of lymph nodes. Lymphoid tissues consist of a scaffold of 
fibers (or reticular network) enwrapped by fibroblastic reticular cells (FRC). The tissue contains ECM 
proteins such as collagens, laminin, fibronectin, and tenascin, and enables T lymphocytes to migrate 
whereas APCs settle within the network (Sobocinski et al. 2010). It has been estimated that DCs can 
scan 0.5-5x103 T lymphocytes per hour within the lymph node and thus the reticular network 
constitutes an optimal structural geometry that promote APC/T lymphocytes contact (Bousso & 
Robey 2003; Miller et al. 2004; Gretz et al. 1996).  
When measuring CMI responses in vitro by IGRA it is not a primary activation that takes place in the 
culture well, but a re-activation of memory cells. Thus the number of cognate T lymphocytes with 
specificities toward the antigen:MHC complex presented by APCs is higher by around two orders of 
magnitude (Kwok et al. 2012). Nevertheless, the cell-cell contact is essential and no special measures 
are done to facilitate this contact in a conventional 2D culture setup.  
4.2 Hypothesis 
Cells cultured in vitro are placed in an environment that is very far from their natural milieu and thus 
might behave somewhat different compared to in vivo. It is hypothesized that when measuring 
cytokine responses from cells cultured on a 2D surface, the full potential of these cells is not obtained 
as they are not able to migrate and engage in cell-cell contact in an optimal way. Therefore, we 
speculated if culturing cells on a 3D surface would facilitate structured cell migration thus facilitating
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contact between T lymphocytes and their cognate antigen presented by non-migrating monocytes, 
resulting in increased IFN-γ levels.  
4.3 Results 
In this section the results from several studies of IGRA-optimization in the form of 3D culture is 
presented.  In an attempt to mimic the structural network of a lymph node in a simplified version, a 
culture setup was developed that included a scaffold made of glass wool coated with a mix of ECM 
proteins and which made use of gravity as a means of generating a flow of cells through the coated 
glass wool fibers. Glass wool fibers were placed in thin 1 ml syringes and bovine whole blood or 
PBMCs from two previously MAP infected animals was added together with antigen (Figure 6). 
Following overnight culture total RNA was purified and used for detection of IFNG and CXCL10 cDNA 
(coding for IFN-γ and IP10 protein, respectively) using qRT-PCR. Both IFNG and CXCL10 was expressed 
at higher levels in both PPDj-stimulated whole blood and PBMC cultures containing glass wool 
compared to control cultures (with no glass wool) (Figure 7). Coating the glass wool with ECM 
proteins did not seem to have a positive effect on the expression levels of IFNG and CXCL10. An 
overall trend was increased non-specific activation within the 3D cultures as seen by elevated 
background expression levels in non-stimulated cultures.      
 
Figure 6: Glass wool-mediated gravity flow culture setup. Left: Illustration showing the culture setup, right: photograph 
of the setup.  
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Figure 7: Glass wool-mediated gravity flow experiment. App. 1 ml of Whole blood or PBMCs from two calves were added 
to 1ml syringes and incubated for 22 hours with or without addition of PPDj (10µg/ml). Prior to addition of cells, the 
syringes were filled with glass wool, MaxGel-coated glass wool or kept empty as control. After incubation, cells from flow 
through were saved and used for IFNG and CXCL10 gene expression analysis using qRT-PCR. Shown is mean+SEM of 
relative expression from the two calves where least expression (highest Cq) is set to 1. Data were normalized to 
peptidylprolyl isomerase A (PPIA).      
 
When looking at expression on RNA levels, the incubation time necessary for mRNA detection is 
shorter than when looking at protein level. Therefore a new experiment was set up with incubation 
times of 1.5, 5 and 22 hours (Figure 8). In this experiment, stabilized whole blood from two previously 
MAP infected calves were stimulated with PPDj for the given time intervals followed by RNA isolation, 
cDNA synthesis and qRT-PCR analysis. This time cells were cultured in 48 well plates, thus no extra 
“gravity” element was included in the setup. Again glass wool was used as 3D scaffold in an ECM-
coated and non-coated version. In addition also shavings made of polypropylene (PPS) were included 
in the experiment as an additional 3D scaffold to be tested.  
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Figure 8: Kinetics of IFNG and CXCL10 gene expression in 3D cultures. Whole blood from two calves was incubated in 
duplicate for 1.5, 5, or 20 hours in 48-well plates with or without the addition of PPDj (10µg/ml). The cell cultures 
consisted of (from left): Three-dimensional glass wool, MaxGel-coated three-dimensional glass wool, three dimensional 
polypropylene shavings and two-dimensional polystyrene (control). After incubation, cells were saved and used for IFNG 
and CXCL10 gene expression analysis by qRT-PCR. Shown is mean+SEM of relative expression from the two calves where 
least expression (highest Cq) is set to 1. Data were normalized to hypoxanthine phosphoribosyltransferase 1 (HPRT1) and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
 
Peak expression of both CXCL10 and IFNG was measured after 5 hours of incubation. Surprisingly the 
background level of expression was equal to, or higher than, the expression from the PPDj-stimulated 
cells. This was seen for both CXCL10 and IFNG. Since the high background levels was observed in both 
3D glass wool and PPS samples as well as the 2D control, this indicated that the cells must have been 
activated prior to culture but as the background expression was found to be higher in 3D cultures this 
suggest an additional 3D effect on the non-specific activation of the cells.   
 
Glass wool fibers are an untraditional choice of 3D scaffold usually used for filtering purposes 
and there are only a few publications reporting its use for cell culture (Snapka 1979; Korohoda 1972). 
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However the well-known ability of monocytic cells to adhere to glass combined with the increased 
surface area provided by the fibers while allowing medium exchange, in theory makes glass wool an 
attractive 3D scaffold. When harvesting cells for RNA purification, a bias may be introduced if some 
cell subsets within the blood preferably stick to the glass wool compared to other subsets, resulting in 
an unrepresentative cell pool used for analysis. To avoid this, the expression of IFN-γ on protein level 
was analyzed on whole blood from two previously MAP infected calves (Figure 9). In this procedure 
cells were not isolated but plasma was harvested and tested for IFN-γ protein using ELISA, thus the 
potential difference in stickiness of cell subsets had no effect on the results.  
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Figure 9: IFN-γ protein expression in 3D cultures. Whole blood from two calves was incubated in duplicate for 22 hours in 
48 well plates with or without the addition of PPDj (10µg/ml). The cell cultures consisted of (from left): three dimensional 
glass wool, MaxGel-Coated three dimensional glass wool, three dimensional polypropylene shavings, two dimensional 
polystyrene coated with MaxGel, two dimensional polystyrene coated with Matrigel and two dimensional polystyrene 
(control). After incubation, plasma was harvested and used for IFN-γ detection by ELISA. Each bar represents the 
mean+SEM of the two calves.    
   
The IFN-γ protein levels were decreased in 3D cultures of glass wool, ECM-coated glass wool and PPS 
cultures compared to conventional 2D culture. Coating the culture surface with either of two 
commercial available ECM protein mixes resulted in the same level of expression as the control 
culture.  
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One of the advantages of using 3D scaffolds is the number of cells that can be cultured. Due to 
increased surface areas, a larger number of cells can be plated without the risk of apoptosis due to 
insufficient nutrient supply. In fact having the right cell concentration might be crucial when testing 
immunological responses using IGRA. This also relates to the size of the culture wells used; a large 
well size with a low cell concentration may not facilitate cell encounter and thus result in IFN-γ levels 
below the detection limit, whereas a high cell concentration in a small well size may result in cell 
crowding and apoptosis. The effect of well size when performing IGRA in a 2D culture setup was 
tested using freshly isolated PBMCs from one previously vaccinated calf (Figure 10). Cells were 
cultured in two concentrations; 1x106 and 1x107 cells/ml, corresponding to 2x105 and 2x106 cells/well, 
in both 12- and 48-well plates (with wells having surface areas of approximately 3.8 cm2 and 0.95cm2, 
respectively).       
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Figure 10: Effect of well size and cell concentration on IFN-γ protein secretion. PBMCs from one calf was incubated for 20 
hours in 12 or 48 well plates in concentrations corresponding to 2x10
5
cells/well and 2x10
6
cells/well, with the addition of 
either 1µg/ml SEB (polyclonal activation), 1µg/ml MAP antigen (specific activation) or PBS (background). After incubation, 
supernatant was harvested and used for IFN-γ detection by ELISA.  
 
Background levels of IFN-γ were low in cultures of both cell concentrations and well sizes. Cells were 
activated with MAP antigen (specific activation) and with SEB (polyclonal activation). A higher 
response was detected from cultures with the high cell concentration. For the polyclonal activated 
cells, IFN-γ secretion levels were ten and three times higher in the high cell concentration cultures 
compared to the low cell concentration cultures in the 12- and 48-well plates cultures, respectively. 
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For the specifically activated cells, the same level of IFN-γ secretion was detected in the 48-well plate 
cultures of both cell concentrations. However the secretion of IFN-γ from specifically activated cells in 
the low cell concentration, was below the limits of detection (5 pg/ml) when cultured in 12-well 
plates. Increasing the cell concentration or reducing the culture area resulted in detectable levels of 
IFN-γ (1002 and 179 pg/ml, respectively). When both reducing the culture area and increasing the cell 
concentration, this did not have a synergistic effect on the level of IFN-γ, suggesting that adding 2x106 
cells in 0.95cm2 (48-well plate) exceeds the optimal cell density.  
 
To test if the addition of a 3D scaffold made of the same material (PS) had an effect on the 
optimal cell density used for IGRA cultures, a commercial available 3D PS scaffold fitting into the well 
of a 12-well plate was tested on PBMCs from the same calf as the previous experiment (Figure 11).   
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Figure 11: Effect of 3D culture and cell concentration on IFN-γ protein secretion. PBMCs from one calf were incubated for 
20 hours in 48 well plates in concentrations corresponding to 2x10
5
cells/well and 2x10
6
cells/well, with the addition of 
either 1µg/ml SEB (polyclonal activation), 1µg/ml MAP antigen (specific activation) or PBS (background). The cell cultures 
consisted of either three dimensional polystyrene scaffolds (3D scaffold, Alvetex®) or two dimensional polystyrene (2D, no 
scaffold). After incubation, supernatant was harvested and used for IFN-γ detection by ELISA.  
 
When cells were cultured on the 3D scaffold in a low cell concentration, secreted IFN-γ was below 
detection limit in both cultures of polyclonal and specifically activated cells. When culturing cells at 
the high cell concentration, 3D cultures resulted in detectable IFN-γ levels (3263 pg/ml and 184 pg/ml 
for polyclonal and specifically activated cells, respectively), but they did not exceed the levels 
detected in 2D cultures (3975 pg/ml and 1002 pg/ml for polyclonal and specifically activated cells, 
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respectively).  This indicated that the surface area in wells of 12-well plates were large enough to 
avoid crowding of cells when 2x106 cells were added, and the addition of a 3D scaffold did not 
increase the activation of cells probably due to too low cell density within the scaffold. Therefore the 
following experiments were done using 48- or 96-well plates in order to minimise the number of cells 
plated in each well.  
Results so far indicated that changing the culture setup from 2D to 3D did not improve cell 
migration and activation in IGRA. Glass wool, PP shavings and 3D PS scaffolds did either not result in 
increased IFN-γ levels compared to 2D cultures, or gave rise to elevated background activation. 
Therefore a new 3D scaffold was tested. This time the 3D scaffold was made of PDMS polymer 
fabricated using sugar cubes resulting in square scaffolds with pore sizes ranging from 300-600µm and 
fitting into wells of 48-well plates. Stabilised whole blood and PBMCs from two calves were cultured 
overnight with or without the addition of a polyclonal activator (SEB) and the level of IFN-γ in plasma 
was measured by ELISA (Figure 12).      
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Figure 12: 3D cultures in PDMS sugar cubes. Whole blood and PBMCs from two calves were incubated for 22 hours in a 48 
well plate (PBMC = 2.5x10
6
cells/well) with or without the addition of SEB (1µg/ml). The cell cultures consisted of (from 
left): three dimensional polydimethylsiloxane scaffolds, Matrigel-coated three dimensional polydimethylsiloxane scaffolds 
and two dimensional polystyrene (control). After incubation, plasma/supernatant was harvested and used for IFN-γ 
detection by ELISA. Each bar represents the mean+SEM of the two calves.  
 
The same level of IFN-γ could be detected in polyclonal activated cultures with 3D PDMS scaffolds, 
ECM-coated 3D PDMS scaffolds and 2D PS cultures with PBMCs. Whole blood cultures resulted in 
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increased IFN-γ levels compared to PBMC cultures, and 3D cultures had a slightly positive effect on 
the IFN-γ levels. However, once again there was a noticeable increase in non-specific activation of 
cells cultured in 3D compared to 2D.  
For routine testing, the costs of IGRAs will have to be kept low as there is no point in 
developing an improved 3D assay if the expense for performing the test makes it unattractive. With 
that in mind, 3D scaffolds made of filter paper disks punched to fit into the wells of 96-well plates 
were prepared.  To increase the T cell motility and thus the chance of activation, disks were coated 
with CCL21 chemokine. When coated onto culture surfaces, CCL21 have previously shown to trigger T 
cell locomotion in vitro (Woolf et al. 2007), as well as being responsible for increased in vitro T cell 
proliferation and activation after TCR stimulation (Gollmer et al. 2009). Therefore, an experiment was 
set up testing the effect of 3D scaffolds made of filter paper combined with CCL21 in a coated and 
soluble form, using stabilized whole blood or PBMCs from two calves (Figure 13).   
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Figure 13: 3D cultures using filter paper. Whole blood and PBMCs from two calves were incubated in triplicate for 20 
hours in 96-well plates (PBMCs = 1x10
6
 cells/well) with or without the addition of SEB (1 or 0.1 µg/ml). The cell cultures 
consisted of (from left): three dimensional filter paper grade 4, CCL21-coated three dimensional filter paper grade 4, three 
dimensional filter paper grade 4 with soluble CCL21 and 2D polystyrene (control). After incubation, plasma/supernatant 
was harvested and used for IFN-γ detection by ELISA. Each bar represents the mean + SD of three technical replicates.    
 
Highest responses were observed in cultures of whole blood. Whereas no difference in the IFN-γ 
levels were detectable in whole blood from calf B in the different culture setups stimulated with 
1µg/ml SEB, a slight increase in IFN-γ concentrations was detected when stimulated with 0.1µg/ml 
SEB in filter paper-cultures compared to control. In calf A, a more profound difference in IFN-γ levels 
in filter paper cultures with CCL21 compared to control was observed in whole blood stimulated with 
both concentrations of SEB. However, the 3D cultures gave once again rise to non-specific activation 
as opposed to conventional 2D culture. For the PBMC cultures, no difference in IFN-γ concentrations 
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was observed in the different culture setups in calf A, whereas a three-fold decrease in IFN-γ 
concentrations was detected in 3D cultures from calf B.   
 
The few number of animals used in the previous experiments, makes it difficult to conclude on 
the results. Therefore, to sum up the results in one final experiment, PBMCs from six calves were 
polyclonal activated in conventional 2D cultures (tissue culture treated and non-tissue culture 
treated) as well as 3D cultures consisting of 3D PS scaffolds, 3D PCL scaffolds and filter paper disks, all 
either coated with CCL21 or non-coated (Figure 14).  
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Figure 14: 3D cultures coated with CCL21. PBMCs from six calves were incubated in triplicate for 21 hours in 96-well 
plates (1x10
5
 cells/well) with or without the addition of SEB (1µg/ml). Half of the wells/scaffolds were coated with CCL21 
chemokine (1µg/ml) prior to cell plating. The cell cultures consisted of (from left): tissue culture treated two dimensional 
polystyrene (control), non-treated two dimensional polystyrene, three dimensional polystyrene scaffolds, three 
dimensional polycaprolactone scaffolds and three dimensional filter paper grade 4. After incubation, supernatant was 
harvested and used for IFN-γ detection by ELISA. Each dot represents the mean of three technical replicates and the 
horizontal line represents the mean of six calves. Statistics = One way ANOVA + Dunnett´s Multiple Comparison Test. 
(n=6), ***p≤ 0.001, *P≤0.5. 
 
Common for all 3D cultures was a decreased concentration of IFN-γ compared to control, and this 
decrease was significant in all but CCL21-coated 3D PCL cultures. Non-specific activation was not 
detected and CCL21 did not seem to have a positive effect on T cell activation and thus IFN-γ levels. 
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There was no significant difference in tissue culture-treated and non-tissue culture-treated 2D 
cultures.  
 
In conclusion, the attempt to improve IGRAs by introducing a 3D scaffold to the cultures did 
not succeed. Several scaffolds resulted in non-specific activation. When using scaffolds of different 
material than the control surface made of PS, it can be difficult to elucidate whether the effect came 
from the 3D architecture or from properties caused by the shift in material. To this end, the 3D PS 
scaffold makes a good candidate for narrowing the change in parameters to only apply to architecture 
and not material. Confocal microscopy was used to visualize the architecture of the 3D PS scaffold 
(Figure 15).       
 
Figure 15: Confocal Images of 3D PS scaffold (Alvetex®). Z-stack images were recorded on a Zeiss LSM710 confocal 
microscope with ZEN 2009 software. Left: maximum projection image of the 3D PS scaffold, middle: topography of 3D PS 
scaffold, right: 3D PS scaffold with incubated PBMCs stained for CD4
+
 T (red) and CD14
+
 monocytes (green) using 
fluorophore-conjugated antibodies. The 3D PS scaffold was autofluorescent and could therefore be visualized without 
staining the scaffold.   
     
Left image illustrate the architecture of the 3D PS scaffold by autoflorescence and the middle image 
show the topography of the scaffold. Right image illustrates the scaffold with cultured PBMCs stained 
for CD4 (red) and CD14 (green), to show CD4+ T lymphocytes and monocytes, respectively. Due to 
bleaching it was not possible to obtain good-quality images/movies for visualization of possible T 
lymphocyte migration within the 3D scaffolds. Migration on 2D surfaces (glass slide) was visualized 
and an example is shown in Figure 16.   
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Figure 16: CD4
+
 T lymphocyte migration on 2D surface. SEB-stimulated, stained cells were imaged by time-lapse on a 2D 
surface (glass slide) using Zeiss LSM710 confocal microscope, ZEN 2009 software. Migration was tracked using Fiji 
software, manual tracking.   
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Chapter 5 - Study III (chip prototype) 
5.1 Introduction 
The miniaturization of tests and assays usually performed in the lab was first described in 1975 when 
C.S Terry designed a miniaturized analytical device for gas chromatography as part of his PhD 
dissertation (Terry 1975). Fifteen years later, in 1990, Manz and colleagues created the term “micro 
total analysis system” or “µTAS” (Manz et al. 1990) and this was the beginning of the lab-on-a-chip 
renaissance (Berthier et al. 2012). The idea with lab-on-a-chip is the integration of one or several 
laboratory functions on a single chip. This has several advantages such as reduced sample and reagent 
consumption, less sample handling and shorter analysis time (Menegatti et al. 2013). Developing a 
fast and low-cost method for detection of diseases (or indirectly by detection of immune responses 
against certain pathogenic microorganisms) would be desirable for the diagnostic of diseases in low-
income countries or where a one-time visit to the medical clinic would ease the logistics and result in 
higher treatment rates and thus prevention of disease spreading.  
5.2 Hypothesis 
In this study, a low-cost microfluidic diagnostic chip was sought developed. The chip would combine 
an optimized 3D cell chamber, facilitating cell migration and thus cell-cell contact and activation with 
detection of IFN-γ or IP10 mRNA by direct blood qRT-PCR as a readout. The idea was that this lab-on-
a-chip device could diagnose the presence of a CMI response against intracellular pathogens (such as 
Mycobacterium tuberculosis in humans) within the same day of blood sampling. It would thus be a 
fast and cheap diagnostic solution ideal for developing countries where tuberculosis represents a 
major cause of death.    
5.3 Results 
A thorough novelty search was conducted at the beginning of the study, concluding that no similar 
invention had previously been described (as per February 2012); see the Novelty Search Report in 
appendix 3. The practical work was split into three parts: (1) chip design and fabrication, involving the
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 manufacturing of a prototype chip, (2) optimization of the direct one-step blood PCR reaction, and (3) 
optimization of cell culture with facilitated cell migration by 3D incubation. The 3D incubation-part 
was optimized off-chip and has been described in chapter 4 - Study II.    
 
Chip design and fabrication 
A prototype chip with micro slide format (75 mm x 25 mm x 1 mm) containing eight cell incubation 
chambers with different microstructures was designed using AutoCAD® 2013 (Autodesk Inc.) and 
CimatronE10 (Cimatron Ltd.) software. A mold was made in aluminum (MetalCentret) using computer 
numerical control (CNC) micro milling (Folken Ind) followed by polishing (metal polish, Autosol). Using 
this mold, microchips made of cyclic olefin copolymer (COC) (TOPAS grade 5013L-10, Tg =135°C) 
(TOPAS Advanced Polymers GmbH) were produced by polymer injection molding (Engel). To close the 
chambers, chips were sealed by another piece of COC with same dimensions as the chips, containing 
holes above the inlets and outlets, using a thermal bonding press (P/O/Weber) set to 115-120°C and 
9.5-10 kN for 5-10 minutes. Prior to bonding, the chips and lids were UV treated for app. 30 sec. to 
activate the surfaces and improve the bonding process. Alternatively the chambers were sealed using 
Microseal® B Adhesive Sealer (Bio-Rad). Finally, Luer ports (provided by Carl Esben Poulsen, 
Department of Micro- and Nanotechnology, Technical University of Denmark) produced using the 
same methods as for the micro slide chips, were attached above inlets and outlets using double 
adhesive tape. The processes involved in the fabrication are shown in Figure 17. 
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Figure 17: Chip design and fabrication. A mold was designed using 3D drawing programs (A) and cut in aluminum using 
CNC micro milling (B). Injection molding (C) was used to fabricate COC polymer chips (D), which were sealed by thermal 
bonding (E). The sealing was successful (F), and to ease liquid loading, Luer ports (G) was attached to the bonded 
prototype chip (H) by double adhesive tape (H insert).   
 
The microstructures in the chambers of the chip prototype are shown in Table 2. The first chamber 
was an “empty” cell incubation chamber with space for a 3D scaffold/protein matrix in case such 
structures were found to be favourable for cell-activation. The remaining seven chambers contained 
additional microstructures at the bottom surface, each with different designs. The idea was that these 
microstructures would capture cells passing by, when the chamber was connected to a fluidic circuit. 
This would make it possible to retain cells of interest while changing the liquid within the chamber, 
for example changing to PCR reagents for direct PCR reaction on the chip.  
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Table 2: Overview of microstructures in the chambers of the prototype chip 
Chamber Microstructure 
Dimension (mm) 
(depth)x(width)
x(length) 
Chamber Microstructure 
Dimension (mm) 
(depth)x(width) 
x(length) 
1 
 
- 5 
 
(0.100) 
x 
 (0.101) 
x 
(2.285-3.788) 
2 
 
(0.100) 
x 
(0.171-0.175) 
x 
(0.813-2.341) 
6 
 
(0.100) 
x 
 (0.204) 
x 
(2.285-3.788) 
3 
 
(0.100) 
x 
(0.100) 
x 
(2.592-5.213) 
7 
 
(0.100) 
x 
 (0.097) 
x 
(3.023-4.091) 
4 
 
(0.100) 
x 
 (0.101) 
x 
(0.838-2.341) 
8 
 
(0.100) 
x 
 (0.101) 
x 
(0.295) 
 
For visualization purposes, and to find out if relevant cells could be captured within the 
microstructures, PBMCs purified from goat blood was used as test-material. PBMCs (5x106 cells/ml) 
were preheated in an incubator (37°C, 5% CO2) for one hour prior to flow test. Using a syringe pump, 
a cells-flow through the chambers on the chip was generated, and images of the cell capture by 
selected microstructures are shown in Figure 18.  
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Figure 18: Cell flow and capture by microstructures on the chip prototype. Images were recorded using an inverted Leica 
DMIL contrasting microscope equipped with a Leica DFC290 camera. 
    
In chamber 1, cells distributed evenly across the chamber surface when applied at a flow rate of 
10µl/min, and could be flushed away when changing to cell-free medium at a flow rate of 50µl/min. In 
chamber 2, cells were detectable both at the surface and within the microstructures when applied at 
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a flow rate of 10µl/min. Increasing the flow rate by flushing with medium at 200µl/min resulted in 
disruption of cells settled within the microstructures (chamber 6), thus the structures could not retain 
trapped cells at high flow rates. There was an overall problem with air bobbles being trapped in the 
microstructures, especially the structures in chamber 8. These structures were very small (app. 
100x100x300µm) and not suited for trapping cells, at least not with the conditions used for this 
experiment (PBMCs, room temperature and no degas of medium prior to experiment).   
 
To verify that the cells of interest, i.e. CD4+ T cells and monocytes, were present among the cells 
trapped within the microstructures, bovine PBMC were stained for CD4 and CD14 using fluorescently 
labeled antibodies and loaded into chambers on the chip, and imaged using a confocal microscope, 
Figure 19. Both types of cells were detectable within the microstructures of analyzed chambers 
(chamber 2 and 3), representing a wide and a narrow structure, respectively.   
 
Figure 19: Images of T cells and monocytes within microstructures from the chip prototype. Fluorescence images were 
taken using a Zeiss LSM710 confocal microscope with ZEN 2009 software. Bovine PBMCs were purified and stained for 
CD4
+
 T (red) and CD14
+
 monocytes (green) using fluorophore-conjugated antibodies. Cells were loaded into the chambers 
on the chip and images were taken to document the capture of relevant cells within the microstructures.  
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Direct one step blood PCR 
The readout for the diagnostic chip was intended to be on-chip qRT-PCR performed directly in the 
blood, detecting IFNG and/or CXCL10 mRNA. For this purpose, a direct one-step blood qRT-PCR SYBR 
Green Kit was tested. This was done off-chip on the Rotor-Gene Q qPCR platform. Numerous 
optimization experiments was performed using both goat- and bovine whole blood, including 
titrations of the percentages of whole blood used in the final reaction (10%, 8%, 6%, 5% and 2%), use 
of stabilizing agent (EDTA or heparin), titrations of SYBR Green concentrations (20x, 10x, 5x) and the 
annealing temperature (63°C and 60°C). IFNG and CXCL10 as well as reference genes could all be 
detected when 2% blood was used in the reaction. To be able to determine a coefficient of 
determination (R2) and PCR amplification efficiency, standard curves were generated using a dilution 
of template material (blood). The best results were obtained using 2% EDTA-stabilized whole blood, 
5x SYBR Green and an annealing temperature of 60°C when testing for the ACTB reference gene 
(Figure 20). 
 
Figure 20: Quantitation- and melting curve analysis of ACTB in titrated samples of goat blood. Quantitation analysis (left) 
of four 4-fold dilutions (F1-F4, start concentration F1 = 2% blood) of EDTA-stabilized goat whole blood. Threshold of 
fluorescence detection set to 0.05. Melting curve analysis (right) with a threshold temperature set to 85°C. NTC = no 
template control. 
 
With the above settings, and using results from F1-F3 depicted in Figure 20 (F4 contained no product, 
and the misplaced melting curve is a sign of primer-dimer), the ACTB primers had a coefficient of 
determination of 0.96 and an efficiency of 2.44, which was not acceptable (coefficient of 
determination should preferable be 0.98 or above and the efficiency should be between 0.90 and 
F1 
F2 
F3 F4 F1 
F2 
F3 F4 
NTC 
NTC 
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1.10). Therefore, additional optimization was necessary, but due to time limitations this was not 
pursued.
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Chapter 6 - Study IIII (differentiation of moDC) 
6.1 Introduction 
The use of monocytes as DC precursors has been an attractive approach in the attempt to generate 
competent APCs able to induce anti-cancer responses via immunotherapy. Immunotherapy has 
advantages over traditional cancer treatments such as chemotherapy, including no or few side effects 
(Janikashvili et al. 2010) and the treatment is personalized (DCs are loaded with antigens originating 
from the patient’s own tumor). It is known that during cancer, DCs are negatively influenced by the 
microenvironment and are not able to mature properly, resulting in poor induction of tumor-targeting 
T lymphocytes (Barbuto 2013). Therefore, it is believed that the generation of DCs outside this 
environment (i.e. by in vitro culture) would increase the functionality of the cells. A large number of 
monocytes can be obtained relatively easy via blood and they can be loaded with tumor antigen 
(Barbuto 2013). Despite this, the generation of effective immunotherapy for the treatment of cancer 
patients using moDCs has not been very successful as moDC-based vaccines have not been able to 
induce durable anti-cancer immunity, reviewed in (Wimmers et al. 2014). In addition, functionally 
biased moDCs generating regulatory T cell responses in vitro has been reported (Ramos et al. 2012). 
Therefore, optimization of the moDC differentiation protocol is needed.  
6.2 Hypothesis 
DCs act as cellular sensors and are able to respond to external stimuli coming from complex cellular 
and molecular signals from their surroundings (Palucka & Banchereau 2012). In relation to this, it was 
hypothesized that changing the surface material and architecture of cultures used for porcine moDC 
differentiation would influence the gene expression profile of the cells, as the cell-to-surface and cell-
to-cell contact would be changed.  
6.3 Results  
Enrichment of monocytes was performed by positive selection of CD172a+ cells from PBMC using 
magnetic separation technology (Miltenyi Biotec). The purity of the monocytes was measured by flow
   Study IIII (differentiation of moDC) 
75 
 
cytometry by staining the positive selected cells with phycoerythrin (PE)-conjugated goat anti-mouse 
IgG1 secondary antibody. PBMC (pre-stained with anti CD172a antibody) were likewise stained with 
the secondary PE-conjugated antibody and the two cell populations were analyzed on a BD 
FACSCanto™ II flow cytometer (BD Biosciences) Figure 21A. 
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Figure 21: Purification of CD172a+ monocytes (A) and viability check of moDCs before and after LPS (B). Viability was 
checked on cells cultured conventionally (on 2D polystyrene surfaces) using the live/dead stain 7-amino-actinomycin D (7-
AAD). LPS, lipopolysaccharide. 
 
Prior to enrichment, monocytes constituted app. 10% of total PBMCs. After enrichment the 
percentages of monocytes exceeded 94% for all three pigs, so the purification was successful. 
Monocytes were then cultured using different culture setups as described in paper II, with addition of 
GM-CSF and IL-4 for the generation of moDCs. After 4 days of culture, monocytes cultured 
conventionally in wells of polystyrene plates, had differentiated into moDCs based on morphology 
and surface marker expression (presented in paper II). A viability check showed that cultured moDC 
were viable, with only 1-2% dead cells, Figure 21B. After additional 24 hrs stimulation with 
lipopolysaccharide (LPS), this resulted in an increased proportion of dead cells, which were between 
app. 25-35%. This did not seem to affect the RNA quality when purified from cell lysates though, since 
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this was found to be very high. The effect of culturing monocytes using different culture setups are 
presented in paper II. 
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Paper II 
 
Investigating the role of surface materials and three dimensional architecture on in 
vitro differentiation of porcine monocyte-derived dendritic cells 
 
Sofie Bruun Hartmanna, Soumyaranjan Mohantyb, Kerstin Skovgaarda, Louise Brogaarda, Frederikke 
Bjergvang Flagstada, Jenny Emnéusb, Anders Wolffb, Artur Summerfieldc and Gregers Jungersena# 
 
a National Veterinary Institute, Technical University of Denmark, Frederiksberg C, Denmark, 
b Department of Micro- and Nanotechnology, Technical University of Denmark, Kgs. Lyngby, Denmark, 
c Institute of Virology and Immunology (IVI), Mittelhäusern, Switzerland 
# Corresponding author 
Manuscript submitted to PLOS ONE 
 
In this study we investigate the effect of culture conditions when generating porcine monocyte-
derived dendritic cells (moDC) in vitro. We compare traditional polystyrene (PS) culture surface 
material with an untraditional culture surface made from polydimethylsiloxane (PDMS), a material 
frequently used for lab-on-a-chip device fabrication. Additionally, we examine the effect on moDC 
when cultured on three-dimensional scaffolds compared to two dimensional surfaces. Interestingly, 
we were able to show that both the culture surface material (PS vs. PDMS) as well as the dimension 
(2D vs. 3D) resulted in changes in gene expression. PDMS generated cells with a macrophage-like 
phenotype and 3D cultures had a positive effect on the activation profile of the cells. With this study, 
we show how sensitive moDCs are to their surrounding environment and that it is possible to 
modulate the gene expression of these cells simply by changing the culture material and architecture. 
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Abstract  
In vitro generation of dendritic-like cells through differentiation of peripheral blood monocytes is 
typically done using two-dimensional polystyrene culture plates. In the process of optimizing cell 
culture techniques, engineers have developed fluidic micro-devises usually manufactured in materials 
other than polystyrene and applying three-dimensional structures more similar to the in vivo 
environment. Polydimethylsiloxane (PDMS) is an often used polymer for lab-on-a-chip devices but not 
much is known about the effect of changing the culture surface material from polystyrene to PDMS. 
In the present study the differentiation of porcine monocytes to monocyte-derived dendritic cells 
(moDCs) was investigated using CD172apos pig blood monocytes stimulated with GM-CSF and IL-4. 
Monocytes were cultured on surfaces made of two- and three-dimensional polystyrene as well as 
two- and three-dimensional PDMS and carbonized three-dimensional PDMS. Cells cultured 
conventionally (on two-dimensional polystyrene) differentiated into moDCs as expected. 
Interestingly, gene expression of a wide range of cytokines, chemokines, and pattern recognition 
receptors was influenced by culture surface material and architecture. Distinct clustering of cells, 
based on similar expression patterns of 46 genes of interest, was seen for cells isolated from two- and 
three-dimensional polystyrene as well as two- and three-dimensional PDMS. Changing the material 
from polystyrene to PDMS resulted in cells with macrophage-like characteristics. When changing to 
three-dimensional culture the cells became more activated in terms of IL6, IL8, IL10 and CCR5 gene 
expression. Further stimulation with LPS resulted in a slight increase in the expression of maturation 
markers (SLA-DRB1, CD86 and CD40) as well as cytokines (IL6, IL8, IL10 and IL23A) but the influence of 
the surfaces was unchanged. These findings highlights future challenges of combining and comparing 
data generated from microfluidic cell culture-devices made using alternative materials to data 
generated using conventional polystyrene plates used by most laboratories today.   
1. Introduction 
Dendritic cells (DCs) are a heterogenic group of antigen presenting cells important for induction of 
immunological responses. In vitro generation of DCs is a technique that has been practiced for 
decades (1). It can be difficult to harvest sufficient quantities of DCs for characterization and study, 
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and therefore in vitro generated monocyte-derived dendritic cells (moDCs) have been used as an 
alternative. With this technique peripheral blood mononuclear cells (PBMCs) are harvested, and 
monocytes isolated and cultured with growth factors, such as granulocyte macrophage colony-
stimulating factor (GM-CSF) and interleukin 4 (IL-4) (2). With the central role of DCs as immune 
modulators and with the observation that cancer patients have DCs with reduced capacity to initiate 
efficient Th1 immune responses (3,4), controlling the differentiation of DCs may result in generation 
of cells able to activate in vivo immune responses against antigenic targets that otherwise are not 
recognized as immunogenic. An example of this is Provenge® (Sipuleucel-T), an FDA registered 
immunotherapy treatment for prostate cancer (5). Thus, in vitro culture systems for controlled DC 
maturation, differentiation and immune priming hold promise for activation or deactivation of the 
immune system against antigenic targets which are inaccessible with current immunization protocols.  
In the present study, the pig was used as monocyte donor. The reason this animal was chosen 
was because of the increasing interest in using porcine models for human diseases. The number of 
research groups working with the porcine model has been steadily expanding for the last 50 years as 
judged by the number of publications in PubMed within this area. Advantages using the pig over 
rodents as animal models for human diseases have been summarized in (6) and includes comparable 
organ size, large number of cells that can be harvested repeatedly, and blood physiology being similar 
to humans. The porcine immune system also resembles the human immune system with respect to 
toll-like receptors (TLR) and DC biology (7). Porcine DCs have been characterized in several studies (8–
14), and much information is already available making the use of this animal as a model for in vitro DC 
differentiation more attractive. 
Today most in vitro cell studies and cultures are performed using standard flat-bottom 
polystyrene (PS) culture plates/flasks. This however, constitutes a very non-physiological environment 
for the cells to grow in and therefore new three dimensional (3D) culture-systems for mammalian 
cells are gaining increasing interest. Cells cultured in a 3D environment, are largely thought to behave 
more like in vivo compared to cells cultured on a two dimensional (2D) surface, thus making data on 
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gene expression, motility and activity more reliable and comparable to in vivo settings (reviewed in 
(15,16)). 
An emerging field within the cell culture area is the use of fabricated micro devices for the 
study of cells or tissues. By the use of microfluidics, these lab-on-a-chip devices allows for the study of 
cells using only a small fraction of reagents, and cell analysis can be performed directly in the chip 
(17). However, these devises are typically not produced in PS due to difficulties of production, 
including challenges associated with bonding of thermoplastic materials and production of molds 
capable of resisting high temperatures and pressures used in hot embossing processes (18). 
Alternative polymers with properties suitable for e.g. soft lithography are preferably used. One of 
these polymers often used is polydimethylsiloxane (PDMS) (19). Since most reported in vitro results 
on cell activity/behavior originates from cells cultured on PS surfaces, not much is known about the 
effect of changing the culture surface material from PS to other materials more frequently used 
within micro devise fabrication.  
However, a few studies do exist, and it has previously been reported that PDMS affects the 
gene expression of adrenal phaeochromocytoma (PC12) cells (20). The authors found that when cells 
were cultured on polymethyl methacrylate (PMMA) 6 genes were up-regulated and 35 were down-
regulated compared to cells cultured on a PS surface. By contrast, when cells were cultured on a 
perforated PMMA surface with a PDMS layer underneath 642 genes were up-regulated and 35 were 
down-regulated compared to cells cultured on PS. They conclude that PDMS opposed to PMMA has a 
major impact on the gene expression of PC12 cells. Many of the genes differently expressed in the 
PC12 cells were involved in neuronal cell development and function and so it would be interesting to 
find out if PDMS had a similar effect on the differentiation of porcine dendritic cells, thus giving rise to 
cells with a more differentiated and activated phenotype. Therefore, in the present study the 
differentiation of monocytes to moDCs was investigated using CD172apos pig blood monocytes 
stimulated 4 days with GM-CSF and IL-4 followed by 24 hr activation with lipopolysaccharide (LPS). 
Monocytes were cultured on PS, PDMS and a pyrolysed (carbonized) form of PDMS (21). Additionally, 
2D culture surfaces were compared with 3D scaffolding variants. The purpose of this study was to 
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explore possible changes in gene expression of moDCs when generated on alternative culture 
surfaces, including materials preferably used for fabrication of micro devices, and 3D vs. 2D 
architecture.  
2. Materials and methods 
2.1. Isolation of PBMCs 
Fresh, heparinized whole blood was collected from three 7-8 weeks old pigs (Yorkshire-Landrace x 
Duroc crossing) housed at the animal facility at The Veterinary Institute, Technical University of 
Denmark. PBMCs were isolated using Ficoll-Paque™ Plus (GE Healthcare) and following two washes, 
cells were counted using an automated cell counter (Nucleocounter® NC-200™, ChemoMetec) and 
diluted in RPMI 1640 medium with GlutaMAX™ (Gibco, Life Technologies™) containing 10% heat 
inactivated fetal calf serum (FCS). Animals were kept and sampled under approval by The National 
Animal Experiments Inspectorate. 
 
2.2. Monocyte enrichment 
Enrichment of CD172a (SWC3) positive monocytes was done using the MACS magnetic separation 
technology (Miltenyi Biotec). Briefly, PBMCs were resuspended in MACS buffer (PBS/5xEDTA/1%FCS) 
and labelled with mouse anti-porcine CD172a IgG1 (clone 74-22-15) at 5.5 µg/106 target cells. After 20 
min incubation on ice followed by two washes, MACS magnetic anti-mouse IgG microbeads was 
added (2 µl/106 target cells) and cells were incubated on ice for 15 min and washed twice. The 
CD172a positive cells were purified using equilibrated LS columns placed in a magnet on a MACS 
multistand. The positive fraction was collected, washed, counted and resuspended in complete cell 
culture medium (see below). The purity was confirmed by incubating with phycoerythrin (PE)-
conjugated goat anti-mouse IgG1 secondary antibody (Southern Biotechnology) followed by analysis 
on a BD FACSCanto™ II flow cytometer (BD Biosciences, USA) and was found to be above 94% (data 
not shown).  
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2.3. Preparation of cell culture surfaces 
The five different surfaces tested in the present experiment are listed in table 1. Microtiter plates 
were from Corning Scientific and were either in 6-well (cat# 3516) or 24-well (cat# 3526) format for 
the 2D and 3D incubations, respectively. They were made in polystyrene, thus empty well on the 6-
well plates represented 2D PS surfaces (control). The 3D PS surfaces were made by placing a porous 
polystyrene 3D scaffold, Alvetex® (Reinnervate) in the bottom of the wells in 24-well plates. For the 
2D PDMS surface, PDMS pre-polymer was mixed with a curing agent (10:1, w/w) according to the 
manufacturer’s instructions (Sylgard® 184, Dow Corning Corporation) and poured in a thin layer into 
the wells of 6 well plates followed by curing in an oven at 60°C for 4 hours.  
The random pore 3D PDMS scaffolds were fabricated using particle leaching technique as 
described previously (22,23) (Fig. 1). Briefly, 10 gram of sugar crystals of size ranging from 300-600µm 
(Sigma-Aldrich) was mixed with 1ml of water on a 100 mm Petri dish. The mixture was placed in an 
oven at 60°C to generate interconnections between the sugar crystals and to evaporate the excess 
water. The hardened sugar cube was cooled at room temperature. The PDMS pre-polymer was mixed 
with a curing agent (10:1, w/w) and poured into the Petri dish containing the sugar cube. The PDMS 
covered sugar cube was placed in a vacuum desiccator for one hour to let the PDMS infiltrate into the 
pores of the sugar cube. The PDMS was cured in an oven at 60 °C for 4-6 hours. The sugar particles 
were then dissolved by soaking in water for 4 hours. After dissolving, random micro-porous 3D PDMS 
scaffolds were cut to cylinders having a diameter of 6 mm and a height of 5 mm, fitting into wells of 
24-well plates, using biopsy punches. Both the 2D PDMS surface and the 3D PDMS scaffolds were 
treated with oxygen plasma (125 W, 13.5 MHz, 50 sccm, and 40 millitorr) to render their surface 
hydrophilic and sterilized by autoclaving.  
The pyrolysed 3D PDMS scaffolds were made by pyrolysing the 3D PDMS scaffolds made by 
square sugar cubes in a furnace at 900°C for one hour in N2 atmosphere, resulting in highly porous 
and hydrophilic square 3D carbonized scaffolds (21). The morphology and microstructure of PDMS 
and carbonized PDMS porous scaffolds were examined using scanning electron microscopy (SEM) 
(JEOL Ltd.). Prior to SEM analysis scaffolds were dried in an oven at 60°C overnight and sputter coated 
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with gold. Samples were then analyzed using 12 kV of accelerating voltage. Pore sizes of the molds 
and scaffolds were evaluated from SEM micrographs using Image J software.  
 
Table 1: Overview of culture surfaces tested 
Surface  Description 
2D PS 
Two-dimensional 
polystyrene 
6-well plate with no insert (Corning 
Scientific) 
2D PDMS 
Two-dimensional 
polydimethylsiloxane 
PDMS moulded in the wells of 6-well plates 
creating a thin surface layer 
3D PS 
Three-dimensional 
polystyrene 
Alvetex® discs inserted into wells of 24-well 
plates (Reinnervate) 
3D PDMS 
Three-dimensional 
polydimethylsiloxane 
Random micro-porous scaffolds inserted into 
wells of 24-well plates (22,23)  
Pyrolysed 
3D PDMS 
Pyrolysed three-
dimensional 
polydimethylsiloxane 
Carbonised random micro-porous scaffolds 
inserted into wells of 24-well plates (21) 
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Fig. 1: 3D PDMS and pyrolysed 3D PDMS scaffold manufacturing. Sugar crystals mixed with water was incubated at 60°C 
to interconnect the sugar crystals (1), pre-cured PDMS was poured on top of the sugar and placed in a vacuum desiccator 
(2) to let the PDMS infiltrate the sugar. After an additional incubation at 60°C (3) the PDMS/sugar cube was soaked in 
water (4) to dissolve the sugar. Disks of random micro-porous PDMS were cut to fit the wells of a 24 well-plate (5). 3D 
PDMS scaffolds made from square sugar cubes were incubated at 900°C in N2 atmosphere resulting in carbonised 3D 
random micro-porous PDMS (6). Bottom photographs are SEM images showing a 3D PDMS scaffold (left) and pyrolysed 3D 
PDMS scaffold (right). 
 
2.4. Cell culture and harvesting 
Cells were kept in culture medium (DMEM minus phenol red, high glucose containing 1xNEAA, 
1xsodium pyruvate, 1xGlutaMax™ supplement, penicillin/streptomycin (100 U/ml and 100 µg/ml, 
respectively), Fungizone (2µg/ml) (all from Gibco/Life Technologies) and 10% porcine serum 
(Biochrom)). Prior to cell plating the 3D PS surface was made hydrophilic by adding 70% ethanol 
followed by two washes with PBS. The 3D PDMS and pyrolysed 3D PDMS surfaces were prepared by 
washing them twice in PBS. For the 3D surfaces, 1 or 2 x106 cells (for flow cytometry or gene 
expression analysis, respectively) in a 100-300µl volume  was carefully placed on top of the scaffolds, 
and the plates were pre-incubated at 37°C, 5% CO2 for 1 hour in order for the cells to settle within the 
   Paper II 
85 
 
scaffold. Media containing recombinant porcine GM-CSF and IL-4 (R&D Systems) at a final 
concentration of 100 and 25ng/ml, respectively, was added to reach a final volume of 2ml per well. 
Plating of cells on 2D surfaces was done similarly except for the 1 hour pre-incubation step. After 
three days of incubation, additional 500µl of fresh medium containing GM-CSF and IL-4 was added to 
all cultures. On day four, half of the cultures received 50µl of LPS (Sigma) at a final concentration of 
1µg/ml and were incubated for additional 24 hours. After four days of incubation (five days for the 
LPS stimulated cultures) cells were harvested by collecting the supernatant and adding ice-cold 
PBS/5xEDTA to the wells followed by 15 min incubation on ice, shaking. The scaffolds from the 3D 
cultures were placed in 15 ml tubes (the 3D PS scaffolds were placed in a pipette tip in a 15 ml tube), 
1 ml ice-cold PBS/5xEDTA was added and tubes were centrifuged (5 min, 5°C, 500 x g). The cell 
solution was pooled with the supernatant, centrifuged (5 min, 5°C, 500 x g) and resuspended in RLT 
buffer (Qiagen) and stored at -80°C for later gene expression analysis or resuspended in FACS buffer 
(see below) for characterization using flow cytometry. For visualization of cell morphology, moDCs 
and monocytes (cultured in media with or without differentiating cytokines, respectively) cultured on 
2D PS surfaces were inspected using an inverted Leica DMIL contrasting microscope equipped with a 
Leica DFC290 camera (Leica Microsystems) at day 1, 4, and 5. 
 
2.5. Flow cytometry 
For characterization of surface marker expression, cells were stained and analyzed by flow cytometry. 
Cells were distributed in 96-well plates and washed once in FACS buffer (PBS, 0.1% sodium azide, 1% 
FCS) and incubated 20 min in the dark with 20µl primary antibodies or isotype controls in four 
antibody cocktails, see table 2. Following three washes, cells were incubated 20 min in the dark with 
20µl secondary antibodies, as listed in table 2. For compensation adjustments and viability check, 
pooled cells were stained with either mouse anti-porcine CD172a IgG1 in combination with PE-, APC- 
or FITC-conjugated anti-mouse IgG1 antibodies, biotin-conjugated CD152 (CTLA-4)-muIg in 
combination with V450-conjugated streptavidin or the dead cell marker 7-aminoactinomycin D (7-
AAD) (Sigma-Aldrich). Cells were washed three times and resuspended in FACS sheath fluid containing 
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0.5% paraformaldehyde. Cells were loaded on a BD FACSCanto™ II flow cytometer (BD Biosciences, 
USA) and the results were analyzed using BD FACSDiva software version 8.0.1. 
 
Table 2: Staining overview 
Primary staining 
Cocktail # Primary antibody Conjugate Isotype Clone Company 
1 
Mouse anti-porcine CD172a 
Mouse anti-porcine SLA class II DR 
CD152(CTLA-4)-muIg (fusion protein) 
- 
FITC 
Biotin 
IgG1 
IgG2b 
IgG2a 
74-22-15 
2E9/13 
- 
DTU Vet
a
 
AbD Serotec 
Ancell 
2 
Mouse anti-porcine CD1 
Mouse anti-porcine CD14 
- 
- 
IgG2a 
IgG1 
76-7-4 
CAM36A 
VMRD 
VMRD 
3 
Anti-mouse IgG2b (isotype control) 
Anti-mouse IgG1 (isotype control) 
Anti-mouse IgG2a (isotype control) 
FITC 
- 
- 
- 
- 
- 
- 
- 
- 
AbD Serotec 
DAKO 
DAKO 
4 muIgFc control (fusion protein) Biotin - - Ancell 
Secondary staining 
Cocktail # Secondary antibody Conjugate Isotype Clone Company 
1 
Goat anti-mouse IgG1 
Streptavidin 
PE 
V450 
- 
- 
- 
- 
Southern Biotechnology 
BD Biosciences 
2 
Goat anti-mouse IgG2a 
Goat anti-mouse IgG1 
FITC 
APC 
- 
- 
- 
- 
Southern Biotechnology 
Southern Biotechnology 
3 
Goat anti-mouse IgG1 
Goat anti-mouse IgG1 
Goat anti-mouse IgG2a 
APC 
PE 
FITC 
- 
- 
- 
- 
Southern Biotechnology 
Southern Biotechnology 
Southern Biotechnology 
4 Streptavidin V450 - - BD Biosciences 
a
Produced at The Veterinary Institute, Technical University of Denmark. FITC, Fluorescein isothiocyanate; PE, 
Phycoerythrin; APC, Allophycocyanin.   
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2.6. RNA extraction  
Total RNA was purified from RLT-buffered cell lysates using the RNeasy Mini kit (Qiagen) including an 
on-column DNase treatment (Qiagen) according to the manufacturer’s instructions. The RNA quantity 
and quality was measured using a NanoDrop ND-1000 spectrophotometer (Saveen Biotech) and the 
Agilent 2100 Bioanalyzer (Agilent Technologies), respectively. The average yield of total RNA was (in 
nanogram ± SD): 2D PS (3698 ± 734); 2D PDMS (5724 ± 785); 3D PS (275 ± 273); 3D PDMS (1340 ± 238) 
and pyrolysed 3D PDMS (1096 ± 381). The RNA integrity number (RIN) was determined using the 
Agilent RNA 6000 Nano Kit (Agilent Technologies) according to the manufacturer’s instructions. All 
RIN numbers were between 8.1 and 10.  
 
2.7. cDNA synthesis and pre-amplification 
QuantiTect® reverse Transcription Kit (Qiagen) was used to reverse transcribe 180ng total RNA in 
duplicate according to the manufacturer’s instructions. For the pre-amplification, cDNA was diluted 
1:5 in low EDTA Tris-EDTA (TE)-buffer (VWR-Bie & Berntsen). TagMan PreAmp Master mix (1µl) 
(Applied Biosystems) was mixed with 2.5µl of a 200nM primer mix (containing all primer pairs used in 
this study) and 2.5µl diluted cDNA. Using a Thermocycler (Biometra), samples were incubated at 95°C 
for 10 min followed by 18 cycles of 95°C for 15 sec and 60°C for 4 min. For removal of excess primers, 
exonuclease I (New England Biolabs) (4U/µl) was added to the pre-amplified cDNA and samples were 
incubated at 37°C for 30 min and 80°C for 15 min. Pre-amplified, exonuclease-treated cDNA was 
diluted 1:5 in low EDTA TE-buffer and stored at -20°C until quantitative real time PCR (RT-qPCR) 
analysis.   
 
2.8. Primer design and validation 
Primers targeting genes involved in differentiation and activation were designed using the free 
software Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/primer3/) as described previously (24) and 
synthesized at TAG Copenhagen (Copenhagen, Denmark) or Sigma-Aldrich (Denmark). All primers, 
primer sequences and amplicon length are listed in suppl. table S1. If possible, primers were designed 
to span introns to prevent amplification of genomic DNA, and BLAST searches were performed to 
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ensure primer specificity and absence of intraspecies polymorphisms at the primer site. For several 
genes, two primer pairs, annealing at different sites at the mRNA transcript, were designed. Primer 
amplification efficiencies and correlation coefficients were obtained by standard curves constructed 
from four separate dilution series of pooled pre-amplified, exonucleated cDNA. To ensure primer 
specificity, melting curves were visually inspected for all primer assays.  
 
2.9 Quantitative real-time PCR 
qRT-PCR was performed in 96.96 Dynamic Array Integrated Fluidic Circuits (IFC) (Fluidigm), combining 
54 samples, 38 dilution curve samples, three minus reverse transcriptase controls and one non-
template control, all pre-amplified (96 samples in total) with 96 primer sets for 9216 individual and 
simultaneous qPCR reactions. Reaction mix was prepared using the following reagents for each of the 
96 reactions: 3µl TaqMan Gene Expression Master Mix (Applied Biosystems), 0.3µl 20XDNA Binding 
Dye Sample Loading Reagent (Fluidigm), 0.3µl 20X EvaGreen (Biotium, VWR-Bie & Berntsen) and 0.9µl 
low EDTA TE buffer. Reaction mix (4.5µl) was mixed with 1.5µl pre-amplified, diluted cDNA. Primer 
mix was prepared for each of the 96 primer sets using 3µl of 20µM primer (forward and reverse) and 
3µl of 2X Assay loading Reagent (Fluidigm). The 96.96 Dynamic Array was primed in the IFC Controller 
(Fluidigm), and reaction mix including cDNA (5µl) and primer mix (5µl) was loaded into appropriate 
inlets on the chip, and again placed in the IFC controller to ensure equal distribution of cDNA and 
primer in the 9216 reaction chambers. The chip was then placed in the BioMark real time PCR 
instrument (Fluidigm), and the following cycle conditions were used: a thermal mix consisting of 2 min 
at 50°C, 30 min at 70°C and 10 min at 25°C, then an uracil-N-glycosylase (UNG) phase with 2 min at 50 
and a hot start phase with 10 min at 95°, followed by 35 cycles with denaturation for 15 sec at 95° and 
annealing/elongation for 1 min at 60°C. Melting curves were generated after each run to confirm a 
single PCR product (from 60°C to 95°C, increasing 1°C/3 sec). Reactions were performed in duplicate 
(cDNA replicates). Minus RT controls (samples generated without reverse transcriptase enzyme) and 
non-template controls (NTC) were included to check for genomic DNA contamination and non-specific 
amplification, respectively. Expression data (Cq values) was acquired using the Fluidigm Real Time PCR 
Analysis software 3.0.2 (Fluidigm). 
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2.10. Data pre-processing and analysis 
Data pre-processing, normalization and relative quantification was done using GenEx5 (MultiD). Data 
were corrected for primer efficiency for each individual assay. If primer efficiency was below 0.85 or 
above 1.15, a default efficiency of 0.90 was assigned and differential expression was later validated 
using the Rotor-Gene Q (Qiagen) qPCR platform. Normalization was done using the geometric mean 
of four reference genes: hypoxanthine phosphoribosyl-transferase 1 (HPRT1), tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase (YWHAE), β-actin (ACTB) and β-2-microglobulin (B2M), 
found to be the most stably expressed ones out of eight reference genes tested using both GeNorm 
(25) and NormFinder (26). Data from the two technical cDNA replicates were averaged, and for each 
specific primer set and sample, a maximum of 10% samples/primer sets with a ∆Cq above ±1.5 for the 
two cDNA replicates was accepted. To visualize differential gene expression, expression was 
calculated relative to the sample with the lowest expression (highest Cq) within each primer assay. 
Finally the data was log2 transformed and autoscaled before principal component analysis (PCA). No 
statistical analyses were attempted since only three pigs were analysed in the present study. For 
comparison of the effect of the different culture surfaces the expression was set relative to the 
control surface (2D PS) and a fold change of ±2 was arbitrarily defined as the cut-off for biologically 
significant changes.   
 
3. Results 
3.1. Monocytes cultured conventionally with differentiating cytokines have moDC morphology and 
surface marker expression  
In the present study, the effect of culture surface architecture and material on the in vitro 
differentiation of porcine moDC was investigated. For this purpose three pigs were used as donors. 
Purified CD172a positive monocytes were cultured with medium containing GM-CSF and IL-4 on 
surfaces that differed in material; PS, PDMS or carbonized (pyrolysed) PDMS, and dimension; 2D or 
3D. After four days of culture on 2D PS in the presence of differentiating cytokines, monocytes 
differentiated into elongated cells with dendrites – a morphology characteristic of moDC (Fig. 2). This 
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was even more profound after 24 hours of activation with LPS. To confirm the differentiation into 
moDCs the expression of surface markers was analysed by flow cytometry. Prior to culture, 
monocytes were CD1 negative, CD80/86negative/low and MHCIIlow (Fig. 3). After conventional (2D PS) 
culture with differentiating cytokines, cells were CD1pos, CD80/86high (especially after activation by 
LPS) and MHCIIhigh which further confirmed their differentiation into moDCs (9,11,12). When cultured 
on 3D surfaces of both materials however, cells were CD1neg, CD80/86low and MHCIIlow, a phenotype 
resembling monocytes more than moDCs. Cells cultured on 2D PDMS had an intermediate phenotype; 
CD1low, CD80/86high and MHCIIhigh. CD14 was equally expressed by cells cultured on all five surfaces.         
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Fig. 2: Light microscopy images of monocytes and moDCs after 1, 4 and 5 days of incubation on a 2D PS surface. At day 5 
the moDCs had been stimulated with LPS for 24 hours. MoDCs were generated by addition of differentiating cytokines 
GM-CSF and IL-4. MoDC, monocyte-derived dendritic cells; LPS, lipopolysaccharide; GM-CSF, Granulocyte-macrophage 
colony-stimulating factor; IL-4, interleukin 4.   
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Fig. 3: Surface marker expression of porcine monocytes compared to non-stimulated (day 4) and LPS-stimulated (day 5) 
moDCs cultured on different surfaces. Shown is the median fluorescence intensity (MFI) of individual surface markers 
(n=3). Filled circles represent relevant antibody-stained samples, open circles represents isotype controls. It was not 
possible to detect CD14 on monocytes as this antibody had same isotype (IgG1) as the antibody used to purify the 
monocytes thus giving rise to false positives. PS, polystyrene; PDMS, polydimethylsiloxane; LPS, lipopolysaccharide.  
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3.2. Gene expression 
The expression of 96 genes - 88 genes of interest and 8 reference genes was examined. Genes were 
selected to cover transcription factors, cytokines, maturation markers and phenotypic markers. The 
following genes were excluded due to expression levels below limits of detections or variable cDNA 
replicates: IL12(p35), IL12(p40), IFN-β, IFN-γ, ITGAM(a), ITGAM(b), CXCL10, IL1B, TNF, CLEC4A(b), 
SIGLEC5(a), CCL2, ITGA4(b), CLEC1A(b), CLEC12A(a), CLEC12A(b) and CD101(b). Validation of 
differential expression was performed on 11 primers assigned with default efficiency. Expression 
levels from primers specific for TLR3 could not be validated on the Rotor-Gene Q qPCR platform  and 
was thus excluded from  the analysis. For genes analyzed using two primer pairs, only one assay was 
analyzed further after checking the correlation coefficients between the two pairs. Thus, the following 
genes were excluded due to double primer assay (correlation coefficient between the two primer sets 
are shown in parentheses): TLR4(a) (0.81), SLA-DRB1(b) (0.95), CD86(b) (0.94), CCR7(b) (0.98), 
TRAF6(a) (0.97), CCR5(b) (0.97), CXCR4(b) (0.83), IRF8(b) (0.92), FLT3(a) (0.99), CCR1(a) (0.88), IRF5(a) 
(0.65), BATF3(a) (0.65), ID2(a) (0.97), BCL11A(a) (0.77), BCL6(a) (0.97), TCF4(b) (0.86), CLEC2D(b) 
(0.88), CD163(b) (0.99), FCGR1A(a) (0.82), FCGR2B(a) (0.96), FCGR3B(a) (0.83), CD1a(b) (0.99), 
LAMP3(b) (0.91) and XCR1(a) (0.91). Thus, a total of 46 genes were evaluated for differential gene 
expression, many of those with two highly correlated primer pairs targeting the same mRNA 
transcript, as a result of surface architecture (2D vs. 3D) and materials used for culturing. (see suppl. 
table S1 for complete list of primers). 
 
3.3. The monocyte-derived cells show distinct gene expression when cultured on surfaces of 
alternative materials and dimension.  
Principal component analysis (PCA) was performed on relative expression data of all 46 genes, to 
reveal patterns or clusters among samples based on co-expression patterns. Distinct clustering of cells 
isolated from 2D PS, 2D PDMS, 3D PS and 3D PDMS/pyrolysed 3D PDMS can be seen in Fig. 4. Most 
variation was explained by PC1 (eigenvalue = 30.4%) separating the cells grown on 2D compared to 
3D. No separation, based on gene expression patterns, was seen between cells grown on the 
carbonized form of 3D PDMS and 3D PDMS. To see how the gene expression changed when cells were 
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cultured on alternative surfaces, the expression was compared relative to the expression on the 
conventional control surface (2D PS), set to 1. Both the gene expression from non-stimulated- and 
LPS-stimulated cells is shown in table 3. Out of the 46 genes analyzed, 29 genes had a fold change 
expression of ± 2 when cultured alternatively compared to control, and for the LPS-stimulated cells 
this number was 34. In agreement with results from the PCA, the two most variable groups of clusters 
(2D PS and 3D PDMS) also showed the highest number of differentially genes both in samples of no 
stimuli and LPS treatment. Fig. 5 summarizes the differently expressed genes across the alternative 
surfaces, with or without LPS.  
In the non-stimulated cells, a common effect of changing the material from PS to PDMS (both 
2D-, 3D- and pyrolysed 3D PDMS) was increased expression of CD163 and decreased expression of 
LAMP3 (CD208) and ITGA4 (CD49d). The same applied for the LPS-stimulated cells, except here also 
the expression of BATF3 was decreased in cells from the PDMS surfaces and the expression of LAMP3 
was, in addition to PDMS surfaces, also decreased in cells cultured on 3D PS. A common effect of 
changing the dimension from 2D to 3D in resting cells (both PS, PDMS and pyrolysed PDMS) was 
increased expression of IL6, IL10, CCR5 and decreased expression of BCL6, CD1a, CD209 (DC-SIGN) and 
FCGR2B (CD32). In the LPS-stimulated cells this was also the case only expression of BCL6 was 
unchanged compared to control, and in addition the expression of ID2 and TCF4 was increased and 
decreased, respectively. The expression of SLA-DRB1 (MHCII) was approximately the same in cells 
from 2D PDMS and 3D PS, but was decreased 2.3 fold (0.43) in cells from 3D PDMS and pyrolysed 3D 
PDMS. The same trend applied for cells stimulated with LPS. The expression of CD86 was unchanged 
across the various surfaces, except for a 2 fold (0.46) downregulation in LPS-stimulated 3D PS cells. 
Common for all the four alternative surfaces tested was an increased expression of IL23A and a 
decreased expression of TLR8 and CD40 when compared to the conventional 2D PS culture surface. 
For the LPS-stimulated cells a decrease in the expression of TLR8 and LAMP3 was observed for all four 
alternative surfaces. The most important findings regarding the gene expression results for all tested 
surfaces are summarized in table 4. 
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Table 3:  
Relative gene expression (fold change) in moDCs from alternative surfaces compared to conventional surface 
 
No stimuli (day 4)  LPS (day 5) 
 
Control 
surface 
 
Alternative 
surfaces 
 
Control 
surface 
 
Alternative 
surfaces 
 2D PS 2D PDMS 3D PS
a 
3D PDMS 
Pyrolysed 3D 
PDMS 
2D PS 2D PDMS 3D PS
b 
3D PDMS 
Pyrolysed 3D 
PDMS 
IL6 1±0.21 0.73±0.13 4.16±1.03 10.31±0.99 11.87±0.87 1±0.13 0.92±0.24 6.03 12.12±2.03 22.37±4.50 
IL8 1±0.12 1.34±0.43 0.71±0.29 4.25±1.41 4.42±1.19 1±0.24 0.67±0.11 1.31 2.61±0.42 4.02±0.69 
IL10 1±0.12 1.90±0.32 8.43±2.06 13.56±2.87 18.58±3.56 1±0.22 1.19±0.12 7.76 9.68±0.88 12.63±0.49 
IL23A 1±0.16 3.36±0.60 5.53±1.52 17.52±2.37 10.16±1.73 1±0.15 0.61±0.07 1.81 1.16±0.38 1.60±0.48 
TLR2 1±0.20 2.20±0.22 0.75±0.24 1.82±0.46 1.77±0.49 1±0.18 2.35±0.25 0.82 1.69±0.21 1.91±0.34 
TLR4(b) 1±0.17 1.40±0.27 0.51±0.08 0.59±0.04 0.58±0.12 1±0.22 1.15±0.14 0.39 0.45±0.07 0.55±0.07 
TLR7 1±0.30 1.00±0.31 0.77±0.04 0.91±0.32 0.84±0.26 1±0.32 0.72±0.24 0.27 0.71±0.25 0.62±0.17 
TLR8 1±0.27 0.09±0.05 0.08±0.02 0.01±0.00 0.03±0.01 1±0.47 0.03±0.00 0.04 0.02±0.01 0.01±0.00 
TLR9 1±0.53 0.83±0.47 1.34±0.69 1.17±0.60 1.00±0.40 1±0.48 0.45±0.27 2.10 0.76±0.39 0.87±0.44 
IFNA 1±0.37 0.99±0.18 1.13±0.26 0.68±0.04 0.94±0.11 1±0.24 0.90±0.12 1.11 0.81±0.16 0.61±0.17 
SLA-DRB1(a) 1±0.15 0.67±0.14 0.98±0.18 0.43±0.10 0.43±0.11 1±0.15 0.59±0.13 1.01 0.32±0.05 0.35±0.02 
CD86(a) 1±0.16 0.97±0.04 0.67±0.02 0.90±0.06 0.95±0.15 1±0.11 0.76±0.09 0.46 0.67±0.04 0.71±0.09 
CD40 1±0.14 0.31±0.04 0.22±0.01 0.50±0.10 0.44±0.14 1±0.17 0.42±0.04 0.53 0.46±0.07 0.57±0.06 
CCR7(a) 1±0.40 0.19±0.07 1.16±0.60 0.74±0.23 0.57±0.17 1±0.30 0.13±0.02 0.61 0.66±0.16 0.45±0.08 
TRAF6(b) 1±0.05 0.83±0.05 0.83±0.10 0.85±0.01 0.83±0.04 1±0.11 0.68±0.08 0.74 0.62±0.04 0.69±0.03 
CLEC4A(a) 1±0.19 2.21±0.62 0.82±0.06 2.19±0.35 1.40±0.22 1±0.29 3.29±0.90 0.62 1.39±0.36 1.11±0.41 
IRF1  1±0.08 1.28±0.07 0.78±0.05 1.29±0.23 1.38±0.17 1 ±0.11 0.98±0.04 0.77 0.76±0.04 0.99±0.03 
CCR5(a) 1±0.23 1.91±0.59 4.10±0.78 8.80±0.33 9.18±1.46 1 ±0.13 1.63±0.35 8.39 9.42±0.63 7.38±0.75 
CXCR4(a) 1±0.17 1.46±0.28 0.27±0.01 1.25±0.27 0.94±0.18 1±0.20 1.79±0.09 0.41 1.50±0.13 1.44±0.19 
IRF8(a) 1±0.02 1.61±0.36 1.07±0.76 1.78±0.65 1.60±0.48 1±0.09 1.24±0.06 0.68 1.58±0.36 1.26±0.44 
FLT3(b) 1±0.24 0.40±0.11 1.85±0.54 1.94±0.46 1.42±0.47 1±0.16 0.20±0.08 1.86 1.24±0.30 1.32±0.28 
SIGLEC5(b) 1±0.07 1.24±0.20 1.54±0.50 3.04±1.14 2.70±0.84 1±0.28 1.24±0.31 1.49 2.58±0.57 2.60±0.41 
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CD209 1±0.10 2.49±0.27 0.08±0.01 0.18±0.07 0.21±0.06 1±0.18 2.86±0.40 0.03 0.14±0.04 0.40±0.11 
ITGA4(a) 1±0.19 0.32±0.03 0.62±0.05 0.39±0.04 0.49±0.05 1±0.14 0.23±0.05 0.54 0.36±0.05 0.49±0.08 
CCR1(b) 1±0.08 1.29±0.10 0.87±0.03 1.07±0.10 1.25±0.17 1±0.04 1.39±0.08 0.90 1.17±0.08 1.18±0.12 
IRF5(b) 1±0.04 1.00±0.21 1.49±0.15 1.02±0.09 1.11±0.20 1±0.11 0.74±0.07 1.45 0.74±0.04 0.88±0.07 
NFKB 1±0.06 0.59±0.04 0.44±0.01 0.59±0.04 0.58±0.03 1±0.06 0.56±0.10 0.59 0.50±0.07 0.61±0.08 
BATF3(b) 1±0.14 0.85±0.05 0.56±0.07 0.83±0.15 0.76±0.14 1±0.20 0.35±0.15 0.80 0.44±0.20 0.45±0.19 
ID2(b) 1±0.11 1.58±0.18 1.73±0.27 1.71±0.28 1.88±0.24 1±0.11 1.57±0.01 3.19 2.18±0.21 2.76±0.07 
BCL11A(b) 1±0.15 0.48±0.08 0.69±0.14 1.23±0.18 0.82±0.19 1±0.17 0.39±0.17 0.86 0.65±0.14 0.50±0.10 
BCL6(b) 1±0.11 0.59±0.06 0.43±0.08 0.47±0.04 0.44±0.04 1±0.18 0.63±0.07 0.57 0.57±0.12 0.64±0.09 
TCF4(a) 1±0.21 0.73±0.21 0.45±0.13 0.51±0.16 0.54±0.13 1±0.24 0.60±0.14 0.34 0.32±0.08 0.39±0.09 
MYD88 1±0.08 0.73±0.15 0.54±0.06 0.51±0.06 0.66±0.02 1±0.10 0.80±0.07 0.54 0.43±0.04 0.53±0.03 
LY96 1±0.06 1.09±0.16 0.65±0.11 0.97±0.11 0.88±0.06 1±0.04 0.77±0.11 0.73 0.81±0.08 1.03±0.14 
CLEC1A(a) 1±0.31 1.33±0.59 0.44±0.04 0.63±0.17 0.61±0.24 1±0.26 1.67±0.45 0.41 0.95±0.07 0.79±0.37 
CLEC2D(a) 1±0.25 0.33±0.00 0.60±0.25 0.84±0.08 0.94±0.17 1±0.10 0.32±0.02 0.70 0.51±0.03 0.56±0.04 
CXCL2 1±0.09 1.68±0.51 1.23±0.48 5.01±1.42 4.82±1.41 1±0.03 0.62±0.10 1.60 2.31±0.56 3.35±0.95 
CD163(a) 1±0.30 8.74±2.93 0.22±0.18 6.17±1.61 4.70±0.89 1±0.30 6.62±1.61 1.20 10.07±3.27 8.84±1.38 
IRF3 1±0.04 1.06±0.05 1.17±0.13 0.98±0.13 0.90±0.05 1±0.22 0.63±0.08 0.96 0.59±0.04 0.74±0.08 
FCGR1A(b) 1±0.27 1.62±0.89 0.38±0.10 0.72±0.30 0.85±0.22 1±0.18 0.87±0.25 0.30 0.67±0.17 0.91±0.22 
FCGR2B(b) 1±0.12 1.19±0.33 0.17±0.01 0.40±0.09 0.38±0.11 1±0.15 1.20±0.12 0.25 0.39±0.09 0.42±0.07 
FCGR3B(b) 1±0.01 1.84±0.25 0.74±0.08 1.59±0.26 1.43±0.15 1±0.01 1.29±0.01 0.86 1.43±0.14 1.58±0.15 
CD1a(a) 1±0.13 0.71±0.21 0.28±0.14 0.03±0.00 0.05±0.01 1±0.29 0.58±0.35 0.06 0.02±0.01 0.02±0.00 
LAMP3(a) 1±0.12 0.20±0.05 0.62±0.20 0.38±0.13 0.27±0.07 1±0.16 0.08±0.04 0.39 0.17±0.06 0.21±0.07 
XCR1(b) 1±0.20 1.12±0.28 0.56±0.11 0.79±0.13 0.81±0.10 1±0.03 1.01±0.12 1.28 0.95±0.06 1.12±0.01 
CD101(a) 1±0.51 1.88±0.10 2.05±0.35 2.86±0.96 1.98±1.14 1±0.26 1.15±0.25 2.65 1.26±0.36 1.20±0.13 
Genes with ≥2-
fold regulation 
- 13 17 19 17 - 14 18 21 19 
Relative gene expression of moDCs from three pigs cultured on alternative material/scaffold relative to conventional culture surface (=1), analysed by qPCR±SEM. A two-
fold or more regulation is marked by bold case. 2D, two-dimensional; 3D, three-dimensional; PS, polystyrene; PDMS, polydimethylsiloxane; qPCR, quantitative PCR; SEM, 
standard error of the mean. 
a
Data generated from only two. 
b
Data generated from only one pig.  Please note that the data resulting from no stimuli and LPS treatment 
cannot be directly compared. 
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 Table 4: Summary of findings 
Culture 
setup 
Regulation of selected genes compared to control 
surfacea 
Phenotype 
Activation status of 
non-stimulated / LPS-
stimulated cells 
2D PS 
(control) 
NA MoDC - / + 
2D PDMS 
FLT3b↓, LAMP3b↓, BATF3↓b,e, CD163c↑, 
IL23A↑d 
MDM + / + 
3D PS 
CD1ab↓, FCGR2Bb↓, CD163c↓, 
IL6d↑, IL10d↑, Il23Ad↑, CCR5d↑ 
MoDC/MDM + +  / + + + 
3D PDMS 
LAMP3b↓, CD1ab↓, FCGR2Bb↓, BATF3↓b,e, 
CD163c↑, IL6d↑, IL8d↑, IL10d↑, IL23Ad↑, 
CCR5d↑ 
MDM + +  / + + + 
Pyrolysed 
3D PDMS 
LAMP3b↓, CD1ab↓, FCGR2Bb↓, BATF3↓b,e, 
CD163c↑, IL6d↑, IL8d↑, IL10d↑, IL23Ad↑, 
CCR5d↑ 
MDM + +  / + + + 
MoDC, monocyte-derived dendritic cell; MDM, monocyte-derived macrophage; NA, not applicable. 
a
In non-
stimulated cells; 
b
DC marker; 
c
macrophage marker; 
d
activation marker; 
e
In LPS-stimulated cells. 
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Fig. 4. Principal component analysis on LOG2, autoscaled expression data of all 47 genes. Distinct clustering of cells 
isolated from 2D PS (dark blue), 2D PDMS (light blue), 3D PS (red) and 3D PDMS/pyrolysed 3D PDMS (green) can be seen. 
The analysis is based on data from 3 pigs, except for the 3D PS culture where 2 pigs were analysed. Non-stimulated cells 
were used for the analysis.  
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Fig. 5: Schematic illustration of the effect of culture surface on the gene expression of moDCs. Genes with at least a two-
fold up- or down-regulation (see table 3) on the four alternative surfaces compared to conventional surface (2D PS) are 
shown for non-stimulated cells (A) and LPS-stimulated cells (B). Red = down-regulated genes, green = up-regulated genes.  
 
4. Discussion 
This study aimed at investigating the effect of changing the culture conditions when generating 
porcine moDCs in vitro. For this purpose conventional PS culture plates (2D PS) were compared with 
plates coated with a thin layer of PDMS (2D PDMS). The reason PDMS was chosen were because of its 
common usage within microfluidic cell culture devices, a field that have undergone significant growth 
in recent years (17,27,28). With PDMS it is easy to create highly complex fluidic features (29), a 
characteristic not shared by polystyrene mainly because of challenges with bonding of the material 
(30). The use of plastic ware for bioanalysis has evolved in two directions during the last 20 years; 
while engineers have become accustomed to use PDMS for fabrication of micro devices, biologists 
have almost entirely used PS as material of choice for culture ware, e.g. Petri dishes, culture flasks and 
microtiter plates (18). Therefore most of the in vitro biological data available today is from cells 
cultured on PS and thus comparison of data generated using other materials might be difficult. There 
is no doubt that fabricated micro devices for testing biological samples will become increasingly 
implemented within biomedical research, and thus generating knowledge of how cells respond to 
growth in/or contact with alternative materials and surface architecture is crucial.  
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The porcine monocytes-derived cells generated with a cocktail of GM-CSF and IL-4 had a 
surface phenotype typically for moDC when cultured on 2D PS (9,11,12). The phenotype when 
cultured on 2D PDMS was similar to 2D PS-cultured cells except for decreased expression of CD1 and 
MHCII. All the 3D-cultured cells had no or low expression of CD1, CD80/86 and MHCII. This was 
consistent with the gene expression analysis; when compared to control, the expression of CD1a was 
slightly decreased in 2D PDMS cells (a fold change of 1.4 (a relative-to-control expression of 0.71) 
which was, however, not categorized as being biologically significant; see material and methods), and 
decreased 3.5-33 fold (0.28-0.03) in cells from all three types of 3D surfaces, Table 1.  
Equal weight of all 46 genes in the PCA analysis revealed a clear separation (and most 
variation) between cells grown at different surface architecture compared to material. Thirteen genes 
were expressed differently in cells from 2D PS and 2D PDMS surfaces. The most interesting 
observation was an increase in CD163 and IL23A, and a decrease in FLT3 and LAMP3 expression in 2D 
PDMS cells compared to 2D PS. As CD163 have been described as a monocyte/macrophage marker 
(6,31) and FLT3 and LAMP3 as markers expressed by DCs (32,33), it seems as if the cells cultured on 
PDMS in contrast to PS developed into macrophage-like cells with an increased activation state in the 
form of inflammatory cytokine expression even without the addition of LPS. Additionally, LPS-
stimulated cells cultured on all three types of PDMS surfaces, had a decreased expression of BATF3 
compared to the control surface. BATF3 is typically expressed by bona fide DC at higher levels (Gael 
Aurey and Artur Summerfield, unpublished data) and the downregulation on PDMS surfaces is in 
accordance with the cells having macrophage-like phenotypes. It was surprising to find expression of 
FLT3 in the monocyte-derived cells as a previous study found this gene to be primarily expressed by 
bona fide DCs originating from bone marrow DC-precursors (32). An explanation could be that 
conventional DCs (cDCs) were present in our monocyte population to begin with as these cells also 
express CD172a (which was used to purify the monocytes), although at a much lower level than 
monocytes (34). Changing the surface to PDMS had a negative effect on the FLT3 expression. 
Adding a third dimension to the culture, i.e. 3D PDMS generated cells that in addition to the 
above mentioned differences in gene expression, also differed from cells on 2D PS by increased 
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expression of IL6, IL8, IL10 and CCR5, inflammatory and regulatory cytokines and a chemokine 
receptor reflecting cells with higher activation status. In addition to LAMP3, also CD1a and FCGR2b 
which is usually expressed by DCs were downregulated. As shown in the PCA plot 3D PDMS and 
pyrolysed 3D PDMS surfaces constituted one cluster. In fact there was not much difference in their 
gene expression profile; only 2 genes were differently expressed compared to control on 3D PDMS 
but not on the pyrolysed version of the surface for non-stimulated cells. Also the level of expression 
was similar on the two surfaces. So the carbonization of PDMS had only minor effect on the gene 
expression.     
Finally the effect of changing only the culture dimension was tested on the 3D PS surface. This 
surface clustered differently from the other surfaces and resulted primarily in downregulation of 
genes compared to control (12 genes were downregulated, 5 were upregulated). Cells from this 
surface were in an activated state based on upregulation of inflammatory and regulatory 
cytokines/chemokines as was the case for all 3D surfaces. Apart from the downregulation of the two 
DC markers, CD1a and FCGR2b, cells on this surface also downregulated the expression of the 
macrophage marker CD163 which were upregulated on all the other alternative surfaces. This 
emphasizes that the skewing of cells toward a macrophage phenotype is dependent on surface 
material (PDMS) more than dimension (3D).  
A concern when working with cells cultured on 3D scaffolds, is the harvesting process. It is 
obviously more complicated collecting cells cultured in a 3D setup compared to 2D. There is a risk of 
losing cells that are stuck in the scaffold and thus basing the further analysis on a fraction of the 
original cell pool. In this study, an equal number of cells were originally pipetted in each culture well. 
The cells were not counted after harvesting, but the quantity of total RNA after purification was 
measured, and this yield can be used as an indirect measure of initial cell quantity. All culture surfaces 
resulted in a relatively high total RNA yield, except for the 3D PS surface. This scaffold is a commercial 
available 200 µm thick porous PS membrane made using emulsion templating (35) and designed for 
3D culture (36). The scaffold has a porosity of 90% and the pore size is approximately 40µm. This 
surface is more compact than the 3D PDMS and pyrolysed 3D PDMS scaffolds which have pore sizes of 
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300-600µm. We may only speculate if cells were left trapped within the pores of the 3D PS scaffold 
due to their relative compact architecture compared to 3D PDMS and pyrolysed 3D PDMS. The low 
RNA yield from 3D PS could also have to do with the material as a higher RNA yield from cells cultured 
on 2D PDMS compared to 2D PS was obtained. In a study on human breast cancer cells Zhang and 
colleagues reports a poor cell attachment on plasma oxygen-treated 2D PDMS compared to 2D PS 
surfaces (37). Thus the decreased RNA yield after retrieval of cells from 3D PS is probably due to a 
combination of cells sticking better to the polystyrene and being “trapped” in the relatively small 
pores of the scaffold. In any case, it seems as if the 3D PS scaffold is preferable for assays that do not 
require retrieval of cells after culture. 
In conclusion, the effect of changing the culture setup when generating porcine moDC was 
tested and it was found that both material (PDMS) and architecture (3D) changed the gene expression 
of the cells. Even though one could wish for more biological replicates, multivariate analysis (PCA) 
suggest that architecture (2D vs. 3D) rather than material (PS vs. PDMS) results in differentially 
expression of genes involved in pattern recognition and inflammation. In contrast, genes involved in 
macrophage phenotype were dependent on surface material (PDMS) more than dimension (3D). 
These findings provide evidence of the necessity of detailed reporting of the culture conditions used 
when presenting gene expression results as it was found to influence the expression, which make 
comparisons difficult. The findings also highlight the challenges for future studies combining the 
analysis or generation of cells having specific phenotypes with for example microfluidic cell culture-
devices fabricated using other materials than PS.   
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Supporting information 
Supplementary Table S1: List of primers used in this study.  
87 primers are listed (9 primers were excluded as they did not work).  
Gene 
symbol 
 Gene name  Sequence  
Amplicon 
length 
ACTB β-actin 
F: CTACGTCGCCCTGGACTTC 
R: GCAGCTCGTAGCTCTTCTCC 
76 
B2M  β-2-microglobulin 
F: TGAAGCACGTGACTCTCGAT 
R: CTCTGTGATGCCGGTTAGTG 
70 
GAPDH  
Glyceraldehyde-3-phosphate 
dehydrogenase 
F: ACCCAGAAGACTGTGGATGG 
R: AAGCAGGGATGATGTTCTGG 
79 
HPRTI  
Hypoxanthine phosphoribosyl-
transferase I 
F: ACACTGGCAAAACAATGCAA 
R: TGCAACCTTGACCATCTTTG 
71 
RPL13A Ribosomal protein L13a 
F: ATTGTGGCCAAGCAGGTACT 
R: AATTGCCAGAAATGTTGATGC 
76 
PPIA  
peptidylprolyl isomerase A  
(cyclophilin A) 
F: CAAGACTGAGTGGTTGGATGG 
R: TGTCCACAGTCAGCAATGGT 
138 
TBP TATA box binding protein 
F: ACGTTCGGTTTAGGTTGCAG 
R: CAGGAACGCTCTGGAGTTCT 
96 
YWHAE 
Tyrosine 3-monooxygenase/ 
tryptophan 5-monooxygenase 
F: GCTGCTGGTGATGATAAGAAGG 
R: AGTTAAGGGCCAGACCCAAT 
124 
IL1B  Interleukin 1b 
F: CCAAAGAGGGACATGGAGAA 
R: GGGCTTTTGTTCTGCTTGAG 
123 
IL6  Interleukin 6 
F: TGGGTTCAATCAGGAGACCT 
R: CAGCCTCGACATTTCCCTTA 
116 
IL8  Interleukin 8 
F: GAAGAGAACTGAGAAGCAACAACA 
R: TTGTGTTGGCATCTTTACTGAGA 
99 
IL10 Interleukin 10 
F: TACAACAGGGGCTTGCTCTT 
R: GCCAGGAAGATCAGGCAATA 
110 
IL12A Interleukin 12 p35 
F: GAACTAGCCACGAATGAGAGTTG 
R: ACTGCTAAGGCACAGGGTTG 
114 
IL12B Interleukin 12 p40 
F: GACCAGAAAGAGCCCAAAAAC 
R: AGGTGAAACGTCCGGAGTAA 
70 
IL23A interleukin 23 
F: GCTGTGATCCTCAGGGACTC 
R: TAGAGAAGGCTCCCCTGTGA 
119 
TLR2 Toll like receptor 2 
F: CGGAGGTTGCATATTCCACAG 
R: TGTGAAAGGGAACAGGGAAC 
128 
TLR3  
Toll like receptor 3 / toll-like receptor 3 
variant 1 (TLR3) 
F: ACATCTACTGAAAGATCCATTGTGC 
R: TCTTCGCAAACAGAGTGCAT 
148 
TLR4(a) Toll like receptor 4 F: TTTCCACAAAAGTCGGAAGG 145 
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R: CAACTTCTGCAGGACGATGA 
TLR4(b) Toll like receptor 4 
F: TGGTGTCCCAGCACTTCATA 
R: CAACTTCTGCAGGACGATGA 
116 
TLR7  Toll like receptor 7 
F: AGAAGCCCCTTCAGAAGTCC 
R: GGTGAGCCTGTGGATTTGTT 
93 
TLR8 Toll like receptor 8 
F: GCAAAGACCACCACCAACTT 
R: ATCCGTCAGTCTGGGAATTG 
129 
 
TLR9 Toll like receptor 9 
F: CCTGTTCTATGATGCCTTCGTG 
R: GGTACCCAGTCTCGCTCCTC 
144 
IFNA  Interferon alpha 1 
F: ATCGTCAGGGCAGAAGTCAT 
R: CCAGGTGTCTGTCACTCCTTC 
86 
IFNB Interferon beta 
F: AGCACTGGCTGGAATGAAAC 
R: TCCAGGATTGTCTCCAGGTC 
83 
IFNG Interferon gamma 
F: CCATTCAAAGGAGCATGGAT 
R: TTCAGTTTCCCAGAGCTACCA 
76 
TNF  Tumor Necrosis Factor alpha 
F: CCCCCAGAAGGAAGAGTTTC 
R: CGGGCTTATCTGAGGTTTGA 
92 
SLA-DRB1(a)  
Major Histocompatibility Complex, Class 
II, DR Beta 1 
F: TGACGGTGTATCCTGCAAAG 
R: GTAGAACCCGGTCACAGAGC 
74 
SLA-DRB1(b) 
Major Histocompatibility Complex, Class 
II, DR Beta 1 
F: GAGGTCTACAGCTGCCGAGT 
R: ATCTTGCCCTGAGCAGATTC 
92 
CD86(a) CD86 
F: CATCGTCTGTGTCCTGCAAC 
R: CACAGGTGGCTTTGCATCTA 
82 
CD86(b) CD86 
F: GAACAGGAAGGCGAGTGAAC 
R: ATCACACTGGGCATCATCAG 
73 
CD40 CD40 
F: TGAGAGCCCTGGTGGTTATC 
R: GCTCCTTGGTCACCTTTCTG 
90 
CCR7(a) Chemokine (C-C Motif) Receptor 7 
F: TCCACGTCTGCAAACTCATC 
R: GTCGATGCTGATGCAGAGAA 
83 
CCR7(b) Chemokine (C-C Motif) Receptor 7 
F: GCCATGAGCTTCTGCTACCT 
R: CCTTGTTGCGCTCGAAGT 
70 
TRAF6(a) 
TNF Receptor-Associated Factor 6,  
E3 Ubiquitin Protein Ligase 
F: CTGCCATGAAAAGATGCAGA 
R: GCGACTGGGTATTCTCTTGC 
62 
TRAF6(b) 
TNF Receptor-Associated Factor 6,  
E3 Ubiquitin Protein Ligase 
F: CCAGTTCCATGCACATTCAG 
R: GCGACTGGGTATTCTCTTGC 
91 
CLEC4A(a) 
C-Type Lectin Domain Family 4,  
Member A 
F: ATGGGGTTGGAATGATGTTC 
R: TCATGGAGAATGTTCCACTCAT 
91 
IRF1  interferon regulatory factor 1 
F: TGAAGCTGCAACAGATGAGG 
R: CTTCCCATCCACGTTTGTCT 
100 
CCR5(a) Chemokine (C-C Motif) Receptor 5  
F: GCCGCAATGAGAAGAAGAAG 
R: AGGGAGCCCAGAAGAGAAAG 
81 
CCR5(b) Chemokine (C-C Motif) Receptor 5  
F: CAACTTGCTGGTTGTCCTCA 
R: GCCAGGTTGAGCAGGTAGAT 
78 
CXCR4(a) Chemokine (C-X-C Motif) Receptor 4 
F: ACGGGTTCCGTATATTCACTTC 
R: GGAAACAGGGTTCCTTTATGG 
87 
CXCR4(b) Chemokine (C-X-C Motif) Receptor 4 
F: CTGCTGGCTGCCATACTACA 
R: TCAAACTCACACCCTTGCTG 
81 
IRF8(a) Interferon Regulatory Factor 8 
F: TGGGAGAACGACCAGAAGAG 
R: CCAGGCCTTGAAGATGGAG 
99 
IRF8(b) Interferon Regulatory Factor 8 F: CCGGATTTTGAGGAAGTGAC 84 
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R: CTCTTCCTCGGGGACAATG 
FLT3(a) Fms-Related Tyrosine Kinase 3 
F: ATGGATCAGCCATTTTACGC 
R: CGTTTCCTGGAGTCAAAAGC 
77 
FLT3(b) Fms-Related Tyrosine Kinase 3 
F: GCTGGAGGAGGAAGAGGACT 
R: TCCCTTTGGCCACTTGATAG 
77 
SIGLEC5(b) Sialic Acid Binding Ig-Like Lectin 5 
F: ACGCCTCGATCAAGGTCAC 
R: AGCTGAGTCTGAGGCTGGAG 
96 
CCL2 Chemokine (C-C Motif) Ligand 2 
F: GCAAGTGTCCTAAAGAAGCAGTG 
R: TCCAGGTGGCTTATGGAGTC 
103 
 
CD209 CD209 
F: CGGAGCAGAAATTCCTGAAG 
R: CATTGCCAGGAACCTTCATT 
94 
ITGA4(a)  
Integrin, Alpha 4 (Antigen CD49D,  
Alpha 4 Subunit Of VLA-4 Receptor) 
F: TCCAGAGCCAAATCCAAAAG 
R: GCGTTTGGGTCTTTGATGAT 
94 
CCR1(a) Chemokine (C-C Motif) Receptor 1 
F: CTGGCCATTTCTGACCTGAT 
R: ACACATGTGATCGCCAAAAA 
93 
CCR1(b) Chemokine (C-C Motif) Receptor 1 
F: TCCAAGAATCCCTGTTCACC 
R: AGGCGATGACCTCTGTCACT 
81 
IRF5(a)  Interferon Regulatory Factor 5 
F: TCTTCAGCCTGGAGCATTTT 
R: CTCCCCAAAGCAGAAGAAGA 
98 
IRF5(b)  Interferon Regulatory Factor 5 
F: AACCCCGAGAGAAGAAGCTC 
R: CAAGAAAGCTCCCCTGAGAA 
88 
NFKB1  
Nuclear Factor Of Kappa Light 
Polypeptide Gene Enhancer In B-Cells 1 
F: CTCGCACAAGGAGACATGAA 
R: GGGTAGCCCAGTTTTTGTCA 
97 
BATF3(a)  
Basic Leucine Zipper Transcription 
Factor, ATF-Like 3 
F: GTTCTGCAGAGGAGCGTTTC 
R: TCTCTCCTTCGGACCTTCCT 
86 
BATF3(b)  
Basic Leucine Zipper Transcription 
Factor, ATF-Like 3 
F: AGGAAGGTCCGAAGGAGAGA 
R: TTTGTCAGCCTTCTGGGTTT 
78 
ID2(a)  
Inhibitor Of DNA Binding 2, Dominant 
Negative Helix-Loop-Helix Protein 
F: GGACATCAGCATCCTGTCCT 
R: AGAGCGCTTTGCTGTCACTT 
74 
ID2(b)  
Inhibitor Of DNA Binding 2, Dominant 
Negative Helix-Loop-Helix Protein 
F: CCAGTGAGGTCCGTTAGGAA 
R: GTTGTACAGCAGGCTCATCG 
99 
BCL11A(a)  
B-Cell CLL/Lymphoma 11A  
(Zinc Finger Protein) 
F: ATGCGAGCTGTGCAACTATG 
R: GTAAACGTCCTTCCCCACCT 
88 
BCL11A(b)  
B-Cell CLL/Lymphoma 11A (Zinc Finger 
Protein) 
F: GAATTCTCGCCCGAACCTC 
R: ACACGTGAGGAGGTCATGGT 
99 
BCL6(a)  B-Cell CLL/Lymphoma 6 
F: ATCGTCAACAGGTCCCTGAC 
R: GGGTGCAGGTAGAGTGGAGA 
71 
BCL6(b)  B-Cell CLL/Lymphoma 6 
F: CAAACCTGAAAACCCACACC 
R: ATGGGCCACCTGTACAAATC 
89 
TCF4(a) Transcription Factor 4 
F: GAGTGATAAGCCCCAGACCA 
R: TTCCTTTCTCGGACTTGCTG 
87 
TCF4(b)  Transcription Factor 4 
F: TCCAGTCTTCCTCCGATGTC 
R: GGCAGGAGGTGTACAGGAAG 
78 
MYD88 
myeloid differentiation primary 
response protein 88 
F: CCAGACTAAGTTTGCACTCAGC 
R: AGGATGCTGGGGAACTCTTT 
99 
LY96   Lymphocyte Antigen 96 (MD2) 
F: CAGTAAAGGTTGAGCCCTGTG 
R: TTTGCGCATTGGTAAAGTCA 
140 
CLEC1A(a) 
C-Type Lectin Domain Family 1,  
Member A 
F: CCAACACTCAGCAAGACAGC 
R. TTCCTGTTCTGGGTTTGGAG 
91 
CLEC2D(a)  C-Type Lectin Domain Family 2,  F: GTCACCACATCACGTTTGGA 82 
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Member D R: GGCACATTCTCCAACTCCTC 
CLEC2D(b) 
  
C-Type Lectin Domain Family 2,  
Member D 
F: CGCAAAGAACTGGACAGTCA 
R: TTCAGCTCCTCTTCGGTTTC 
84 
CXCL10  Chemokine (C-X-C Motif) Ligand 10 
F: CCCACATGTTGAGATCATTGC 
R: GCTTCTCTCTGTGTTCGAGGA 
141 
CXCL2  Chemokine (C-X-C Motif) Ligand 2 
F: GAAGATGCTAAACAAGAGCAGTG 
R: AGCCAAATGCATGAAACACA 
147 
CD163(a)  CD163  
F: CACATGTGCCAACAAAATAAGAC 
R: CACCACCTGAGCATCTTCAA 
130 
CD163(b)  CD163 
F: GGAAGTGAGCAGGTCTGGAG 
R: ACTCTGGTTCCCTGAGCAGA 
141 
IRF3  Interferon Regulatory Factor 3 
F: GTCAAGAGGCTGGTGATGGTC 
R: CTGTTGGAAATGTGCAGGTC 
119 
FCGR1A(a) 
Fc Fragment Of IgG, High Affinity Ia, 
Receptor (CD64) 
F: GGCAGTGATCACCTTGCAG 
R: ATGGGGTCCCTCACATTGTA 
79 
FCGR1A(b)  
Fc Fragment Of IgG, High Affinity Ia, 
Receptor (CD64) 
F: GCCACAGAAGATGGAAAGGT 
R: CGACATGAAACCAGACAGGA 
94 
FCGR2B(a) 
Fc Fragment Of IgG, Low Affinity IIb, 
Receptor (CD32) 
F: AGGAGTGACTGGGCTGATTG 
R: AACAGGAGCCAGGAATAGCA 
84 
FCGR2B(b)  
Fc Fragment Of IgG, Low Affinity IIb, 
Receptor (CD32) 
F: ACCACCCAGTGGTTCCATAA 
R: TCTCCTGGCCTTAAAGCTGA 
75 
FCGR3B(a) 
Fc Fragment Of IgG, Low Affinity IIIb, 
Receptor (CD16b) 
F: CCGAAGTCTGTGGTGATCCT 
R: CCTGGCACTTCAGAGTCACA 
76 
FCGR3B(b) 
Fc Fragment Of IgG, Low Affinity IIIb, 
Receptor (CD16b) 
F: ACCACATTCCAAATGCAACA    
R: ACTTTCACAGCCTCCGAAGA 
94 
CD1A(a) CD1a 
F: TAGGAGGCCAGGACATCATC 
R: GGCACAATCACTGCCAATAA 
76 
CD1A(b) CD1a 
F: CACGTCTCTGGCTTCTACCC 
R: GATGTCACCTTGCTGAGTGC 
87 
LAMP3(a)  
Lysosomal-Associated Membrane 
Protein 3 
F: TTTGGAAATGTGGACGAGTG 
R: ACAATCAAACCCACAGCACA 
95 
LAMP3(b)  
Lysosomal-Associated Membrane 
Protein 3 
F: GCACTCCTTCAAGTGCGTAA 
R: CCTGAAGCTGGACGTTCATT 
83 
XCR1(a) Chemokine (C Motif) Receptor 1 
F: CTGCTGAAACTTGGGGTCAT 
R: CAGTGGGAGAAGGCAATGTT 
92 
XCR1(b) Chemokine (C Motif) Receptor 1 
F: CTGGATTACGCCTTGCTCAT 
R: AGACATAGAGCACCGGGTTG 
73 
CD101(a)  CD101 
F: ATTGAAACTCAGGCCCACAG 
R: CCTGGCTGTGTTCTGTAGCA 
80 
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Chapter 7 - General discussion 
In this chapter, general considerations concerning in vitro culture is presented and discussed. Detailed 
discussions on topics related to study I and IIII is presented in paper I and II, respectively. 
 
Conventional in vitro culture 
Conventional in vitro culture of cells is usually performed in tissue culture treated 2D culture plates 
made in polystyrene, with varying well sizes. IGRA has been used for more than 25 years for 
measuring CMI responses within individuals for the purpose of testing vaccine efficacy or as a 
diagnostic tool. The test relies on the locomotion of one cell type, namely the T cell and its 
engagement with APCs presenting cognate antigen via pMHC complexes. In this sense it can be seen 
as a co-culture, where the two cell subtypes need to be in physical contact for the de novo production 
of IFN-γ to occur. The culture can be performed using whole blood or PBMCs. By using PBMCs, the 
“co-culture” is purest in the sense that only lymphocytes (T-, B- and NK-cells) and monocytes are 
present, whereas whole blood cultures also include erythrocytes and granulocytes. In cultures of 
PBMCs, cells sediment to the bottom of the well after some time, thus it may be expected that any 
migration that takes place is carried out directly on the plastic surface. As whole blood consist of app. 
95% erythrocytes, in this type of culture erythrocytes “coat” the bottom well surface thus migration 
of T lymphocytes may take place within/on top of the erythrocyte layer. Whether this results in some 
migratory advantages/disadvantages needs to be confirmed.   
 
An observation from study I was increased IFN-γ concentrations in polyclonal-activated 
cultures of whole blood compared to PBMCs, despite the cell concentration of PBMC cultures 
exceeding that of whole blood cultures (7.9 vs. 10x106 cells/ml). This suggests that factors other than 
the overall cell concentration may influence the level of IFN-γ detected in the cultures used for IGRA.  
An interesting discovery from 2011 reported by Antunes and colleagues, revealed that erythrocytes 
are capable of releasing factors into the culture medium, increasing the survival and growth of CD3+ T 
lymphocytes (Antunes et al. 2011). Previous studies had shown that the addition of erythrocytes to in
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 vitro cultured human T lymphocytes, resulted in increased proliferation regardless of the 
erythrocytes being added at the start of culture or 24 hours later, suggesting that the effect exerted 
by the erythrocytes were applicable for already activated lymphocytes (Arosa et al. 2004). 
Additionally, the mechanisms behind the inhibition of T lymphocyte apoptosis was found to be linked 
to upregulation of cytoprotective proteins and downregulation of oxidative stress within the T 
lymhocytes (Fonseca 2001; Fonseca et al. 2003).  
Antunes and colleagues were able to show that the effect supporting proliferation and survival 
of activated T lymphocytes (not B lymphocytes or NK cells) originated from soluble protein/factors 
released by intact erythrocytes, which they termed EDGSF (erythrocyte-derived growth and survival 
factors). They concluded that erythrocytes are regulatory cells that support growth, proliferation and 
survival of dividing T cells by the release of novel factors. This correlates with the finding that addition 
of plasma could rescue PBMCs from apoptosis during culture (Hodge et al. 2000), as discussed in 
paper I. Thus, testing IFN-γ levels on cells in whole blood format may be desirable for cultures of 
intermediate length (overnight cultures) as this seems to protect the T lymphocytes from apoptosis, 
yet the nutrient supply should still be adequate within this timeframe.  
However, the use of either PBMCs or whole blood cultures for measuring CMI responses is still 
under debate. When using IGRA for vaccine efficacy testing, the point is to measure the presence of 
antigen-responsive T lymphocytes. Therefore, creating a setting that, despite it being artificial, 
resemble the conditions surrounding the cells in vivo, would favor optimal T lymphocyte activation. In 
the 2D cultures (whole blood or PBMCs) this is not the case as T lymphocyte migration must be 
expected to occur in one plane with no directionality, thus possibly resulting in a sub-optimal setting 
for antigen presentation which could lead to decreased sensitivity of the assay. The consequence of 
this is rejection of drug/vaccine candidates that might have good in vivo effects, but suffer from poor 
in vitro performance due to insufficient antigen-presentation in the 2D culture well.  
 
3D cultures 
In the attempt to imitate in vivo conditions during in vitro culture, the obvious next step was to 
include a third dimension to the culture. The unnatural 2D environment when culturing cells in vitro 
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on glass or plastic surfaces, may provide inaccurate and unreliable data in regards to predictive 
outcomes of drug screening tests (Gurski et al. 2010). This “mismatch” between in vitro and in vivo 
outcome is causing huge economical losses due to money spent on clinical trials based on pre-studies 
using poor correlating in vitro cultures (Hartung 2013). A major limitation of the 2D model is that it 
cannot capture the complexity of the in vivo microenvironment, and cell-cell and cell-matrix 
interactions important for differentiation, proliferations and cellular functions, are lost (Mazzoleni et 
al. 2009). Furthermore studies performed using 2D cultures may also results in misrepresentation of 
findings since cells are forced to adapt to an artificial, flat and rigid surface (Mazzoleni et al. 2009).  
 
The development of physiologically relevant 3D in vitro models has mostly focused on long 
term culture of cells used for drug screenings etc. In this thesis, focus was on short term culture of 
primary immune cells and the hypothesis was, that when culturing cells used for diagnostic 
measurements in 2D, as in the case of IGRA, this may not reproduce a CMI response similar to the 
response present in vivo, thus decreasing the diagnostic value of the tests. With this in mind, in the 
attempt to mimic the in vivo structure of a lymph node in order to increase the changes of T 
lymphocyte-APC encounter during in vitro culture, and at the same time keeping the culture format 
relatively simple, several 3D incubation setups were tested. The different 3D setups were based on 
the addition of 3D scaffolds acting as a network for cell attachment and migration. These were made 
from glass wool (with/without extended gravity flow), shavings made in PP, commercial available 3D 
scaffolds made in PS or PCL, filter paper disks and a PDMS scaffold. Additionally, coating of some of 
these scaffolds with ECM proteins (MaxGel or Matrigel) or CCL21 chemokine to improve cell 
attachment and migration, respectively, was also tested.  
 
We did not succeed in developing a 3D platform for IGRA resulting in increased levels of 
secreted IFN-γ as compared to the standard assay platform in 2D. This could be due to several causes. 
First of all, it would have made sense to look at the kinetics of IFN-γ protein secretion, as was done for 
the mRNA expression. Even though the 20-22 hour culture time is a generally accepted and frequently 
used time interval when looking at IFN-γ protein, this might not be optimally for 3D cultures. It could 
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be speculated if the time interval was simply too short for the 3D architecture to add any advantages 
in regards to cell-cell contacts. Secondly, if the cells failed in attaching properly to the tested scaffolds, 
but rather “sank” to the bottom of the well, then obviously the scaffolds would lose their effect. 
Theoretically this could be the case for a fraction of the cultured cells, but most of the cells would be 
expected to reside within or on the scaffolds since caution was made when plating the cells. Also as 
some of the scaffolds tested had relatively small pore sizes (20 and 40µm in filter paper and 3D PS 
scaffolds, respectively), it would be unlikely if cells sank to the bottom. Also, in the case with ECM-
coated scaffolds, which is believed to increase the surface attachment of the cells (Kleinman et al. 
1987; Cooke et al. 2008), this did not seem to improve the assay. Retrospective it would have been 
relevant to confirm the inclusion of cells within the different scaffolds for example by scanning 
electron microscopy (SEM). Thirdly, 3D culture using artificially scaffolds may simply not be applicable 
for this type of short term assay, and it seems as if T lymphocytes are able to migrate (as shown in 
Figure 16) and engage with APCs in the 2D plane of a culture well surface even more efficiently than 
in an 3D environment, at least the for the type of 3D scaffolds tested in this thesis.      
 
Non-specific activation 
A common tendency was elevated background levels of IFN-γ in the 3D cultures compared with 2D 
cultures. This suggests that factors other than activation via antigen presentation must have led to the 
IFN-γ production in these 3D cultures. It has previously been reported that NK cells are capable of 
non-specific IFN-γ secretion in overnight antigen-stimulated cultures from young calves (Olsen et al. 
2005). This does not explain the differential finding of non-specific activation in 3D compared to 2D 
cultures though.  Flow cytometry combining surface labeling with intracellular staining of IFN-γ would 
clarify whether this non-specific IFN-γ originated from T lymphocytes or if other cells present in the 
cultures such as NK cells or γδ T lymphocytes contributed to the IFN-γ levels. Interestingly, the finding 
that 3D culture resulted in increased non-specific activation of cells (at least judged by the level of 
IFN-γ) in cultures used for IGRA, correlates with the finding that changing of culture surface 
architecture (2D to 3D) resulted in moDCs with increased activation status (paper II). This suggests 
that external factors mediated by the shift in culture architecture somehow activate the cells, and this 
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applies to both cells of porcine moDC origin and mixed cultures of bovine PBMCs. We only see what 
we look for, thus a broader analysis of the nature of activation in the PBMCs, or even in the different 
cell subtypes within the PBMC population, would be relevant. 
 
Cells on chip 
A lot of research is performed within the development of 3D culture models since they offer a 
somewhat complex microenvironment for the cells compared to 2D cultures. Also, the development 
of in vivo-correlating in vitro 3D culture models in general would contribute to a reduction in the use 
of animal models, which is in accordance to the ethical guidelines concerning the use of animals in 
research, defined by the three R´s: Replacement, Reduction and Refinement (Russell & Burch 1959). 
In fact, the US National Research Council has recommended that animal models are replaced with in 
vitro human cell based assays (Krewski et al. 2010). We aimed at developing a “lymph node-on-a-
chip” system, combining a cell chamber that facilitated lymphocyte migration and activation with 
direct detection of IFN-γ using direct one-step qRT-PCR. This combination turned out to be a novel 
invention (cf. the novelty search report, appendix 3). It would not only be applicable as a diagnostic 
test, it would also be suitable for testing immune-stimulatory/inhibitory agents and thus contribute to 
reducing the use of in vivo animal models. Unfortunately we were far from reaching this goal since 
neither the 3D “lymph node like” scaffolds seemed to work (off chip), nor did the qRT-PCR reaction.  A 
prototype chip with different incubation chambers was fabricated. The idea was that by applying a 
steady flow through the chamber, relevant cells would attach to the 3D scaffold and liquid be 
exchanged without flushing out the cells. The microstructures within the chambers were designed as 
a “plan b” if no scaffold-solution was found, and their function was to retain cells while shifting from 
blood-flow to qRT-PCR reagent flow. More research was needed for the chip to become a reality and 
unfortunately this exceeded the time-frame of the thesis.     
 
Generation of moDCs 
Paper II describes the generation of moDC cultured with GM-CSF and IL-4 on various culture surfaces. 
It has long been under debate whether in vitro generated moDC could be classified as DC or not (Artur 
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Summerfield, personal communication). Classification of DC subsets is complicated and it can be 
difficult to differentiate between DCs, macrophages and monocytes since many of the proposed 
unique markers and functions have been shown to be shared between cell types (Guilliams et al. 
2014). Also the fact that specific markers are not conserved across species as well as the change in 
morphology and location of the cells further complicates the nomenclature. However, attempts are 
being made to standardize the nomenclature for DC subsets/precursors, and it has been proposed to 
simply group these cells under the term “monocyte-derived cells” (Guilliams et al. 2014). The 
monocyte-derived cells generated on alternative surfaces in the present study, appeared 
macrophage-like in their gene expression profile, whereas monocytes cultured on conventional 
surfaces showed “classical” moDC expression and morphology. The fact that external stimuli in the 
form of changes in culture surroundings could lead to the differentiation of what appeared to be a 
different cell type, argue for the huge plasticity of these cells and that the classification into either DC 
or macrophage may be misleading. In fact, this viewpoint is shared by others who suggest a “modular 
spectrum model” that argue that monocyte-derived cells being particular plastic are able to express 
combinations of multiple transcriptional modules depending on received signals from their 
microenvironment (Ginhoux et al. 2015; Xue et al. 2014; Guilliams & van de Laar 2015). 
 
Immunotherapy using moDC generated in vitro have shown varying therapeutic effects and 
they often fail in activation of cytotoxic T lymphocytes (Barbuto 2013). In order to induce a strong 
response in vivo, the moDC must be able to migrate to the draining lymph node which requires them 
to be in an activated state. Lack of activation and migration is usually the reason for the poor 
therapeutic effect of these treatments (Wimmers et al. 2014). It would be interesting to investigate if 
the different culture methods, apart from changes in gene expression, also gave rise to differential 
antigen-presenting abilities and if the migratory capacities of these cells were affected as well. At 
least the cells cultured alternatively show an activated phenotype, and it could be speculated that the 
flat culture surface generally used for moDC culture is partly the reason for lack of migratory cells and 
instead results in “lazy” cells with a gene expression profile adapted to 2D and therefore are not able 
to migrate to the draining lymph node when re-introduced to the patient. 
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Chapter 8 - General conclusion  
The work presented in this thesis included a revision of procedures commonly used when culturing 
cells for immunological studies. We questioned the reliability of IGRAs in terms of its sensitivity 
toward changes in culture setup, and challenged the traditional 2D culture by addition of an extra 
dimension in the form of 3D scaffolds. Additionally, we examined the effect of external factors on the 
differentiation of moDCs by means of changing the material of culture surfaces as well as dimension. 
In study I, blood from pre-vaccinated calves with required CMI responses against a MAP 
peptide-antigen, was used to investigate factors of influence for the validity of IGRA performed with 
cultures of whole blood, diluted whole blood or purified PBMCs in concentrations ranging from 10-
0.625x106 cells/ml. We found large differences in the optimal diagnostic culture conditions with each 
individual animal; some calves showed highest specific IFN-γ responses in cultures of whole blood 
whereas PBMC cultures of 10x106 or 5x106 cells/ml were found optimal in other calves. Furthermore, 
we did the worrying discovery that PBMC cultures were amenable to differences in cellular 
composition compared to whole blood; by analyzing the percentages of cellular subsets using flow 
cytometry, we found a significantly reduced population of γδ T lymphocytes. Lastly, we were able to 
show effect of culture plates from different suppliers, although not significant, and following specific 
activation, six out of eight calves tested had optimal response in the same plate from Corning®. These 
findings highlights the need for caution when analyzing and comparing IGRA data, as different 
conditions infer different results in the same animal. 
Culturing cells in 2D is unnatural and cell activation requiring cell-cell contact and thus 
migration, is forced down on one plane as opposed to the migration in vivo. In study II, we sought to 
alleviate the process of cell activation by facilitating the in vitro migration of cultured cells using 3D 
scaffolds and protein coatings. However, these 3D IGRAs did not show superior qualities in terms of 
increased cell activation and thus concentrations of IFN-γ compared to 2D IGRAs. A surprising 
discovery was that the addition of an extra dimension to the cultures seemed to activate the cells in a
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non-specific manner. We did not go into detail regarding the circumstances behind this non-specific 
activation. 
The finding that 3D cultures had an activating effect on cells as well as previous reports 
showing a dramatic effect on the gene expression levels of PC12 cells when changing culture material 
(Łopacińska et al. 2013), led us to investigate possible effects of changing the culture condition during 
the in vitro differentiation of porcine moDC in study IIII. We compared traditional culture surface 
material (PS) with an untraditional culture surface made from PDMS, a material frequently used for 
lab-on-a-chip device fabrication. The results showed that both the culture surface material (PS vs. 
PDMS) as well as the dimension (2D vs. 3D) caused changes in gene expression. PDMS generated cells 
with a macrophage-like phenotype and 3D cultures had a positive effect on the activation profile of 
the cells. Thus, this study show how sensitive moDCs are to their surrounding environment and it 
opens up for the possibility of influencing the expression profile of cultured cells simply by designing 
culture setups that favor a desired differentiation path.  
Taken together, a microfluidic diagnostic chip for direct detection of CMI responses in a blood 
sample was not developed as planned originally. A prototype chip was produced (study III), consisting 
of eight chambers having space for a 3D scaffold or with varying microstructures for the capture of 
cells. However, neither the detection platform, consisting of direct qRT-PCR nor a 3D scaffold for 
increased activation was established. Instead focus within this thesis changed into optimization of in 
vitro cell culture conditions. In conclusion, IGRAs, as well as in vitro assays in general, suffer from 
severe limitations in terms of imitating in vivo conditions. This might have detrimental consequences 
when translating in vitro results into in vivo predictions. Therefore, improved in vivo-like culture 
formats applicable for both long and short term routine cultures would be useful and is worth 
pursuing.  
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10 Appendices 
Appendix 1 – images of 3D scaffolds used in the thesis 
Scaffolds used in study II: 
(PP, Polypropylene; PCL, polycaprolactone; PS, polystyrene; PDMS, polydimethylsiloxane) 
 
 
Additional scaffolds/surfaces used in study IIII:  
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Appendix 2 - List of primers used in study II and III 
 
List of primers used with the Rotor-Gene Q platform  
Symbol  Gene  Sequence 
IFNGa,b IFN-γ 
F: AAATTCCGGTGGATGATCTG 
R: TTCTCTTCCGCTTTCTGAGG 
CXCL10a,b IP10 
F: TCATTCCTGCAAGTCAATCCT 
R: CAGACATCTTTTCTCCCCATTC 
CXCL10b IP10 
F: TGGGGAGAAAAGATGTCTGAA 
R: CTCTTTCCGTGTTCGAGGAG 
PPIAa Peptidylprolyl isomerase A 
F: CGCGTCTCTTTTGAGCTGTT 
R: TCCTTTCTCTCCAGTGCTCAG 
GAPDHa,b 
Glyceraldehyde 3-phosphate 
dehydrogenase 
F: GAGCTCAATGGGAAGCTCAC 
R: GGCAGGTCAGATCCACAACT 
 HPRT1a 
Hypoxanthine 
phosphoribosyltransferase 1 
F: TGGCTCGAGATGTGATGAAG 
R: CAACAGGTCGGCAAAGAACT 
HPRT1b 
Hypoxanthine 
phosphoribosyltransferase 1 
F: CACTGGGAAGACAATGCAGA 
R: ACACTTCGAGGGGTCCTTTT 
ACTBb β-actin 
F: TCCCTGGAGAAGAGCTACGA 
R: ATTCCATGCCCAGGAAGG 
a
Used for testing 3D IGRA, 
b
Used for optimization of direct one-step blood qRT-PCR SYBR Green Kit 
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Appendix 3 - Novelty Search Report (study II) 
 
Diagnostic reticular chip combining micro fluidics with qRT-PCR for the 
detection of antigen-specific cell-mediated immune responses 
 
Aim and background of the invention 
The present invention aims at developing a chip that can be used as a simple and quick diagnostic tool 
for the indirect detection of an intracellular infection (e.g. tuberculosis) in a blood sample by 
detecting the presence of a specific cell-mediated immune response directed against antigens from 
the infectious agent.  
In the diagnostic methods presently used for testing a cell-mediated immune response against 
tuberculosis, blood is incubated together with antigen in a plate or tube for 16-24 hours. The 
supernatant is harvested and tested for the presence of cytokines using ELISA (QuantiFERON-TB Gold 
or QuantiFERON-TB Gold In-Tube), or the specific cytokine-producing T cells are counted using 
ELISPOT (T-SPOT.TB). In the plate or tube, the T cells will have to interact with antigen-presenting 
monocytes to become activated and start to produce the cytokines that are used as a measure for the 
presence of a specific cell-mediated immune response. The cell-cell contact is a concern, however, 
since there is the risk that some specific T cells will not become activated because they do not interact 
with the monocytes. This would give rise to false negative results (i.e. where a positive blood sample 
does not give a positive read-out because of lack of specific T cell-monocyte interaction in the test 
tube/plate). 
In vivo, once activated, the antigen-presenting cells (APCs), mainly dendritic cells, will migrate via the 
lymphatic system to the draining lymph node. Lymph nodes are specialized structures located in the 
interface of the blood and the lymphatic system, and therefore facilitate the interaction between 
APCs entering through the lymph and naïve T cells entering via blood vessels. In this way the lymph 
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nodes contribute efficiently to the initiation of adaptive immune responses. Lymph nodes are divided 
into different areas termed B-cell zones and T-cell zones, according to the primary type of lymphocyte 
found in these areas. Naïve T cells, as well as antigen-experienced T cells, constantly circulate the 
body via blood and lymph in search for antigen presented to them by APCs. When T cells arrive at a 
lymph node they enter the T cell zone. Here, special cells called fibroblastic reticular cells (FRCs) 
produce and ensheath a 3 dimensional (3D) reticular network consisting of extracellular matrix 
proteins, including collagens, laminin, fibronectin and tenascin1. T cells travel along this network via 
chemotaxis toward “trapped”, activated APCs. This extracellular lymph node-architecture is a clever 
solution to the challenge of enabling physical contact between specific cells that are only present in 
negligible numbers.    
 
Description of the invention 
In the context of diagnostics, imitating the extracellular reticular network of a lymph node using a 
protein matrix, increases the chance of specific cell-cell contact. In the present invention, a stabilized 
blood sample is applied to a chip, together with antigens from the pathogen of interest, and lead 
through the extracellular protein matrix. Due to the “stickiness” of the monocytes (APC precursor 
cells) present in the blood sample, these cells will stick to the matrix, take up the antigen, process it, 
and present it on their cell surface. Additionally, they will start to secrete chemokines as a result of 
their activation. T cells, which are less sticky, are able to “travel” along the matrix following the 
chemokine gradients created by the stationary, activated APCs. This will increase the chance of 
specific T cell-APC encounter and thus increase the reliability of the results, since the risk of false 
negatives is decreased. Only if the specific T cells already have been exposed to the antigen prior to 
the test (hence in an infected individual), the induced immune-response in the form of cytokine 
release, will exceed a threshold and yield a positive readout. The result is read directly on the chip 
using a built-in quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Since the 
                                                          
1 Sobocinski GP, Toy K, Bobrowski WF, Shaw S, Anderson AO, Kaldjian EP (2010): Ultrastructural localization of extracellular matrix 
proteins of the lymph node cortex: evidence supporting the reticular network as a pathway for lymphocyte migration. BMC Immunol. 
Aug; 11(42). 
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readout is based on the presence of mRNA and not proteins the result is expected to be ready after 
only a few hours.  
The main advantages of this chip compared to presently used in vitro cell culture tests, is that since 
the result is expected to be read after only a few hours, the patient tested can get the result within 
the same day. This is important when diagnosing for example patients in developing countries that 
might have travelled a long way to get to the clinic, and does not have the possibility to wait a few 
days for the result. In developed countries the chip will ease the diagnosis of, for example, homeless 
people that do not have a contact address. Instead they can get the results directly at the clinic after a 
few hours, and a treatment can be initiated. Another advantage is that the blood is directly added to 
the chip, and therefore does not need to first be transported to a laboratory, thus it is not a concern 
whether the cells are still viable. Since the blood does not need to be incubated and then analyzed by 
trained personnel and since the volume of blood, and therefore also reagents, is minimal, this 
diagnostic chip will be cheaper than the present solutions. It is, however, a necessity that the clinics 
that are performing the tests have a reader that can translate the qRT-PCR results, but this is a one-
time expense.  
This invention is generic – the chip is not restricted to one specific disease, but can in principle be 
used to diagnose other infections that elicit a cell-mediated immune response in humans as well as 
animals, such as HIV, malaria, brucellosis and paratuberculosis. Also it might be useful in the 
prognosis of cancer since the activity of the cancer-specific cell-mediated immune response is 
important in controlling cancer development. 
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Intellectual property right (IPR) landscape - Novelty search 
Searched patent/literature databases: 
 Patents 
o Derwent Innovations Index 
 Papers 
o Web of Science 
o PubMed – NCBI 
 Others 
o Google search 
 
 
Search profile (words used): 
 Same words used when searching for patents and papers: 
1. Topic=(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab on a chip* or 
lab-on-a-chip* or LOC) 
2. Topic=(polymerase chain reaction or PCR or qRT PCR or qRT-PCR or quantitative real time 
polymerase chain reaction) 
3. Topic=(diagnostic* or diagnose*) 
4. Topic=(cell-mediated immune respons* or CMI or cell mediated immune respons* or cell 
mediated immunerespons*) 
5. Topic=(micro fluidic* or microfluidic*) 
6. Topic=(detect* or discover* or measure*) 
7. Topic=(interferon gamma* or IFN-g or interferon-gamma or interferon-g or interferon* or 
IFN) 
 
 Derwent  
o (Chemical Section, Electrical and Electronic Section,  Engineering Section, Timespan = All 
Years) 
 Web of Science  
o (Databases = Science Citation Index Expanded, Social Sciences Citation Index, Arts & 
Humanities Citation Index, Timespan = All Years) 
 PubMed –NCBI  
o (All Fields) 
 Google 
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o “tuberculosis + low cost + diagnostic + blood” 
o “artificial lymph node” 
 
Patents or papers from cooperative scientists:  
Patents  
 Hansen, Mikkel Fougt; Damsgaard, Christian Danvad; Larsen, Niels Bent; Wolff, Anders (2011) 
Sample processing device and method. Patent No 20110818 
 Christer Spegel, Simon Pedersen, Ras K. Vestergaard, Tautgirdas Ruzgas, Rafel, Taboryski, 
Anders Wolff (2007). Determining and monitoring system for properties in single particle e.g. 
biological cell, has one interface used for interfacing the substrate with an analyzing system. 
WO2007104565 
Papers 
 Gregers Jungersen 
 
References related to diagnosis of cell-mediated immunity 
o Cordes H., Riber, U., Jensen, T.K., and Jungersen, G. Cell-mediated and humoral immune 
responses in pigs following primary and challenge-exposure to Lawsonia intracellularis. 
Veterinary Research In press 
 
o Thomsen, V.T., Nielsen, S.S., Thakur, A., Jungersen, G. Characterization of the long-term 
immune response to vaccination against Mycobacterium avium subsp. paratuberculosis in 
Danish dairy cows. Veterinary Immunology and Immunopathology In press 
 
o Jungersen G., Mikkelsen, H. and Grell, S.N. Use of the johnin PPD interferon-gamma assay 
in control of bovine paratuberculosis. 2011. Veterinary Immunology and Immunopathology 
In press 
 
o Mikkelsen H, Aagaard C, Nielsen SS, Jungersen G. 2011. Novel antigens for detection of cell 
mediated immune responses to Mycobacterium avium subsp. paratuberculosis infection in 
cattle. Veterinary Immunology and Immunopathology 143: 46-54. 
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o H Mikkelsen, C Aagaard, S S Nielsen, and G Jungersen. 2011. Review of Mycobacterium 
avium subsp. paratuberculosis antigen candidates with diagnostic potential. Veterinary 
Microbiology 152: 1-20. 
 
o Riber, U., Boesen, H.T., Jakobsen, J.T., Nguyen, L.T.M. and Jungersen, G. 2011. Co-
incubation with IL-18 potentiates antigen-specific IFN-γ response in a whole-blood 
stimulation assay for measurement of cell-mediated immune responses in pigs 
experimentally infected with Lawsonia intracellularis. Veterinary Immunology and 
Immunopathology 139: 257-263.  
 
o D J Begg, K de Silva, K Bosward, L Di Fiore, D L Taylor, G Jungersen and R J Whittington. 
2009. Enzyme Linked Immuno Spot: An alternative method for the detection of Interferon 
gamma in Johne’s disease. Journal of Veterinary Diagnostic Investigation 21: 187-196. 
 
o H Mikkelsen, G Jungersen and S S Nielsen. 2009. Association between milk antibody and 
interferon-gamma responses in cattle from Mycobacterium avium subsp. paratuberculosis 
infected herds. Veterinary Immunology and Immunopathology 127: 235-241. 
 
o Riber, U. and Jungersen, G. 2007. Cell-mediated immune responses differentiate infections 
with Brucella suis from Yersinia enterocolitica serotype O:9 in pigs. Veterinary Immunology 
and Immunopathology 116: 13-25.  
 
o Olsen, I., Boysen, P., Kulberg, S., Hope, J.C., Jungersen, G. and Storset, A. 2005. Bovine NK 
cells can produce gamma interferon in response to the secreted mycobacterial proteins 
ESAT-6 and MPP14, but not in response to MPB70. Infection and Immunity 73: 5628-5635. 
 
o Huda, A., Jungersen, G. and Lind, P. 2004. Longitudinal study of interferon-gamma, serum 
antibody and milk antibody responses in cattle infected with Mycobacterium avium subsp. 
paratuberculosis. Veterinary Microbiology 104: 43-53. 
 
o Huda, A., Lind, P., Christoffersen, A.B. and Jungersen, G. 2003. Analysis of repeated tests 
for interferon-gamma (IFN-γ) response and faecal excretion for diagnosis of subclinical 
paratuberculosis in Danish cattle. Veterinary Immunology and Immunopathology 94: 95-
103. 
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o Jungersen, G., Huda, A., Hansen, J.J. and Lind, P. 2002. Interpretation of gamma-interferon 
test for diagnosis of subclinical paratuberculosis in cattle. Clinical and Diagnostic 
Laboratory Immunology 9, 453-460.  
Papers submitted to peer-reviewed journals: 
o Mikkelsen H, Aagaard C, Nielsen SS, Jungersen G. Correlation of antigen-specific IFN-γ 
responses of fresh blood samples from Mycobacterium avium subsp. paratuberculosis 
infected cattle with responses of day-old samples co-cultured with IL-12 or anti-IL-10 
antibodies. Veterinary Immunology and Immunopathology. 
 
 Anders Wolff 
 
References related to lab-on-a-chip and PCR 
o Bui, Thanh Xuan; Wolff, Anders; Madsen, Mogens; Bang, Dang Duong (2011) Reverse 
transcriptase real-time PCR for detection and quantification of viable Campylobacter jejuni 
directly from poultry faecal samples. Research in Microbiology, p. 1-9 (2011) 
 
o Yi Sun, Raghuram Dhumpa, Dang Duong Bang, Jonas Høgberg, Kurt Handberg and Anders 
Wolff (2011) A lab-on-a-chip device for rapid identification of avian influenza viral RNA by 
solid-phase PCR. Lab Chip, 2011, 11 (8)   Pages: 1457-1463   DOI: 10.1039/c0lc00528b  
 
o Yi Sun, Raghuram Dhumpa, Dang Duong Bang, Kurt Handberg, Anders Wolff (2011). DNA 
microarray-based solid-phase RT-PCR for rapid detection and identification of influenza 
virus type A and subtypes H5 and H7. Diagnostic Microbiology and Infectious Disease 2011, 
69(4) 432-439  
 
o Haukur Gudnason, Martin Dufva, D.D. Bang and Anders Wolff, Comparison of multiple DNA 
dyes for real-time PCR: effects of dye concentration and sequence composition on DNA 
amplification and melting temperature. Nucleic Acids Research, 35, (19) Art No e127 (8 
pages) Oct (2007) 
 
o Christensen, T.B., Pedersen, C.M., Gröndahl, K.G., Jensen, T.G., Bang, D.D. & Wolff, A. PCR 
biocompatibility of Lab-on-a-chip and MEMS materials. J. Micromech. Microeng. 17, 1527-
1532 (2007).  
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o Ahlford, A; Brivio, M; Gudnason, H; Wolff, A; Sylvanen, A. Development of a lab-on-a-chip 
for point-of-care genetic diagnostics. European Journal of Clinical Investigation. 37, 82 
(2007) 
 
o Zhenyu Wang, Andrea Sekulovic, Jörg P. Kutter, Dang. D. Bang and Anders Wolff. Towards 
a portable microchip system with integrated thermal control and polymer waveguides for 
real-time PCR. Electrophorecis,  2006, 27, (24), 5051-5058. 
 
Publications in Refereed Proceedings 
o Minqiang Bu, Ivan R. Perch-Nielsen, Yi Sun, and Anders Wolff (2011) A Microfluidic Control 
System With Re-Usable Micropump/Valve Actuator and Injection Moulded Disposable 
Polymer Lab-on-a-Slide. Transducers '11, 16th International Conference on Solid-State 
Sensors, Actuators and Microsystems, Beijing, China (2011), pages 1244-1247 
 
o Dang Duong Bang, Dhumpa Raghuram, Cao Cuong, Flora laouenan, Berganzo Javier, Rafal 
Walczak, Yuliang Liu, Minqiang Bu, Jan Dziuban, Jesus Miguel Ruano, and Anders Wolff A 
Trip from a Tube to a Chip Applied Micro and Nanotechnology in Biotechonology, 
Veterinary and Life Sciences. Proceedings of the 3rd International Conference on the 
Development of BioMedical Engineeering in Vietnam, 11-14th Jan 2010 Publisher: Springer 
(ISSN: 1680-0737) , pages: 290-293, 2010 
 
o Dang Duong Bang, Raghuram Dhumpa, M. Agirregabiria, Rafal Walczak, Yuliang Liu, 
Mingiang Bu, Sun Yi, Jan Dzuiban, Jesus Miguel Rruano, and Anders Wolff (2009) From a 
Tube to a Chip - Application of Micro and Nanotechnology in Biotechnology, Veterinary 
and Life Sciences. Smart Systems Integration Brussels Belgium  On line publication March 
2009 (Keynote lecture) http://www.mesago.de/en/SSI/Proceedings/index.htm  
 
o Xuan Thanh Bui, Anders Wolff, Dang Duong Bang. Detection and quantification of 
Campylobacter jejuni and Campylobacter coli mRNA in poultry fecal samples. Proceedings 
of CHRO 2009. pp 68-  
 
o M. Brivio, D. Snakenborg, E. Søgaard, A. Ahlford, A.-C. Syvänen, J.P. Kutter, and A.Wolff On-
Chip Integration of Sample Pretreatment and Multiplex Polymerase Chainreaction (PCR) 
for DNA Analysis. Proc. Micro Total Analysis Systems 2008, Kluwer Academic Publisher, 
Dordrecht, The Netherlands, pp. 1737-1739, (2008). 
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o Patrycja Szczepańska, Rafał Walczak, Anders Wolff, Jan A. Dziuban (2008). SU-8 planar 
waveguides for real-time PCR chips. Proceedings of EUROSENSORS XXII 2008 Pp 383-386 
 
Number of found and discarded patents/papers 
 Patents (searched February 7, 2012 and February 20, 2012 in Derwent) 
Combination of Search words 
# found patents 
/applications 
# relevant patents 
/applications 
Patent 
/application ID 
Search 1    
(chip* or micro chip* or microchip* or nano chip* or 
nanochip* or lab on a chip* or lab-on-a-chip* or LOC) 
>100.000 - - 
(chip* or micro chip* or microchip* or nano chip* or 
nanochip* or lab on a chip* or lab-on-a-chip* or LOC) 
AND (polymerase chain reaction or PCR or qRT PCR or 
qRT-PCR or quantitative real time polymerase chain 
reaction) 
911 - - 
(chip* or micro chip* or microchip* or nano chip* or 
nanochip* or lab on a chip* or lab-on-a-chip* or LOC) 
AND (polymerase chain reaction or PCR or qRT PCR or 
qRT-PCR or quantitative real time polymerase chain 
reaction) AND (diagnostic* or diagnose*) 
217 0 - 
Search 2    
(chip* or micro chip* or microchip* or nano chip* or 
nanochip* or lab on a chip* or lab-on-a-chip* or LOC) 
>100.000 - - 
(chip* or micro chip* or microchip* or nano chip* or 
nanochip* or lab on a chip* or lab-on-a-chip* or LOC) 
AND (micro fluidic* or microfluidic*) 
1.461 - - 
(chip* or micro chip* or microchip* or nano chip* or 
nanochip* or lab on a chip* or lab-on-a-chip* or LOC) 
AND (micro fluidic* or microfluidic*) AND (polymerase 
chain reaction or PCR or qRT PCR or qRT-PCR or 
quantitative real time polymerase chain reaction) 
83 - - 
(chip* or micro chip* or microchip* or nano chip* or 
nanochip* or lab on a chip* or lab-on-a-chip* or LOC) 
AND (micro fluidic* or microfluidic*) AND (polymerase 
chain reaction or PCR or qRT PCR or qRT-PCR or 
quantitative real time polymerase chain reaction) AND 
(diagnostic* or diagnose*) 
18 2 
US2009317874-A1 
WO2008117209-A1 
Search 3    
(detect* or discover* or measure*) >100.000 - - 
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(detect* or discover* or measure*) AND (cell-mediated 
immune respons* or CMI or cell mediated immune 
respons* or cell mediated immunerespons*) 
752 - - 
(detect* or discover* or measure*) AND (cell-mediated 
immune respons* or CMI or cell mediated immune 
respons* or cell mediated immunerespons*) AND 
(interferon gamma* or IFN-g or interferon-gamma or 
interferon-g or interferon* or IFN) 
20 3 
WO2009144478-A2 
WO200259605-A1 
US5334504-A1 
 
 
 Papers (searched February 7, 2012 in PubMed) 
Combination of Search words 
# found 
papers 
# relevant 
papers 
Paper(s) 
Search 1    
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab 
on a chip* or lab-on-a-chip* or LOC) 
32346 - - 
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab 
on a chip* or lab-on-a-chip* or LOC) AND (polymerase chain reaction 
or PCR or qRT PCR or qRT-PCR or quantitative real time polymerase 
chain reaction) 
3257 - - 
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab 
on a chip* or lab-on-a-chip* or LOC) AND (polymerase chain reaction 
or PCR or qRT PCR or qRT-PCR or quantitative real time polymerase 
chain reaction) AND (diagnostic* or diagnose*) 
348 - - 
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab 
on a chip* or lab-on-a-chip* or LOC) AND (polymerase chain reaction 
or PCR or qRT PCR or qRT-PCR or quantitative real time polymerase 
chain reaction) AND (diagnostic* or diagnose*) AND (cell-mediated 
immune respons* or CMI or cell mediated immune respons* or cell 
mediated immunerespons*) 
1 1 Chang et al., 2010 
Search 2    
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab 
on a chip* or lab-on-a-chip* or LOC) 
32346 - - 
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab 
on a chip* or lab-on-a-chip* or LOC) AND (micro fluidic* or 
microfluidic*) 
4749 - - 
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab 
on a chip* or lab-on-a-chip* or LOC) AND (micro fluidic* or 
microfluidic*) AND (polymerase chain reaction or PCR or qRT PCR or 
qRT-PCR or quantitative real time polymerase chain reaction) 
343 - - 
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(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab 
on a chip* or lab-on-a-chip* or LOC) AND (micro fluidic* or 
microfluidic*) AND (polymerase chain reaction or PCR or qRT PCR or 
qRT-PCR or quantitative real time polymerase chain reaction) AND 
(diagnostic* or diagnose*) 
61 0 - 
Search 3    
(detect* or discover* or measure*) 3377434 - - 
(detect* or discover* or measure*) AND (cell-mediated immune 
respons* or CMI or cell mediated immune respons* or cell mediated 
immunerespons*) 
3379 - - 
(detect* or discover* or measure*) AND (cell-mediated immune 
respons* or CMI or cell mediated immune respons* or cell mediated 
immunerespons*) AND (interferon gamma* or IFN-g or interferon-
gamma or interferon-g or interferon* or IFN) 
535 - - 
(detect* or discover* or measure*) AND (cell-mediated immune 
respons* or CMI or cell mediated immune respons* or cell mediated 
immunerespons*) AND (interferon gamma* or IFN-g or interferon-
gamma or interferon-g or interferon* or IFN) AND (diagnostic* or 
diagnose*) 
44 3 
Harrington et al., 
2007 
Cesur et al., 2005 
Pai 2005 
 
Additional papers found using the same search profile in Web of Science (February 21, 2012) 
Combination of Search words 
# found 
papers 
# relevant 
papers 
Paper(s) 
Search 1    
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab on a 
chip* or lab-on-a-chip* or LOC) 
89648 - - 
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab on a 
chip* or lab-on-a-chip* or LOC) AND (polymerase chain reaction or PCR or 
qRT PCR or qRT-PCR or quantitative real time polymerase chain reaction) 
3340 - - 
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab on a 
chip* or lab-on-a-chip* or LOC) AND (polymerase chain reaction or PCR or 
qRT PCR or qRT-PCR or quantitative real time polymerase chain reaction) 
AND (diagnostic* or diagnose*) 
404 - - 
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab on a 
chip* or lab-on-a-chip* or LOC) AND (polymerase chain reaction or PCR or 
qRT PCR or qRT-PCR or quantitative real time polymerase chain reaction) 
AND (diagnostic* or diagnose*) AND (cell-mediated immune respons* or 
CMI or cell mediated immune respons* or cell mediated immunerespons*) 
0 - - 
Search 2    
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab on a 89648 - - 
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chip* or lab-on-a-chip* or LOC) 
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab on a 
chip* or lab-on-a-chip* or LOC) AND (micro fluidic* or microfluidic*) 
7538 - - 
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab on a 
chip* or lab-on-a-chip* or LOC) AND (micro fluidic* or microfluidic*) AND 
(polymerase chain reaction or PCR or qRT PCR or qRT-PCR or quantitative 
real time polymerase chain reaction) 
750 - - 
(chip* or micro chip* or microchip* or nano chip* or nanochip* or lab on a 
chip* or lab-on-a-chip* or LOC) AND (micro fluidic* or microfluidic*) AND 
(polymerase chain reaction or PCR or qRT PCR or qRT-PCR or quantitative 
real time polymerase chain reaction) AND (diagnostic* or diagnose*) 
132 1 
Park  et al., 
2011 
Search 3    
(detect* or discover* or measure*) 4762821 - - 
(detect* or discover* or measure*) AND (cell-mediated immune respons* or 
CMI or cell mediated immune respons* or cell mediated immunerespons*) 8675 - - 
(detect* or discover* or measure*) AND (cell-mediated immune respons* or 
CMI or cell mediated immune respons* or cell mediated immunerespons*) 
AND (interferon gamma* or IFN-g or interferon-gamma or interferon-g or 
interferon* or IFN) 
2492 - - 
(detect* or discover* or measure*) AND (cell-mediated immune respons* or 
CMI or cell mediated immune respons* or cell mediated immunerespons*) 
AND (interferon gamma* or IFN-g or interferon-gamma or interferon-g or 
interferon* or IFN) AND (diagnostic* or diagnose*) 
77 2 
Kalis et al., 2003 
Schiller et al., 
2010 
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Summary of relevant patents, papers and others  
Patents 
 Apparatus for performing thermocyclic process such as amplifying DNA comprises 
microfluidic chip with fluid channel formed in it, and at least two temperature zones; and 
thermal distribution elements disposed over portions of the chip 
Patent Number(s): US2009317874-A1 
Inventor(s): DALE G A, HASSON K C, STONE M, ZENG S 
Patent Assignee Name(s) and Code(s):CANON US LIFE SCI INC(CANO-C) 
Derwent Primary Accession Number: 2009-S64755 [02] 
Abstract: NOVELTY - Apparatus (100) to perform thermocyclic process comprises microfluidic 
chip (200) having fluid channel (202), and is formed with at least two temperature zones; and 
thermal distribution element(s) disposed on portions of the chip. Each thermal distribution 
element is constructed to distribute thermal energy from external thermal energy source 
uniformly over the portion of chip thus defining the portions as one of the temperature zones 
within chip. The channel is arranged so that fluid flowing through the channel would enter and 
exit several times from each temperature zone. 
USE - for performing thermocyclic process such as amplifying DNA (claimed). 
ADVANTAGE - The microfluidic chips are prepackaged for optimized assay designs, e.g. specific 
diagnostic/analytical tests that optimize the PCR reaction. During chip fabrication, a label is 
affixed to the chip so that the instrument readily identifies the chip via an optical detector 
reading the label. The microfluidic chips are preferably disposable. 
DETAILED DESCRIPTION - An apparatus (100) for performing a thermocyclic process comprises 
a microfluidic chip (200) having a fluid channel (202), and is configured with at least two 
temperature zones; and at least one thermal distribution element in thermal communication 
with an associated portion of the chip. The thermal distribution element is constructed and 
arranged to distribute thermal energy from an external thermal energy source uniformly over 
the associated portion of the chip thus defining the associated portion as one of the 
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temperature zones within the chip. The channel is arranged such that a fluid flowing through 
the channel would enter and exit several of times from each temperature zones of the chip. 
The thermal distribution element comprises a thermally conductive material adhered to the 
associated portion of the microfluidic chip. The thermal distribution element comprises a 
metal plate, and a rectangular metal block. The apparatus further comprises a label including 
information which is used to identify characteristics of the thermocyclic process that can be 
performed with the apparatus based on characteristics of the temperature zones of the chip. 
The label comprises a machine-readable label; a bar code; and radiofrequency identification 
tag. The apparatus also comprises a thermal energy source associated with each thermal 
distribution element and configured to apply thermal energy to the thermal distribution 
element; and a detector (115) configured to detect emissions originating from at least one 
location within the channel. An INDEPENDENT CLAIM is included for a DNA amplification 
method involving providing the apparatus for amplifying DNA; applying thermal energy to the 
thermal distribution elements to generate temperatures in the portion of the chip; and 
pumping a solution containing a nucleic acid sample through the channel so that the solution 
alternately flows through the first, second, and third portions of the chip and is alternately 
exposed to the temperatures, while the solution is pumped, detecting emission originating 
from solution flowing through a portion of the channel disposed within one of the first, 
second, and third portions of the chip. 
 
 Integrated micro-fluidic device for molecular diagnostics of fluids e.g. blood, has chamber 
circuit integrated on substrate switches signals related to chambers accommodating fluids 
and chip has controller coupled to chamber circuit 
Patent Number(s): WO2008117209-A1 
Inventor(s): FIH D A, HOEVENAARS A A M 
Patent Assignee Name(s) and Code(s):KONINK PHILIPS ELECTRONICS NV(PHIG-C) 
Derwent Primary Accession Number: 2008-M80548 [59] 
Citing Patents: 1 
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Abstract: NOVELTY - The integrated micro-fluidic device comprises several polymerase chain 
reaction (PCR) chambers (11-MN) provided on a glass substrate for accommodating fluids. A 
chamber circuit such as thin film transistor (TFT) is integrated on the substrate for switching 
signals related to the chambers. An integrated circuit (IC) chip bonded to the substrate 
comprises a controller which is coupled to the chamber circuit. The TFT comprises a 
polycrystalline, microcrystalline or amorphous semiconductor material and the IC chip 
comprises a monocrystalline semiconductor material. 
USE - Integrated micro-fluidic device with local temperature control for molecular diagnostics 
of fluidic samples such as blood, urine, saliva, anal and vaginal secretions, agricultural samples, 
soil samples, bacteria, viruses, fungi or parasites. 
ADVANTAGE - The improved integrated micro-fluidic device enables more uniform heating of 
the chamber with local temperature control. 
 
 Detecting a cell-mediated immune response to purified antigens of Mycobacterium avium 
subsp. paratuberculosis (Map) comprises detection of a cell-mediated immune response by 
measuring extent of lymphocyte activation and/or proliferation 
Patent Number(s): WO2009144478-A2; WO2009144478-A9; WO2009144478-A3; 
AU2009252922-A1; EP2286230-A2; US2011135578-A1; CN102159952-A 
Inventor(s): HUGHES V M, STEVENSON K, HUGHES V 
Patent Assignee Name(s) and Code(s): MOREDUN RES INST (MORE-Non-standard), 
STEVENSON K(STEV-Individual), HUGHES V M(HUGH-Individual) 
Derwent Primary Accession Number: 2009-R90374 [60] 
Abstract: NOVELTY - Detecting a cell-mediated immune response to purified antigens of 
Mycobacterium avium subsp. paratuberculosis (Map) in an animal comprises detection of a 
cell-mediated immune response by measuring the extent of lymphocyte activation and/or 
proliferation in response to the purified antigens of Map. 
USE - The method is useful for detecting a cell-mediated immune response to purified 
antigens of Map in an animal; diagnosing Map infection in an animal; and for protecting an 
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animal against Map infection or for reducing Map colonization or the severity of a disease 
caused or contributed to by Map, where the disease caused or contributed to by Map is 
Johne's disease (all claimed). 
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are: 
(1) a kit for carrying out a method of diagnosing a Map infection comprising purified Map-
specific proteins or immunogenic fragments capable of eliciting a cell-mediated immune 
response, further comprising other reagents for use in the method of diagnosis, such as an 
anti-interferon gamma (IFN- gamma ) antibody; 
(2) proteins, e.g. mitogen activated protein (MAP) 0268c; MAP1297; MAP1365; and 
MAP3651c; and fragments, for raising an immune response in an animal; 
(3) an immunogenic formulation vaccine comprising proteins, e.g. MAP0268c; MAP1297; 
MAP1365; and MAP3651c; and their fragments; 
(4) a method of vaccinating or immunizing an animal against a MAP infection comprising 
administering MAP antigens, e.g. MAP0268c; MAP1297; MAP1365; and MAP3651c; and their 
fragments; and 
(5) use of proteins, e.g. MAP0268c; MAP1297; MAP1365; and MAP3651c; and their fragments, 
for protecting an animal against Map infection or for reducing Map colonization or the severity 
of a disease caused or contributed to by Map. 
Technology Focus/Extension Abstract: TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred 
Method: In detecting a cell-mediated immune response to one or more purified antigens of 
Map in an animal, the cell-mediated immune response is measured by detecting a level of 
cytokine such as IFN- gamma , tumor necrosis factor alpha (TNF- alpha ), transforming growth 
factor beta (TGF- beta ), interleukins (IL-2, IL-6, IL-10, IL-12, IL-17) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) using antibodies or indirectly from mRNA by 
reverse transcription (RT)-PCR or microarray. The method is carried out on a blood sample or 
fraction, isolated from a subject, or a skin test such as a delayed hypersensitivity skin test. The 
sample of blood or fraction is incubated with the one or more purified Map antigens, to allow 
any cell-mediated response to develop. The antigens are proteins or fragments that are 
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expressed by Map and elicit a detectable immune response in animals infected by Map greater 
than that elicited by the antigens of other closely related subspecies of M. avium (M. avium 
subsp. avium and M. avium subsp. silvaticum). The antigens are display little or no cross-
reactivity with other related species such as other subspecies of M. avium, M. bovis, and/or 
Mycobacterium tuberculosis. The method uses two or more Map-specific antigens, e.g. 
MAP0268c; MAP1297; MAP1365 and MAP3651c. 
 
 In vitro detection of a human or animal cell-mediated immune response to one or more 
specific antigens from the Mycobacterium tuberculosis complex, comprises using 
erythrocyte lysing buffer and detecting presence of gamma interferon 
Patent Number(s): WO200259605-A; WO200259605-A1; AU2002219017-A1 
Inventor(s): MUNK M, ANDERSEN P 
Patent Assignee Name(s) and Code(s):STATENS SERUM INST (STAT-Non-standard) 
Derwent Primary Accession Number: 2002-608468 [51] 
Patents Cited by Examiner: 12, Articles Cited by Examiner: 6 
Abstract: NOVELTY - Detecting in vitro a cell-mediated immune response to specific antigens 
from the Mycobacterium tuberculosis complex, comprises treating a blood sample containing 
lymphocytes within a leukocyte population and erythrocytes to lyse the erythrocytes present, 
incubating the lymphocytes with the antigen from the complex, and detecting the cell-
mediated immune response of the lymphocytes to the antigen. 
USE - The method above is useful in in vitro detection of a human or animal cell-mediated 
immune response within a small fresh whole blood sample to one or more specific antigens 
such as those from the Mycobacterium tuberculosis complex (claimed). 
ADVANTAGE - The method is capable of decreasing the time and expenses for a cell-mediated 
tuberculosis diagnostic test, and it provides a significantly higher IFNgamma release, with less 
amount of cells, compared to other method that uses fresh blood samples. Thus, this method 
is reliable and suitable for specific T-cell response purposes. 
DETAILED DESCRIPTION - Detecting in vitro a cell-mediated immune response to one or more 
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specific antigens from the Mycobacterium tuberculosis complex (M. tuberculosis, M. 
africanum and M. bovis) in a human or animal, comprises treating a whole blood sample 
containing lymphocytes within a leukocyte population and erythrocytes to lyse the 
erythrocytes present, incubating the lymphocytes with the antigen from the complex, and 
detecting the cell-mediated immune response of the lymphocytes to the antigen. 
AN INDEPENDENT CLAIM is also included for a diagnostic kit suitable for use in the above 
method, comprising a source of one or more specific antigens, latex beads coated with one or 
more specific antigens, and erythrocyte lysing buffer. 
Technology Focus/Extension Abstract: TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred 
Method: The lymphocyte concentration in the above method is concentrated between the 
steps of treating the whole blood sample and incubating the lymphocytes. The lymphocytes 
are enriched by centrifugation and are resuspended in the cell culture medium to produce a 
resuspension volume that is less than the volume of the whole blood sample by a factor of at 
least 1.5. The step of detecting the cell-mediated immune response is carried out by detecting 
the presence of gamma-interferon (IFNgamma) released by sensitized lymphocytes from the 
whole blood sample to indicate a cell-mediated immune response to the antigen. The 
IFNgamma released from the sensitized lymphocytes can be detected in an immunoassay, 
such as an enzyme-linked immunosorbant assay (ELISA). The lymphocytes cited above are also 
contacted with latex beads that are coated with the antigen. 
EXAMPLE - Peripheral blood cells from each of several donors (healthy individuals or patients 
with tuberculosis) was either left untreated (fresh whole blood) or enriched (improved whole 
blood). In this procedure, 200 mul from the enriched leukocyte cell suspension were added 
into each well of a 96-well flat-bottom plate in the presence or absence of PHA (1 mug/ml), 
PPD (5 mug/ml), ESAT6 (5 mug/ml), or CFP7 (5 mug/ml) and incubated at 37 degreesC in 5% 
CO2 air saturation. After 4-6 days in the culture, 100 mul/well of supernatant samples were 
removed and added into another 96-well plate for storage or for further use. Quantitative 
determination of IFNgamma secreted into the cell-culture supernatants were analyzed by 
ELISA technique using monoclonal antibodies specific for human IFNgamma. Briefly, 96-well 
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plates were incubated with a catching anti-human IFNgamma monoclonal antibody diluted in 
PBS at 4 degreesC for 18 hours. After washing and blocking of the wells, cell culture 
supernatants were added and the wells wee incubated for 2 hours. The wells were washed 
and biotin-labelled polyclonal goat-anti-human IFNgamma antibodies were added. The 
reaction is visualized by adding alkaline phosphatase-conjugated streptavidin followed by p-
nitrophenyl phosphate diluted in the appropriate buffer. Concentrations of IFNgamma in the 
samples were calculated using the standard curve generated from the recombinant human 
IFNgamma and results were expressed in pg/ml. The minimum assay sensitivity was 10 pg/ml. 
The absence of interfering erythrocytes increased cell contact and performance of IFNgamma 
production by enriched cells. 
 
 In vitro assay for detecting cell-mediated immune responses - by incubating whole blood 
with specific antigen and detecting gamma interferon 
Patent Number(s): US5334504-A1; US5494799-A1; WO8705400-A1; WO8705400-A; 
AU8771659-A ; JP63502695-W; EP296158-A; CA1299099-C ; EP296158-B1; DE3779909-G ; 
US5334504-A; EP296158-A4; US5494799-A; JP2642112-B2 
Inventor(s): CORNER L A, WOOD P R, WOOD R P, CORNER A L 
Patent Assignee Name(s) and Code(s): COMMONWEALTH SCI & IND RES ORG(CSIR-C), WOOD 
P R(WOOD-Individual) 
Derwent Primary Accession Number: 1987-264177 [74] 
Citing Patents: 21, Patents Cited by Examiner: 34, Articles Cited by Inventor: 1, Articles Cited 
by Examiner: 56  
Abstract: An in vitro method of detecting a cell-mediated immune response to a specific 
antigen in a human or animal comprises (a) incubating a whole blood sample from the human 
or animal with the specific antigen and (b) detecting the presence of gamma interferon 
(gamma IFN) released by sensitised lymphocytes in the whole blood sample to indicate a cell-
mediated immune response to the specific antigen. Pref. the gamma IFN is detected using an 
emxyme-linked immunosorbent assay or a radioimmunoassay. 
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USE/ADVANTAGE-The assay is far simpler and faster than those previously described. A single 
blood sample provides sufficient material for testing a patient's responsiveness to a wide 
variety of antigens. The method is used esp. for detecting immune response to the M.bovis 
antigen, tuberculin purified protein deriv. (PPD) in whole blood samples from cattle. The assay 
does not compromise the immune status of animals as does the current in vivo tuberculin skin 
test. The assay can also be used in detecting cellular responses to e.g. M. leprae, M. 
tuberculosis, mumps, Candida, Brucella, histoplasmin, trichophyton, coccidioidin and malaria. 
 
Papers 
 Chang HJ, Huang MY, Yeh CS, Chen CC, Yang MJ, Sun CS, Lee CK, Lin SR (2010): Rapid 
diagnosis of tuberculosis directly from clinical specimens using a gene chip.  Clin Microbiol 
Infect.  Aug;16(8):1090-6.  
Abstract: The aim of this study was to explore a gene chip capable of detecting the presence 
of Mycobacterium tuberculosis isolates directly in clinical sputum specimens and to compare it 
with current molecular detection techniques. At first, we selected 13 M. tuberculosis-specific 
target genes to construct a gene chip for rapid diagnosis. Using the membrane array method, 
we diagnosed M. tuberculosis by gene chip directly from 246 sputum specimens from patients 
suspected of having tuberculosis. Among 80 M. tuberculosis complex (MTBC) culture-positive 
sputum specimens, the MTBC detection rate was 62.5% (50/80) by PCR-restriction fragment 
length polymorphism (RFLP), 70% (56/80) by acid-fast staining, and 85% (68/80) by the 
membrane array method. Furthermore, subspecies showed different gene expression patterns 
in the membrane array. In conclusion, MTBC could be detected directly in sputum by the 
membrane array method. The rapidity of detection and the capability of differentiating 
subspecies could make this method useful in the control and prevention of tuberculosis. 
 
 Harrington NP, Surujballi OP, Waters WR, Prescott JF (2007): Development and evaluation of 
a real-time reverse transcription-PCR assay for quantification of gamma interferon mRNA to 
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diagnose tuberculosis in multiple animal species. Clin Vaccine Immunol. Dec;14(12):1563-71. 
Abstract: Tuberculosis of free-ranging and captive wildlife, including species implicated in the 
maintenance and transmission of Mycobacterium bovis, is a difficult disease to diagnose and 
control. Historically, diagnosis of tuberculosis has relied largely upon assays of cell-mediated 
immunity (CMI), such as tuberculin skin testing. This approach, however, is problematic or 
impractical for use with many wildlife species. Increasingly, in vitro diagnostic tests, including 
gamma interferon (IFN-gamma)-based assays, are replacing or complementing skin testing of 
cattle and humans. Analogous assays are unavailable for most wildlife because of a lack of 
species-specific immunological reagents. This report describes the development and validation 
of a whole-blood assay to quantify antigen-specific IFN-gamma mRNA expression by 
quantitative real-time reverse transcription-PCR. Oligonucleotide primers and probes were 
designed and tested for reactivity towards several susceptible species of interest with respect 
to tuberculosis infection. The assay was subsequently optimized to quantify the IFN-gamma 
mRNA expression in elk and red deer (Cervus elaphus) and was evaluated for its ability to 
detect mycobacterial antigen-specific responses of experimentally tuberculosis-infected 
animals. The assay was a simple, rapid, and sensitive measure of antigen-specific CMI. The IFN-
gamma mRNA responses correlated well with IFN-gamma protein production and showed 
performance in determining an animal's infection status superior to that of either lymphocyte 
proliferation or IFN-gamma protein enzyme-linked immunosorbent assay methods. An 
additional advantage is the ease with which the assay can be modified to reliably quantify IFN-
gamma expression by using consensus sequences of closely related species or of other species 
for which IFN-gamma sequence information is available. 
 
 Cesur S, Saka D, Tarhan G, Ceyhan I, Calişir H, Ogretensoy M (2005): [Evaluation of a 
commercial enzyme immunoassay for the detection of interferon gamma levels in active 
tuberculosis patients and vaccinated healthy subjects]. Mikrobiyol Bul. Jan;39(1):73-7. 
[Article in Turkish].  
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Abstract: The detection of plasma interferon gamma (IFN-g) levels has an important value for 
the evaluation of cell mediated immune response to Mycobacterium tuberculosis. The aim of 
this study was to investigate the plasma IFN-g levels by a commercial enzyme immunoassay 
(ELISA) and to compare the levels between recently diagnosed culture positive lung 
tuberculosis patients and BCG vaccinated healthy controls. Twenty-three patients with active 
lung tuberculosis (13 males, 10 females) and 34 BCG vaccinated healthy adults (16 male, 18 
female) have been included in the study. The control subjects were questioned about passed 
tuberculosis infection and/or a contact with tuberculosis patients. No risk factors for exposure 
to M. tuberculosis were found in the control group. IFN-g levels were measured by 
QuantiFERON-TB (Cellestis, Australia) kit, and 22 of patients and 17 of control subjects were 
found to be positive. As a result, the sensitivity of QuantiFERON-TB test was high (95.6%), 
however its specificity was quite low (50%). In conclusion, QuantiFERON-TB may be used as a 
supplementary diagnostic test in patients considered to have active tuberculosis, before 
treatment. As BCG is in routine vaccination programme and the number of active tuberculosis 
cases is high in our country, this test seems to be invalid for the diagnosis of latent 
tuberculosis. Therefore, more specific tests that are not affected by the vaccine response, are 
required for the diagnosis of latent tuberculosis. 
 
 Pai M (2005): Alternatives to the tuberculin skin test: interferon-gamma assays in the 
diagnosis of mycobacterium tuberculosis infection. Indian J Med Microbiol. Jul;23(3):151-8.  
Abstract: For nearly a century, there were no alternatives to the tuberculin skin test (TST) for 
diagnosing latent tuberculosis infection. Because of advances in immunology and genomics, 
for the first time, an alternative has emerged in the form of T cell based interferon-g (IFN-
gamma) assays, a new generation of in vitro tests of cellular immunity. These assays measure 
cell mediated immune response by quantifying IFN-gamma released by T cells in response to 
stimulation by Mycobacterium tuberculosis antigens. Although early versions of IFN-gamma 
assays used purified protein derivative (PPD) as the stimulating antigen, newer versions use 
antigens that are significantly more specific to M. tuberculosis. These specific antigens include 
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ESAT-6 and CFP-10. These proteins, encoded by genes located within the region of difference 1 
(RD1) segment of the M. tuberculosis genome, are more specific to M. tuberculosis than PPD 
because they are not shared with any BCG substrains or several nontuberculous mycobacterial 
species. A review of current evidence on the performance of IFN-gamma assays and TST 
suggests that both the TST and IFN-gamma assays have advantages and limitations, and both 
tests appear to be useful at this time. The emergence of IFN-gamma assays is a much 
anticipated, welcome development that has, for the first time, increased the choice of tests 
available for diagnosing latent tuberculosis infection. Because both tests have their strengths 
and limitations, the decision to select one over the other will depend on the population, the 
goal of testing, and the resources available. To fully evaluate the utility of IFN-gamma assays in 
high burden countries such as India, long-term cohort studies are needed to determine the 
association between positive IFN-gamma results and the subsequent risk of active disease. 
 
 Kalis CHJ, Collins MT, Hesselink  JW, Barkema HW (2003): Specificity of two tests for the 
early diagnosis of bovine paratuberculosis based on cell-mediated immunity: the Johnin skin 
test and the gamma interferon assay. Veterinary Microbiology. Dec;97(1-2):73-86. 
Abstract: Paratuberculosis in cattle is a chronic debilitating infectious disease caused by 
Mycobacterium paratuberculosis. Control of paratuberculosis is based on tests that principally 
detect advanced stages of infections: faecal culture and serology. Tests measuring cell-
mediated immunity (CMI) could improve control of paratuberculosis if able to diagnose 
mycobacterial infections earlier, before animals become infectious. A drawback of CMI tests 
for paratuberculosis has been a reported low specificity. This study re-examined CMI 
specificity and factors that may affect it. The specificities of the Johnin skin test and its in vitro 
equivalent, the gamma interferon (IFNgamma) assay, were estimated in 35 uninfected dairy 
herds. In each herd a random sample of 20 young (6-24 months old) and 20 adult (greater than 
or equal to24 months old) female dairy cattle were tested by both tests simultaneously. Skin 
test specificity was 93.5% using a skin thickness increase of greater than or equal to4 mm as 
the cut-off value. IFNgamma assay specificity when interpreted using a newly developed 
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algorithm was 93.6%. When interpreted according to two alternative algorithms provided by 
the IFNgamma kit suppliers, the assay had specificities of 66.1 and 67.0%. If the skin test and 
IFNgamma assay were used in parallel, and only animals positive on both tests were 
considered as M. paratuberculosis-infected, the specificity was 97.6%. Agreement between 
skin test and IFNgamma assay on 1631 total animals was fair (kappa = 0.41). Antigen batch 
influenced the specificity of both the skin test, ranging from 92 to 95%, and the IFNgamma 
assay, ranging from 71 to 99% among batches. Test specificity also varied among herds ranging 
from 58 to 100% for the skin test and 57 to 100% for the IFNgamma assay. While factors 
affecting CMI test specificity and agreement need further evaluation, the high specificity and 
general agreement among these CMI tests, coupled with the excellent results obtained in the 
control of bovine tuberculosis using CMI tests, support their potential value in the early 
diagnosis and control of paratuberculosis.  
 
 Schiller I, Oesch B, Vordermeier HM, Palmer MV, Harris BN, Orloski KA, Buddle BM, Thacker 
TC, Lyashchenko KP, Waters WR (2010): Bovine Tuberculosis: A Review of Current and 
Emerging Diagnostic Techniques in View of their Relevance for Disease Control and 
Eradication. Transboundary And Emerging Diseases. Aug; 57(4): 205-220. 
Abstract: Existing strategies for long-term bovine tuberculosis (bTB) control/eradication 
campaigns are being reconsidered in many countries because of the development of new 
testing technologies, increased global trade, continued struggle with wildlife reservoirs of bTB, 
redistribution of international trading partners/agreements, and emerging financial and 
animal welfare constraints on herd depopulation. Changes under consideration or newly 
implemented include additional control measures to limit risks with imported animals, 
enhanced programs to mitigate wildlife reservoir risks, re-evaluation of options to manage 
bTB-affected herds/regions, modernization of regulatory framework(s) to re-focus control 
efforts, and consideration of emerging testing technologies (i.e. improved or new tests) for use 
in bTB control/eradication programs. Traditional slaughter surveillance and test/removal 
strategies will likely be augmented by incorporation of new technologies and more targeted 
control efforts. The present review provides an overview of current and emerging bTB testing 
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strategies/tools and a vision for incorporation of emerging technologies into the current 
control/eradication programs. 
 
 Park S,  Zhang Y, Lin S, Wang TH, Yang S (2011): Advances in microfluidic PCR for point-of-
care infectious disease diagnostics. Biotechnology Advances. Nov-Dec; 29(6): 830-839. 
Abstract: Global burdens from existing or emerging infectious diseases emphasize the need 
for point-of-care (POC) diagnostics to enhance timely recognition and intervention. Molecular 
approaches based on PCR methods have made significant inroads by improving detection time 
and accuracy but are still largely hampered by resource-intensive processing in centralized 
laboratories, thereby precluding their routine bedside- or field-use. Microfluidic technologies 
have enabled miniaturization of PCR processes onto a chip device with potential benefits 
including speed, cost, portability, throughput, and automation. In this review, we provide an 
overview of recent advances in microfluidic PCR technologies and discuss practical issues and 
perspectives related to implementing them into infectious disease diagnostics.  
 
Other (found on Google) 
Search words: “tuberculosis + low cost + diagnostic + blood” 
 Pai NP and Pai M (2012): Point-of-Care Diagnostics for HIV and Tuberculosis: Landscape, 
Pipeline, and Unmet Needs. Discov Med. Jan;13(68):35-45. 
Abstract: Early diagnosis and rapid initiation of treatment remains a key strategy to control 
both HIV and tuberculosis (TB). However, HIV and TB control programs have had completely 
contrasting successes, especially with the development and deployment of point-of-care (POC) 
diagnostics. Clinicians, researchers, and public health staff who work at the frontlines of HIV 
care and control have had access to an outstanding array of POC diagnostics at their disposal, 
including those used for screening, initial diagnosis, staging, treatment monitoring, and early 
infant diagnosis. The field has also advanced to consider over-the-counter, self-testing options 
for HIV and the use of multiplexed platforms that allow for simultaneous detection of 
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infections associated with HIV. In sharp contrast to HIV, suboptimal and delayed diagnosis of 
TB has perpetuated the epidemic in many high-burden countries. Although the TB diagnostics 
pipeline is substantially better today than it was even five years ago, absence of a simple POC 
test continues to be a gaping hole in the pipeline. In this review, we compare the POC 
diagnostics landscape and pipelines for these two important infectious diseases, and highlight 
gaps and unmet needs. 
(http://www.discoverymedicine.com/Nitika-Pant-Pai/2012/01/18/point-of-care-diagnostics-
for-hiv-and-tuberculosis-landscape-pipeline-and-unmet-needs/) 
 
 Post.doc, Ph.D. Thomas Steen Hansen's Project: Low cost polymer device for tuberculosis 
diagnostics using electrical readout. 
Abstract: Tuberculosis is a serious threat to the people in numerous developing countries. One 
of the reasons this dangerous disease is difficult to control is the lack of a cheap and reliable 
diagnostic tool. In our project we aim at developing a polymer device that with a high 
sensibility can diagnose TB without the use of advanced laboratory equipment. The device is 
based on a new type of advanced polymer that can both conduct electricity and bind 
molecules with biological relevance. We can e.g. bind antibodies that are distinct in the 
manner that they can very specifically recognize a given molecule. Using this setup we can 
measure the presence of a TB related molecule in a blood sample from a patient. This is to be 
used in association with collaborators from Hvidovre Hospital who have identified a new signal 
protein in the blood from TB patients. In this project we will combine the advanced polymer 
with antibodies against the new signal protein to produce a simple and cheap polymer device 
that can diagnose TB in a health clinic in developing countries. The method is generic and can 
be transferred to other areas where antibodies are used for diagnostics, herein HIV. 
(http://www.nanotech.dtu.dk/English/Research/Externally_Funded_Projects/Low_Cost_Poly
mer_Device.aspx) 
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Search words: “artificial lymph node”  
 Okamoto N, Chihara R, Shimizu C, Nishimoto S, Watanabe T (2007): Artificial lymph nodes 
induce potent secondary immune responses in naive and immunodeficient mice. J Clin 
Invest.April;117(4):997–1007.  
Abstract: We previously demonstrated that artificial lymph nodes (aLNs) could be generated in 
mice by the implantation of stromal cell–embedded biocompatible scaffolds into their renal 
subcapsular spaces. T and B cell domains that form in aLNs have immune response functions 
similar to those of follicles of normal lymphoid tissue. In the present study, we show that the 
aLNs were transplantable to normal as well as SCID mice, where they efficiently induced 
secondary immune responses. Antigen-specific secondary responses were strongly induced in 
aLNs even 4 weeks after their transplantation. The antigen-specific antibody responses in 
lymphocyte-deficient SCID mice receiving transplanted aLNs were substantial. The cells from 
the aLNs migrated to the SCID mouse spleen and BM, where they expanded to generate large 
numbers of antigen-specific antibody-forming cells. Secondary responses were maintained 
over time after immunization (i.e., antigen challenge), indicating that aLNs can support the 
development of memory B cells and long-lived plasma cells. Memory CD4+ T cells were 
enriched in the aLNs and spleens of aLN-transplanted SCID mice. Our results indicate that aLNs 
support strong antigen-specific secondary antibody responses in immunodeficient mice and 
suggest the possibility of future clinical applications.  
(http://www.jci.org/articles/view/30379) 
 
 Patent application title: ARTIFICIAL LYMPH NODE FOR TREATING CANCER 
Inventors:  Takeshi Watanabe (Yokohama-Shi, JP)  Kouji Tanaka (Yokohama-Shi, JP)  
Assignees:  RIKEN  
IPC8 Class: AA61K3900FI  
USPC Class: 4242771  
Class name: Cancer cell or component thereof  
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Publication date: 10/22/2009  
Patent application number: 20090263428 
Abstract: Provided is an artificial lymph node that is persistently effective in cancer treatment 
in vivo. A method of producing an artificial lymph node capable of inducing cancer antigen-
specific immune responses, comprising the following steps: (a) a step for immunizing a non-
human animal using a cancer antigen and an adjuvant capable of inducing cellular immunity; 
and (b) a step for transplanting an artificial lymph node material consisting of a polymeric 
biomaterial comprising cytokine-producing stromal cells and dendritic cells to the immunized 
non-human animal, an artificial lymph node capable of inducing cancer antigen-specific 
immune responses obtained by the method of production, a cancer therapeutic agent 
comprising the artificial lymph node, and a kit for producing an artificial lymph node for cancer 
treatment comprising the following: (a) a cancer antigen; (b) an adjuvant capable of inducing 
cellular immunity; (c) a cytokine expression vector and stromal cells, or stromal cells 
incorporating a cytokine expression vector; (d) dendritic cells; and (e) a polymeric biomaterial. 
(http://www.faqs.org/patents/app/20090263428)  
 
Information about closest relevant techniques 
In the “lab-on-a-chip”- field, most devises combining micro fluidics with on-chip PCR are designed to 
identify the presence of an infection in a sample by detecting the pathogen and not the immune 
response directed against it. One method for on-chip detection of proteins is the use of antibodies 
coated on the chip surface. The binding of proteins to these antibodies can either result in a 
detectable change in the conductivity of the coated surface or the binding can be visualized via 
fluorescence.  
Presently used methods of diagnosing tuberculosis consist of either in vitro cell culture test such as 
QuantiFERON-TB Gold, QuantiFERON-TB Gold In-Tube, and T-SPOT.TB, or tuberculin skin test such as 
the Mantoux test. In the latter test, purified protein derivatives (PPD) tuberculin is intradermally 
injected in the skin of a test person and the result is read 48 to 72 hours later. If the person is 
infected, this will result in a local swelling due to a rapidly activated immune response.   
